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Abstract
A randomised control trial (RCT) is considered to be the gold standard for investigating the e cacy
of new and novel treatments. However, in RCTs with longitudinal outcomes and high percentages of
dropout, a poor handing of missing data can be problematic when trying to establishing the e cacy
of an intervention. Joint modelling of longitudinal and time-to-event data is a novel methodology
that can be used to monitor a longitudinal outcome while simultaneously accounting for time-to-
dropout. This is achieved using a mean zero latent Gaussian process, and relies on the estimation
of the parameter   which models the association between the longitudinal and time-to-event com-
ponents. However, joint modelling is still a relatively new topic for research. The aim of this thesis
is to provide and develop a greater understanding for both the design and analysis elements of joint
modelling.
In Chapter 2 a simulation study to test the success of various missing data handling methods
is presented. This demonstrated that for RCTs with missing data, joint modelling performs as well
as the common alternative methods when estimating longitudinal treatment e↵ect. Despite these
benefits, a systematic review conducted in Chapter 3 showed that Joint Modelling is rarely used in
practice in RCTs with longitudinal outcome data. One contributing factor to the underuse of joint
models may be the lack of understanding and research into sample size calculations for a trial using
joint modelling. In Chapter 4, sample size formulae are derived for  2 and   in the Henderson et al.
(2000) random slope and intercept specification of the joint model. These sample size and power
calculations depend on knowledge about the value of   in a trial. Currently, the understanding
of the interpretation of   is limited, and no previous investigations into the relationship between
magnitude of   and change in longitudinal outcome for dropouts has been carried in published
literature. In Chapter 5, a visualisation of this relationship is presented.
In Chapter 6, software is developed in R to carry out and apply some diagnostic procedures for
joint models. Chapter 7 demonstrates the applicability of the methods described in this thesis, in
which joint modelling is utilised to analyse a wide range of datasets.
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Chapter 1
Introduction
1
1.1 Introduction
A randomised control trial (RCT) is considered to be the gold standard for investigating
the e cacy of new and novel medical interventions [1]. However, designing and running
an RCT is an intricate and lengthy procedure, as these studies are prone to bias. Even in
well-designed trials, some problems may inevitably arise that need to be addressed in order
to ensure that the results of a trial are applicable in a wider context. One such issue is
the occurrence of missing data [2], as it is the ethical prerogative of a patient randomised
within a trial to withdraw or dropout from an RCT at their discretion [3]. However, if a
large number of patients dropout from a trial this can prove problematic when establishing
the e cacy of an intervention.
In many trials with missing data present, the standard approach is to only include pa-
tients that completed the measurement schedule, which can lead to biased results. In more
recent times an appreciation has developed for the need to adjust the standard statistical
analyses to compensate for missing data [4]. The topic of methods for missing data han-
dling has become widely discussed in the biostatistical community, where both pre-analysis
methods i.e. imputation [5–7] and models which compensate for missingness i.e. mixed
models, joint models [8, 9] have been developed. Designing and running an RCT is both
a time consuming and financially costly procedure, and an inaccurate assessment of treat-
ment e↵ect due to mishandling or ignoring missing data can lead to erroneous conclusions
being drawn [4].
In this chapter, the basic foundations for designing and running a clinical trial are pre-
sented and the potential causes of bias are discussed. The main topic of the thesis, joint
modelling of longitudinal and time-to-event data, is introduced alongside the MAGNETIC
trial, which acts as a motivating dataset for the work. Joint modelling of longitudinal and
time-to-event data is a flexible novel methodology that can be used to model a longitudinal
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outcome over time alongside the time to a clinical event or dropout. [10].
1.2 Randomised Control Trials
In the past 100 years, great developments have been made in the area of medicine. An
increase in knowledge and resources has led to the current advanced climate. The rise
of scientific methods along with the developments in biological and medical research have
saved an immeasurable number of lives, and improved prognoses for billions of people.
The development and refinement of the RCT has played a large part in these medical
advances [11]. An RCT is a prospective experiment in a clinical environment in which
interventions are tested on human subjects for the benefit of evaluation [12]. Each indi-
vidual in a trial is prescribed a treatment based upon a random mechanism, the e↵ect of
the intervention on the prognosis of the patients is monitored and the results from each
treatment group are compared at the end of the study using a pre-specified statistical
analysis plan [13].
Conclusive results from an RCT are more reliable than any other type of clinical re-
search study according to a classification provided by Sackett et al, 2000 [14]. However,
inappropriate or lacklustre RCT designs and analyses can lead to incorrect results [15].
The main objective of a trial is to obtain clinical results from a sample of patients which
are reflective of the treatment e↵ects when applied to a general population [16] and, in
order to accomplish this, every aspect of an RCT needs to be carefully controlled to ensure
the results obtained are reflective of a wider audience. To aid with these issues, guidelines
have been published on the design and analysis of RCTs [17]. In Section 1.2.1 the general
format of an RCT is discussed as well as potential problems that could arise.
3
1.2.1 General Randomised Control Trial Characteristics and Consider-
ations
The first recorded RCT was conducted in 1931 to evaluate sanocrysin for pulmonary tu-
berculosis [18]. In the trial, 24 patients were randomised to 2 groups using the flip of a
coin and the outcomes for each patient was analysed. While the basic premise is the same,
in modern day trials a greater attempt is made to avoid bias and ensure the safety of
participants which makes the designing of RCTs a more detailed procedure.
The intention of an RCT is to compare the results from a novel treatment against a
control within a sample of patients that reflect a whole population and thereby improve
understanding of a disease and its prevention or treatment [15]. The first step is to identify
a potentially beneficial intervention to a given ailment. After preliminary testing has
been done on the chemical and medical properties of the intervention, some are eligible
for greater investigation in an RCT setting. To ensure that patients are not exposed to
unnecessary risks during these studies, trials are carried out in 4 di↵erent phases [19–21].
• Phase I - A preliminary study designed to investigate the toxicity and safety of an
intervention. These are carried out on a small number of patients with a view to
establishing the optimal dose and to test for potentially harmful side e↵ects.
• Phase II - Further tests are carried out on a larger number of patients who are ill
to assess whether the benefits of the intervention outweigh the risks.
• Phase III - Interventions that progress through phases I and II are tested and
compared against the standard treatment (control) or a placebo in a larger scale
trial. This is commonly to establish whether the new novel treatment outperforms
or is as good as the current treatment being used. In a two-arm trial patients are
randomly allocated to one of the two treatments. These trials typically take more
than a year to conduct.
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• Phase IV - After a treatment has progressed through phases I - III and been granted
marketing licences, phase IV trials are carried out. These may be to establish late
e↵ects or morbidity when patients have been given a treatment, as well as monitoring
previously identified side e↵ects and e↵ectiveness on a larger scale.
By approaching trials in this way, harmful and non-beneficial treatments can be estab-
lished within the smaller scale phase I and phase II studies before they are exposed to a
wider audience.
To ensure the transparency of a trial and a reduction in the risk of bias a trial protocol
is developed and prepared prior to the commencement, which outlines various aspects of
the trial design. These include a clear definition of outcome, eligibility criteria, sample
size, methods of randomising patients to each treatment group and blinding [1].
Outcomes
The outcome recorded in a clinical trial should be well defined, with a clear interpretation
in a clinical environment. If it is di cult to interpret or ambiguous, then when statistical
analyses are carried out the prognostic value of the outcome may be redundant. Similarly
it should apply to the research questions posed in the trial protocol [1] and be both at-
tainable and unbiased [19]. In the cases where an outcome is di cult to measure in some
patients, this would both require a larger sample size in a study and could potentially
exclude a proportion of the population which could influence the results. Therefore, the
methods of outcome measurement should be clearly stated in the RCT protocol [19]. These
considerations apply to all trial designs and properties. However, additional trial specific
considerations should be addressed dependent on the nature of the study.
In this thesis, the majority of the work will be related to trials with longitudinal data.
Longitudinal data is defined as outcomes that are measured repeatedly over time [22], and
typically these outcomes are categorical, discrete or continuous. For these type of trials,
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extra considerations have to be made at the design stage. By developing a measurement
schedule that may suit a large proportion of patients, missing data can be minimised [23].
The main focus for this thesis will be longitudinal studies with a balanced design, in which
longitudinal responses are recorded at the same times for each patient [24].
In some trials, the primary interest is not in a measurement recorded at a single or
multiple timepoints after randomisation, but the time taken for an event to occur. This
is known as time-to-event data. Some frequently used time-to-event outcomes in RCTs
are time-to-death, time-to-remission in cancer trials and time-to-dropout. The statistical
techniques used for this type of analysis are vastly di↵erent to longitudinal outcomes or
standard linear modelling analyses of treatment e↵ect. One method used to model this
type of data is the Cox-Proportional Hazards model [95], which is discussed later in the
chapter.
Eligibility Criteria
In the trial protocol, the eligibility criteria for patients is also defined. This is the list of
conditions that need to be satisfied for a patient to be allowed into a study [1]. It should be
a sample of individuals comparable to the entire population that an intervention is aimed
to treat. However, this is not the only factor to consider. The safety of patients is also
important and often the eligibility criteria will exclude any patients that are at greater
risk of adverse e↵ects. For example, many trials do not include pregnant women in non
pre-natal studies [25]. To ensure the ethics of an RCT are upheld, in general, patients
included in a study should be capable of giving true informed consent [26].
Sample Size
The number of patients inducted into a study is determined by a multitude of factors in-
cluding the nature of the condition, the trial design, the desired precision of the results and
the availability of participants [15]. Before a study is carried out, a power and significance
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level is set for the trial. The power is defined as the probability of a di↵erence in treatment
e↵ect being detected, given that one exists [27], and the higher the sample size the greater
the power. The approach to establishing sample size may be di↵erent depending on the
aims of the study and the methods of analysis. For example an equivalence trial [28] will
require a di↵erent number of patients than a superiority trial [29], or trials with a longitu-
dinal outcome recorded over time will require di↵erent numbers of patients to a trial with
an outcome recorded once. Based on all these factors, a sample size for the trial is derived
using mathematical methods, and included in the trial protocol prior to the randomisation
of patients. In some cases where closed form estimates of the sample size are not obtain-
able, simulation methods are used to establish the sample size. Greater discussions about
the factors e↵ecting sample size are discussed in Chapter 4, however these include the true
di↵erence in treatment e↵ect, the significance level, the aforementioned power of a trial
and the specific trial design.
Randomisation
Randomisation is the method by which patients admitted to a clinical trial are assigned to
one of the interventions [15]. In order for the results of a trial to be valid it is important that
there are no important prognostic di↵erences between the patients in each treatment group.
To ensure this, there are many di↵erent randomisation techniques to assign treatments.
The following is a selection of the most common methods [30];
• Simple Randomisation - For example flipping a coin, as used in the first ever
recorded RCT, or using random number tables to allocate patients to each treatment
group.
• Stratified Randomisation - Stratified randomisation ensures that equal or close to
equal numbers of patients with a chosen characteristic are allocated to each treatment
arm. This characteristic is usually something which may have an e↵ect on prognosis.
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• Block Randomisation - Blocks of random sequences are generated to assign pa-
tients to di↵erent treatments. For example in a block of six, the patients in order of
recruitment could be allocated to treatment group’s ABBAAB. In this case the first
patient admitted to a study would be placed in treatment group A, the second and
third treatment group B etc. After the first 6 patients an alternative block can be
generated to allocate patients 7-12, e.g BAAABB. This will ensure a similar number
of patients are randomised to each group. There are many software programs that
are capable of carrying out this allocation process.
• Pairwise Randomisation - Two patients with similar prognostic factors are cou-
pled and one allocated to treatment group A, and the other to treatment group B.
Like block randomisation this ensures a balance in the groups in terms of numbers,
but also in important prognostic factors.
• Minimisation - Minimisation uses algorithmic procedures to ensure that the treat-
ment groups are balanced in terms of important prognostic factors of the patients.
Clearly there are advantages and disadvantages to using each method, and the appro-
priateness in each case may be dependent on the specific aims and requirements of the
trial. Using simple randomisation is a straight forward procedure, however it can lead to
an imbalance in the number of patients per treatment group [31]. Similarly there are issues
with the potentially non random nature of stratified randomisation, blocking randomisa-
tion in smaller scale clinical trials and the di culty in finding two patients with similar
prognostic factors in pairwise randomisation [31]. To ensure transparency, the eligibility
of patients should be established before randomisation and baseline readings should also
be taken before treatment groups are assigned [1].
Blinding
In the first clinical trial in 1931, one phenomenon which the trialists were almost certainly
unaware of was the placebo e↵ect. The placebo e↵ect is a beneficial e↵ect produced by a
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placebo or treatment which is not accounted for by the medical properties of the interven-
tion itself [15]. In layman’s terms, patients who believe a treatment will be successful may
display di↵erent prognostic results to those who believe the treatment will be unsuccessful.
In RCT analysis it is important to obtain data which eliminates a disparity caused by
the placebo e↵ect across treatment groups as much as possible, which can be achieved by
blinding the treatment.
The following are types of blinding in RCTs [15]:
• Single Blind - The patient is unaware of whether they are a member of the control
or experimental group in a trial, or which intervention they are receiving. However,
the physician is aware of these details.
• Double Blind - Both the patient and the doctor are unaware what treatment is
being administered to each individual. This reduces the potential for physicians to
manipulate the results and reduce the influence of the placebo e↵ect.
• Triple Blind - The patient, the physician and the data analyst/statisticians are
all unaware of which group was administered each treatment. This addresses not
only the problems that can arise from the physician and patient having knowledge
of treatments, but also reduces the potential for reporting bias.
• Open - Both the doctor and the patient are aware of the treatment being received.
In some instances blinding in a trial may not be possible. For example it can be
di cult to blind a trial where a surgical treatment is being compared to a pill.
Statistical Analysis Plan
After the methods of blinding have been chosen, sample size formulae calculated and pa-
tients have been randomised to an intervention, the follow up of patients can commence.
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Relevant outcomes are collected and the patients are monitored for the entire duration of
the trials.
The nature of the statistical analysis should be discussed in detail in the trial proto-
col and a statistical analysis plan should be approved prior to conducting the analysis.
In general, RCTs can be separated into one of three types; superiority, equivalence and
non-inferiority trials. Each of these will require di↵erent guidelines for statistical analysis.
Superiority trials are the most common, in which the aim of a trial is to prove a new novel
treatment is better than the current gold standard treatment by observing an outcome [29].
In superiority trials we generally look for a treatment e↵ect which is significantly better
than the control at the 95% significance level. In equivalence trials the aim is to show that
the novel treatment is “equivalent” to the current standard treatment [28]. For this we de-
fine a two sided equivalence margin, which is centred around the treatment e↵ect estimate
of the control. If the confidence interval for the treatment e↵ect of the novel treatment
falls within this margin, the treatments can be deemed clinically equivalent. This term is
defined clinically in the trial protocol. By showing two treatments are clinically equivalent,
it may be possible to establish that the new novel treatment is more appropriate for the
population if the side e↵ects for the new treatment are less severe. Likewise the aim of a
non-inferiority trial is to show that the novel treatment is “no worse” than the standard
treatment used [32]. For this we establish a one sided inferiority margin, and if the confi-
dence interval for the new treatment e↵ect is shows the novel treatment to be better than
the e↵ect of the control minus this inferiority margin at the 95% level, a novel intervention
is said to be non inferior. The majority of the research in this thesis will be applied to
superiority trials.
For trials with repeated measures data, there are many longitudinal data analysis ap-
proaches that can be employed. Arguably the most common of those utilised in clinical
trial literature are linear mixed models [33], which are presented in greater detail in Chap-
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ter 2, Section 3.3. These linear mixed models are capable of taking into account both fixed
e↵ects (constant across all patients) and random e↵ects (unique to each individual patient)
in order to estimate the parameter of treatment e↵ect, while accounting for individual pa-
tient variation. One advantage of carrying out a longitudinal trial is that a greater amount
of clinical information can be gained by observing the individual outcome trajectories of
patients [22]. Consequently a greater understanding of the e↵ect of the treatment can be
obtained. After results have been collected for an RCT, conclusions are drawn as to the
clinical significance of a treatment, based upon the parameter estimates and statistical
significance.
1.2.2 Sources of Bias
Section 1.2.1 provides a description of how RCT protocols and procedures are used to max-
imise the applicability of results within a trial. However, despite the rigorous guidelines,
it is impossible to ensure a trial is completely free from bias. Trialists need to be mindful
of potential sources of bias so that these can be addressed in the trial design stage. The
following is a summary of the most common types of bias in RCTs. [34]
• Selection Bias - This arises when there are characteristic prognostic di↵erences
between the patients in each treatment group, which can be caused by use of incorrect
randomisation methods. This imbalance can result in a di↵erence in performance for
the interventions and provides an inaccurate reflection of the comparative treatment
e↵ects when applied to the general population.
• Performance Bias - This is caused by a di↵erence in the care provided to patients
in each treatment group, which may be due to insu cient blinding methods.
• Detection Bias - When outcomes are determined using di↵erent methods of mea-
surement in di↵erent treatment groups there may be discrepancies within the results.
• Attrition Bias - This is caused by a misrepresentation of the data which is induced
by inappropriate methods of dealing with the missingness in a study. For example,
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if patients who dropped out from the study in one treatment arm are prognostically
di↵erent to those in another, ignoring all patients that dropped out can provide
skewed results in an analysis.
• Reporting Bias - This arises from selective reporting of statistical results and ma-
nipulation of results to fit a given conclusion. A subset of this, “within-study publica-
tion bias’”, also known as outcome reporting bias, has become one of the main target
areas in clinical trial research as it has been identified as one of the most substantial
biases a↵ecting results from individual studies [35].
• Other Biases - Along with the common biases, some biases may be specific to
certain outcomes or specific trials. These non generalisable biases may be dealt with
on a case by case basis.
One of the main areas of focus for this thesis is dealing with the problem of attrition
bias caused by a mishandling of missing data. Methods to address these problems are
discussed in detail in Chapter 2.
1.3 MAGNETIC trial
MAGNETIC is a recently conducted double blind Phase III RCT with longitudinal mea-
surements taken, which tested the e cacy of adding magnesium nebuliser treatment to the
standard asthma treatment for children with acute severe asthma. Many of the studies
and investigations in this thesis will be based around and motivated by the circumstances
and data from this trial.
In 2011, figures show that there were 1,167 deaths as a result of asthma in the UK
and one of the main reasons for acute hospital admission was acute asthma in children.
Studies indicate that one of the main risk factors leading to death for asthma is inadequate
treatment of the disease, and up to 90% of deaths are considered to be preventable [36].
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The standard treatment for acute severe asthma in children is a nebuliser containing a
combination of salbutamol and ipratropium bromide. The dose is dependent on the age of
the child in question [37]. Early phase studies had showed that the inclusion of magnesium
sulfate in the nebuliser may have a clinically positive e↵ect on the severity of asthma score.
The aim of the MAGNETIC trial was to test this hypothesis in children with acute severe
asthma.
The outcome of interest in the MAGNETIC trial was the disease severity, which was
measured by Yung asthma severity score (ASS) [38]. ASS is measured on a scale ranging
from 0 to 9 and contains three equally weighted components; wheeze score, muscle use and
heart rate. Each patient was given a rating of 0 to 3 for each of the subcomponents and
the sum of these is defined as the asthma severity score. A higher ASS indicates more
severe symptoms.
In MAGNETIC, ASS was measured repeatedly over time. The intervention was ad-
ministered to each patient for the first 60 minutes post randomisation, with patients in
the control group being given standard treatment + placebo and the experimental group
given standard + magnesium sulphate. ASS was measured at baseline, 20 minutes, 40
minutes and 60 minutes during treatment, and at follow up times of 120 minutes, 180 min-
utes and 240 minutes. The primary outcome was ASS score after 60 minutes, however in
this thesis the focus will be on monitoring the ASS score over time in a longitudinal context.
Children from the age of 2-15 that showed signs of acute severe asthma were admitted
to the study from 30 hospitals in the UK. To reduce the chance of bias, block randomisa-
tion was used and stratified by hospital and the trial was triple blinded so that the patient,
physician and data analyst were unaware of which treatment group corresponded to which
intervention. Over a period of 28 months, 508 children were admitted into the trial with
256 being given the standard treatment + placebo and 252 were randomised to standard
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treatment + McSO4.
Patients were followed through until 240 minutes and after the trial, a data analysis
was carried out using t-tests to establish the di↵erence between treatment groups after
60 minutes. This analysis showed that in the treatment group with magnesium added,
the ASS was approximately 0.25 (2.77 s.d.) lower on average after 60 minutes, which was
statistically significant. However, the MAGNETIC trial also had a number of patients
that withdrew or dropped out of the study, which could potentially skew the results. The
following table represents the amount of missing values at each time point:
Time (minutes)
Group 20 40 60 120 180 240
Magnesium 7 (2.7%) 13 (5.1%) 24 (9.4%) 27 (10.5%) 44 (17.2%) 60 (23.4%)
Placebo 3 (1.2%) 8 (3.2%) 12 (4.8%) 18 (7.1%) 27 (10.7%) 35 (13.9%)
Table 1.1: Number of missing values of patients in MAGNETIC
By the end of follow up, there was found to be 26.7% of patients that had missing
data at at least one time point, which we will define in this thesis as a dropout (32.6% in
the magnesium group and 20.3% in the placebo group). The reasons for dropout included
children being discharged due to positive prognosis, children being discharged due to a
negative e↵ect of the treatment and causes unrelated to prognosis (for example children
not liking the taste of the nebuliser). To have a greater understanding of the prognostic
e↵ect of adding magnesium nebuliser to the standard acute severe asthma treatment, a
longitudinal data analysis of this trial would be beneficial. However, due to the diversity
of the reasons for dropout, excluding missing data from the analysis may provide misleading
conclusions. From a clinical perspective it is of interest to be able to model the change in
longitudinal outcome over time while accounting for patients that dropped out.
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1.4 Joint Modelling of Longitudinal and Time-to-event Data
One method of accounting for these types of missingness within the data is joint modelling
of longitudinal and time-to-event data [39]. In many studies, the time at which a patient
experiences a pre-defined clinical event, or the time-to-dropout is recorded alongside some
longitudinal measurements. Joint modelling is a novel methodology which takes into ac-
count patient events or dropout while monitoring a longitudinal outcome over time.
1.4.1 History
The concept of joint models stem from a paper written in 1995 by Tsiatis et al. which was
motivated by the di culty in establishing a reliable surrogate marker for disease progres-
sion in AIDS [40]. The aim of this paper was to establish whether CD4 count could be used
as a surrogate marker for AIDS in HIV trials to establish the e cacy of a treatment more
e ciently. At the time, a clear correlation between CD4 count and disease progression
had been established in the literature [41], but a greater understanding of the outcome
needed to be provided before this knowledge could be applied in a clinical environment.
Large biological variation and CD4 counts only being measured on rare occasions rendered
standard models invalid. This led to the innovative approach of developing a two stage
joint model. This two stage approach allowed longitudinal biomarkers to be taken into
account when modelling for a survival outcome. The first stage involved modelling the
counts using a repeated measures random components model. A derivation was then made
in the second stage for estimating the parameters of a Cox Model to establish a relationship
for the time-to-event. The results of the paper showed that CD4 count was an appropriate
surrogate marker for AIDS, which has proved to be valuable in this area of research.
In 1996 this concept was developed further by Faucett and Thomas, who proposed a
random e↵ects model with proportional hazards to monitor the event time to jointly es-
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timate data of this nature [43, 44]. Wulfsohn and Tsiatis developed this approach further
by considering the scenario where data was measured infrequently [45]. In this paper, the
expectation maximisation (EM) algorithm was used to estimate parameters by maximising
the joint likelihood of a Cox-Proportional Hazards model with longitudinal covariates based
upon random e↵ects models incorporated [42]. Henderson, Diggle, and Dobson (2000) built
upon this work by introducing a stationary Gaussian process, which also utilises the EM
algorithm to estimate longitudinal and event-time components, alongside an association
parameter  . Software is available to fit models of this type in R, using the joineR pack-
age [46]. Greater details of this model specification are presented in Section 1.4.3 and
Section 2.3.4. Further joint model classifications have been made, by Ibrahim, Chen, and
Sinha (2004) [49], Xu and Zeger (2001b) [51], and Song, Davidian, and Tsiatis (2002) [52]
who all extended the longitudinal model to the multivariate case using both Bayesian and
Frequentist methods.
1.4.2 Aims of Joint Modelling
There are three primary aims and inferences that can be drawn from joint models. These
are:
• Inferences about longitudinal measurements being adjusted to compensate for infor-
mative events or dropout.
• Modelling of time-to-event or dropout while compensating for longitudinal measure-
ments.
• Analysis of how the model evolves with respect to both the longitudinal measurements
and an event process/dropout.
The level of information gained by using joint models when analysing both the longitu-
dinal and time-to-event elements of a model, as well as details of the relationship between
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them, would be far more complicated to obtain by using separate analyses.
The main focus of the thesis will be the random slope and intercept latent Gaussian
variable classification of the joint model as introduced by Henderson et al, 2000 [10].
1.4.3 Model Specification
To form this joint model, the longitudinal and time-to-event elements are specified sep-
arately and linked via a latent Gaussian process. For this thesis, we specify the basic
longitudinal element as
Yij = µi(tij) +W1i(tij) + Zij . (1.1)
In this model, µi(tij) is the mean response defined as µi(t) = x1i(t)0 1, where x1i represent
a set of explanatory variables,  1 is the corresponding regression coe cients and W1i is a
latent Gaussian variable. The Zij ⇠ N(0, 2z) components are the measurement errors. Yij
is the set of longitudinal measurements for patient i at their jth timepoint.
The event-time model is defined as
 i(t) =  0(t) exp{x2i(t)0 2 +W2i(t)} (1.2)
where  0(t) is the baseline hazard, x2i is the set of explanatory variables modelled in the to
time-to-event component with corresponding regression coe cients  2 and W2i is a latent
gaussian variable. In this part of the model, x2i and  2 may have elements in common
with x1i(t) and  2, but this is not a requirement. For this thesis, we generally fit the
model described by equations (1.1) and (1.2) such that  1 = {↵, 0, 1}, where ↵ is a time
parameter,  0 is the intercept and  1 is the treatment e↵ect of the longitudinal element,
and  2 = { 2} is the log hazard ratio between di↵erent treatment groups.
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The link between these two models is the latent zero mean Gaussian process Wi(t) =
{W1i(t),W2i(t)}, which is present in both components, and calculated for each patient i.
The nature of the model allows for a wide range of definitions for the function linking the
longitudinal and time-to-event elements of the model. However in this thesis we define
W1i(t) = U1i +U2it and W2i(t) =  W1i(t) where (U1i, U2i) are the subject specific random
e↵ects such that U1i ⇠ N(0, 21),U2i ⇠ N(0, 22) and Cov(U1, U2) =  u1,u2 . By estimating
the   parameter, the relationship between longitudinal measurements and likelihood of
experiencing an event can be established. A positive gamma indicates that individuals
with higher longitudinal readings were more likely to experience an event. Similarly, a
larger proportion of patients dropping out with a lower longitudinal value will result in a
negative  .
Estimating the   parameter can be useful tool for assessing the relationship between
these two elements of the model. Establishing a relationship between the longitudinal out-
comes and event time without using joint models can be a complicated procedure. While
graphical representations of this relationship can be produced, by using joint models the
statistical significance of this relationship can be established, and the magnitude of the
relationship can be quantified (see Chapter 5). The   parameter can be estimated using
a mathematical method known as the EM algorithm, using a one step Newton-Raphson
procedure.
1.4.4 The EM Algorithm
The EM Algorithm is an iterative procedure proposed in 1977 by Dempster, Laird, Ru-
bin [53]. By using this algorithm, maximum-likelihood estimates can be generated for data
sets which have incomplete data. It can be particularly useful in the situation where latent
Gaussian variables are present in a model. An advantage of this method is its flexibility in
terms of dealing with a wide range of data, and also the fact that while computation can
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be extensive it is a relatively simple method to comprehend.
The EM algorithm is a two stage procedure that alternates between an Expectation (E)
and Maximisation (M) step. In the E-step, an expectation of the log-likelihood function
is calculated for the complete data based on the observed data, and predicted values for
the missing data are generated. In the M-step, parameter estimates that maximise the
function generated in the E-step are calculated. This process is then repeated using the
new parameter estimates until convergence is achieved [39].
In the context of a random slope and intercept joint model as proposed by Henderson
et. al., the following are details of how the EM algorithm is utilised. We refer to the
event-time as T . In the E-step, initially the random e↵ects U = (U1, U2) are treated as
missing data and expected values of h(U), the functions of U1, U2 appearing in the log
of the complete data likelihood, are calculated based upon the observed data (Y, T ) and
current parameter estimates [10]. Wulfsohn and Tsiatis [42] show that the conditional
expectations can be written as
E[h(U)|Y,N ] = {
Z
h(U)f(T |U)f(U |Y )dU}/f(T |Y )
where
f(N |Y ) =
Z
f(N |U)f(U |Y )dU.
Where f(U |Y ) is the distribution of the random e↵ects, and f(T |U) is each patients
contribution to the event-time component of the complete-data likelihood. The integrals
above are approximated using Gauss-Hermite quadrature [10] [55]. This is due to the ker-
nel having the same form as the Gaussian distribution.
The M-Step is then carried out. The complete data log-likelihood is maximised with
each function h(U) replaced by its corresponding expectation. This is estimated using
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a combination of a one step approximation for the event-time parameters and a Breslow
estimator for the cumulative baseline hazard, while closed form estimates are available for
the other parameters [57]. Greater details of how these estimates can be achieved are found
in published literature [10, 42,56].
1.5 Discussion
RCTs are said to be the best method for successfully establishing the e cacy of clinical
interventions. Years of medical research has resulted in the refinement of this method, and
in modern trials significant measures are taken to ensure that potential bias is minimised.
An overview of RCTs has been provided in this chapter and the guidelines for a good trial
design has been provided. In longitudinal trials, where multiple measurements are taken
over time, patients dropping out from a clinical trial lead to an incomplete measurement
schedule. If these patients are ignored or the missing data are handled incorrectly, then
this could lead to attrition bias. However, joint modelling of longitudinal and time-to-event
data is a method capable of monitoring the change in longitudinal outcome over time while
compensating for this dropout. In this thesis the benefits of using joint modelling of lon-
gitudinal and time-to-event data as applied to trials with dropout is determined, and the
e↵ectiveness of the method is analysed. Furthermore, methodological and design elements
for the random slope and intercept model introduced in 1.4.2 are explored and developed.
In Chapter 2, greater details of the consequences of mishandling missing data are out-
lined and some alternative techniques for accounting for the missingness are discussed. In
addition, a simulation study is used to compare the successes of the various methods used,
including the joint modelling approach. In Chapter 3, a comprehensive systematic review is
carried out to establish how often the various missing data methods are used in practice in
longitudinal trials, and to determine the extent of the problem of missing data mishandling.
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Little work has been completed in the area of power and sample size calculations in
joint modelling. In Chapter 4 a sample size formula is developed for the random slope
and intercept joint model, and a simulation study is used to compare the power of trials
that use joint models to ones which only utilise a complete case analysis. These sample
size and power calculations depend on the value of   in a trial. Our understanding of the
interpretation of the   parameter is limited, so Chapter 5 investigates the properties of
the   parameter further using simulations. In this chapter, a visualisation of the relation-
ship between   and the mean change in longitudinal outcome prior to dropout is presented.
In Chapter 6, software is developed in R to carry out some diagnostic procedures for
this type of modelling. These methods are then applied to the framework of a real trial
dataset (MAGNETIC), which has not been previously done in statistical literature. In
Chapter 7, demonstrations of how to apply joint models in RCT scenarios are given. In
Chapter 8 we draw conclusions from the work by presenting the reader with further ideas
for research in the field of joint modelling.
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Chapter 2
Methods For Handling Missing
Data In Longitudinal Studies
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2.1 Introduction
In order to establish a successful method of missing data handling in a given RCT, it is
essential to obtain as much information as possible about potential missing data [2]. While
it is impossible to account for and be aware of all the properties of non observed data in a
trial, some inferences can be made [54]. In clinical trial literature, many di↵erent methods
of missing data handling methods have been proposed. While some methods are applicable
to a wider range of trial designs, the most suitable method for each RCT is dependent on
the unique properties of that trial [23]. A method that may be perfectly acceptable for one
RCT analysis may result in misleading conclusions for another [60]. In order to establish
which methods for missing data handling are appropriate in a given RCT, it is necessary
to categorise the missing data [54]. In this chapter, the current methods of missing data
handling are presented. However, as a prelude to this information, a description of the
common missing data classification is provided.
While many articles discuss the nature of missing data handling methods in longitu-
dinal studies [4, 24, 58, 59], no simulation study has been carried out which quantitatively
compares these standard methods with a joint model analysis accounting for dropout. The-
oretically the advantages and drawbacks of each missing data method can be discussed,
however to gain a fuller understanding it is necessary to observe the results of each method
being used in practice. To establish the impact of using di↵erent missing data handling
methods in a longitudinal analysis, a series of simulation studies based on MAGNETIC
data [47] are carried out in Section 2.4 to determine the extent to which di↵erent missing
data methods give di↵erent results.
Furthermore, an illustration of how joint modelling can be used in an RCT for handling
missing data is demonstrated through the analysis of the MAGNETIC data set. This trial
had a su cient amount of dropout (26.7%) to suggest that a complete case analysis alone
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may not be an accurate reflection of the true treatment e↵ect.
2.2 Classification of Missing Data
In general, missing data within a trial can be categorised as; Missing Completely at Random
(MCAR), Missing at Random (MAR) or Missing Not At Random (MNAR). [61].
2.2.1 Missing Completely At Random
Data are Missing Completely at Random (MCAR) if the missingness indicator is unrelated
to any inference that can be drawn from the dataset [59], [62]. In this case, the probability
of a value being missing is unrelated to both the observed values and the values that the
subject would have recorded had the data been available. An example of this is when
some measurements are lost by a clinician or an equipment failure has led to a patient
outcome not being recorded [63]. In both instances, the patient’s status is irrelevant when
considering the probability of missingness. Formulaically, let r be the missingness and
yobs, ymis be the observed and missing values within a dataset respectively. In this thesis
yobs is defined as the longitudinal values for each patient pre-dropout, and ymis are the
potential longitudinal readings post dropout. Missing completely at random data is defined
as [64]
Pr(r|yobs, ymis) = Pr(r).
In MCAR, the average intervention e↵ect is the same when an analysis is performed
with just the observed values as when no missing data is present. However, this may re-
sult in a significant loss of information and wider confidence intervals if the percentage of
missing data is high.
In practice it is uncommon that data are MCAR [65], and there are various issues
associated with determining whether data is MCAR after a patient has dropped out. By
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using simple t-tests, it is possible to test for the relationship between the values of ob-
served covariates and subject missingness. However, if no relationship is found between
any covariate value and the completion of the measurement schedule by a subject, this
only confirms that the data has missing properties equivalent to MCAR, which alone is
not su cient to assume MCAR data [4]. This di culty in establishing the MCAR mecha-
nism highlights the importance of encouraging clinicians to record the reasons behind each
patient’s missing data.
2.2.2 Missing At Random
In some cases when the missingness mechanism is not MCAR, data may be classified as
Missing At Random (MAR). In MAR data, the missingness is dependent on observed
values within the dataset [59, 61]. This can refer to baseline variables, covariate values,
or previous longitudinal measurements taken in the trial. For example, in some clinical
trials patients with a worse prognostic factor at baseline are less likely to complete the
measurement schedule in a study for reasons unrelated to the outcome of interest. This is
an example of MAR data. In terms of a mathematical formula, this is denoted [66];
Pr(r|yobs, ymis) = Pr(r|yobs).
In the case of MAR, the missingness is not dependent on the outcome itself, however
vital information is being lost by omitting the patients that had missing values [59] as the
patients included in the analysis may have di↵erent prognostic outcomes to those which are
omitted. This can lead to patients with a specific set of prognostic profiles being omitted
from the analysis in some cases.
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2.2.3 Missing Not At Random
If missing data is not classifiable as MCAR or MAR, the data is Missing Not At Random
(MNAR), also known as non ignorable. In the MNAR mechanism, the missing values are
not only dependent on the observed covariate values, but also of the missing non-observed
values themselves [59, 61]. An example of a trial with MCAR data could be one which is
designed to analyse the percentage of patients that have given up smoking. At the end of
the trial, those patients who have stopped smoking are more likely to disclose the result of
the trial than those who have failed to quit smoking. In a longitudinal framework, when
data is MNAR there is a link between the values post-dropout and the patient dropping
out. In terms of a mathematical formula, this denoted as [67]
Pr(r|yobs, ymis) = Pr(r|yobs, ymis).
For a trial with MNAR data some standard modelling methods of missing data handling
may be ine cient, and more sophisticated methods of analysis need to be employed as a
simple analysis may fail to compensate for important prognostic details [4].
This diversity of potential missing data should further emphasise the importance of
good trial design. While in recent years many techniques of missing data handling have
now been established, one of the initial aims within a trial should be to ensure that the
amount of missing data is minimised [60]. Furthermore, in many cases it is di cult to
classify the missingness within a trial, although this can be estimated with higher levels
of clinical information [23]. To ensure that a mishandling of missing data is avoided, tech-
niques should be discussed when the trial protocol is being constructed, as this will lead
to a more transparent statistical analysis.
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2.3 Methods for Missing Data Handling: Dropout in Lon-
gitudinal Studies
Longitudinal trials have an additional benefit when adjusting for missing outcome data,
as measurements recorded prior to dropout for those patients can be used to enhance
the accuracy of treatment e↵ect estimates [68]. Additionally, the individual complete
patient profiles for the outcome can be used as a predictive mechanism for those who did
not complete the measurement schedule. While intermittent missing data in RCTs can
also prove problematic, the focus of this thesis will be on missing data caused by patient
dropout. In this section, an overview of the methods of missing data handling used in RCTs
with longitudinal outcomes are presented, including methods of case deletion, imputation
methods and modelling methods. These methods are demonstrated using data from the
MAGNETIC trial.
2.3.1 Case Deletion
Case deletion is defined as the exclusion from an analysis of some individuals based on a
chosen property; which may be a prognostic factor or a feature of the data for each patient.
In the scenario where all patients that dropped out or had missing values are excluded,
this is known as a complete case analysis [4, 78]. This is based upon the assumption that
patients with missing values represent a random sample of the complete dataset (MCAR).
As an example, Figure 2.1 shows a potential longitudinal dataset:
Time (minutes)
Patient Number 0 20 40 60 120 180 240
1 3 4 7 6
2 8 3 1 4 6 2 3
3 1 5 6 5 6 3
4 3 4 7 6 9 8 8
Figure 2.1: Example Full dataset
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A complete case analyses would result in following data being analysed,
Time (minutes)
Patient Number 0 20 40 60 120 180 240
2 8 3 1 4 6 2 3
4 3 4 7 6 9 8 8
Figure 2.2: Complete Cases of Figure 2.1
where patients 1 and 3 excluded. In datasets with a low percentage of patients with
missing data, a complete case analysis may provide an accurate approximation to the ac-
tual treatment e↵ect [71]. However this method is less appropriate in trials where MCAR is
not a valid assumption. In particular, when higher percentages of missingness are present,
this method can lead to incorrect conclusions being drawn; for example in a trial where a
large number of patients drop out due to poor prognosis [73]. Also, the loss of information
when using a complete case analysis will have a substantial e↵ect on the power of the trial
and confidence intervals if the percentage of missing data is too high [4, 74].
2.3.2 Imputation Methods
In order to address the problems associated with case deletion, missing values can be
imputed prior to analysis. This involves substituting the missing values in a dataset for
predicted values based upon the observed data [4]. Data is then analysed using standard
methods. Imputation methods can be categorised as simple or multiple.
Simple Imputation Methods
In simple imputation, missing values are replaced with a single imputed value to generate
a full dataset [4]. This dataset is then analysed using standard techniques. Some methods
of simple imputation are outlined below.
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Last Observation Carried Forward The last observation carried forward (LOCF)
method takes the last observed value of a patient prior to dropout and imputes it for the
rest of the values until the end of follow up [4]. While this method may be appropriate
in the case of a chronic longitudinal outcome, in general LOCF fails to take into account
individual patient variation post-dropout, as the imputed values are only dependent on the
last available longitudinal reading. Therefore, the individual reasons for dropout are not
taken into account. Figure 2.3 is an example illustrating LOCF, where values are imputed
at 120-240 minutes.
Time (minutes)
0 20 40 60 120 180 240
Observed 3 4 7 6
Imputed 3 4 7 6 6 6 6
Figure 2.3: Last Observation Carried Forward
In RCT analysis, the aim is usually to find an overall distribution for the data rather
than focusing on individual patient profiles, and therefore using LOCF can lead to distorted
results and an underestimation of variance for an outcome when applied to an entire
dataset. [4,75,77]. However, if the majority of patients within a trial are at a steady state
prior to dropout or if a patients condition is believed to have stabilised post dropout, then
LOCF may be viable. Past literature suggests that LOCF is a commonly used method
despite its lack of flexibility to many di↵erent trial properties [78]. If data is MCAR, the
LOCF method would be inappropriate as this would induce bias [4]. A variation of the
LOCF method is the final observation carried backwards (FOCB) approach.
Best/Worst Value Imputation Unlike LOCF, some forms of imputation take individ-
ual reasons for dropout into consideration. In best value imputation, patients believed to
have dropped out of the study due to good prognosis will have their best observed longitu-
dinal reading imputed in place of the missing data. [78,79]. The flexibility of this method
allows it to be used both for patients who felt they were recovering at the time of dropout
29
and those that believe they have been cured completely.
Likewise if patients dropped out of the study due to poor prognosis, their previously
observed worst prognostic value is imputed. In order to ensure the correct justifications
for these imputation, the reasons for dropout should be verified within the study by a
clinician. In some trials a combination of the best and worst case scenario is used [79].
Figure 2.4 demonstrates this imputation method:
Time (minutes)
0 20 40 60 120 180 240
Observed 3 4 7 6
Best 3 4 7 6 3 3 3
Worst 3 4 7 6 7 7 7
Figure 2.4: Best/Worst Value Imputation
The issues with using this method are similar to that of LOCF, where its appropriate-
ness is based upon the specific prognostic factor in question. Without clinical justification,
this method can also provide confusing or misleading results due to the e↵ect on variance
that excessive imputation of best and worst values can cause.
Mean Value Imputation Mean value imputation can be implemented in one of two
ways; either by imputing the mean value of the patient’s longitudinal outcomes for the
missing values post-dropout, or by imputing the mean value of the longitudinal outcome
for each timepoint [4]. This method takes into account longitudinal outcome values prior
to dropout, but not the trend of each subject individually. Figure 2.5 illustrates the first
procedure of mean value imputation:
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Time (minutes)
0 20 40 60 120 180 240
Observed 3 4 7 6
Imputed 3 4 7 6 5 5 5
Figure 2.5: Mean Value Imputation using the mean of an individual’s observed outcomes
The first type of mean imputation results in the missing outcomes having no rela-
tion to any other covariate value for each patient. This will result in a reduction in the
variance estimates if the level of missing outcome data is high, or the data collected is
multi-dimensional. For a longitudinal analysis with a particular interest in the change in
outcome over time, this method may not be the most informative when applied to a full
dataset. In the case of discrete data where the mean imputed values do not result in integer
imputation, a decision must be made as to whether the values are rounded to the nearest
whole number or the mean is simply imputed.
Maximum/Minimum Value Imputation Maximum and Minimum value imputation
uses a similar mechanism as best and worst value imputation. After an individual has
dropped out from a study, either the maximum or minimum possible value is imputed post
dropout, depending on the dropout reason. For example, in the MAGNETIC trial, “9”
would be imputed for patients who dropped out due to poor status and “0” for patients
who dropped out due to good status, as these were the highest and lowest possible values of
the asthma severity [37]. This method can be used with data that has bounded outcomes,
as demonstrated in Figure 2.6. One patient in this figure dropped out due to poor status,
and another due to good status with a longitudinal outcome in the range of 0 to 9.
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Time (minutes)
0 20 40 60 120 180 240
Observed 3 5 7 8
Imputed by max 3 5 7 8 9 9 9
Time (minutes)
0 20 40 60 120 180 240
Observed 3 2 2 1
Imputed by min 3 2 2 1 0 0 0
Figure 2.6: Maximum/Minimum Value Imputation
As we would expect, the issues that arise when using this form of imputation are similar
to those mentioned for best/worst value imputation. Variance estimates can become skewed
when a large percentage of patients have values of one type imputed. Treatment e↵ect can
also be overestimated/underestimated if the number of dropouts due to positive/negative
status is disproportionate between treatment groups. For example, if a large number
of patients drop out for negative reasons in both treatment groups, this will result in an
underestimation of treatment e↵ect as patients these dropouts will all have the same values
imputed. Likewise, the opposite is true if the reasons for dropout were di↵erent in each
group, as the extreme positive and negative values will be imputed.
Multiple Imputation
Multiple imputation is a missing data handling technique conceived by Rubin in 1987 [80].
It involves replacing missing values with at least two potentially feasible sets of values.
This o↵ers a more flexible method of missing data analysis than simple imputation meth-
ods and also manages to address the issue of variability which is not covered by simple
methods [80]. Simple imputation methods generally overestimate the level of precision as
there is an omission of the between imputation variability component [81]. In order to
compensate for the uncertainty of missing data, multiple datasets can be generated and
the results pooled to give more accurate estimates [7]. As with simple imputation methods,
multiple imputation methods when poorly planned are likely to induce misleading results.
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While the concept of multiple imputation may not seem too appealing to the clinician
at times, as some may feel it is merely creating data, the subject is mature and rigorous
in it’s development. With the technological advances leading to a greater power of com-
putational software in the past few years, the generation of multiple imputed datasets has
become a more manageable procedure, with software such as R [46], SAS [76] and WIN-
MICE all having multiple imputation capabilities.
MICE is a commonly used variation of multiple imputation, as developed originally by
Van Buuren, Oudshoorn in 1999 [82]. It utilises an imputation algorithm which stochas-
tically draws from a distribution generated from the observed values of each variable in
order to provide multiple approximations for the missing data.
The MICE algorithm works as follows, [82], let X = {X1, X2, . . . , Xk} be the set of
random variables in a study, which can include outcome variables. All these variables
can have missing data. These are made up of the observed and missing components,
Xj = (Xobsj , X
mis
j ).
To impute, draw from the unconditional multivariate distribution of X, by assuming the
data is missing at random. The algorithm generates the estimates as follows:
• Set the counter a = 1.
• Draw values of Xmis,21 from P (X1|X12 , X13 , . . . , X1k).
• Draw values of Xmis,22 from P (X2|X21 , X13 , . . . , X1k).
...
• Draw values of Xmis,2k from P (Xk|X21 , X22 , . . . , X2k 1).
...
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• Draw values of Xmis,a+1k from P (Xk|Xa+11 , Xa+12 , . . . , Xa+1k 1).
...
This procedure continues until the values converge. A common occurrence is that this
algorithm is repeated 5 times to create separate imputed datasets. Applying the MICE
algorithm in practice requires the conditional distributions, from which the missing data
can be drawn, for each variable to be specified. These distributions are easily specified
when using linear modelling techniques. For the purpose of using MICE in a longitudi-
nal framework, the outcome measurements taken at each time point, Yi1, Yi2, . . ., can be
treated as separate variables. Each completed dataset is then analysed, with the estimates
pooled using standard methods. As the number of imputations in MICE tends to infinity,
the imputed complete model corresponds to a mixed model for linear regression based
imputation [85].
The flexible nature of this algorithm means that it is not limited to imputing only contin-
uous variables. For example, if a binary variable is being imputed then these values can
be drawn from a logistic regression model. Similarly there are many methods of drawing
from distributions for ordered categorical variables and discrete variables [86].
2.3.3 Modelling Methods
Linear Mixed Models
An alternative to case omission or imputation methods is simply by fitting linear mixed
models to the observed values in a dataset [87]. These models are a su cient method
of analysis in the case where the missingness mechanism is MAR, or missing data and
dropout percentages are low [87].
In this thesis, the focus will be on linear mixed e↵ects models with a random slope and
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intercept, which has the following form:
Yij = x1i(t)
0 1 + b1i + b2it+ ✏ij (2.1)
bi1 ⇠ N(0, 2z1), bi2 ⇠ N(0, 2z2), Cov(bi1, bi2) =  z12
✏ij ⇠ N(0, 2!ij).
In formula 2.1, the fixed e↵ects are denoted by  1, and the random e↵ects by b1i and
b2i. In general  1 is analysis specific, however for this thesis, as in Section 1.4.3 we define
 1 = {↵, 0, 1}, where ↵ is a time parameter,  0 is the intercept and  1 is the treatment
e↵ect of the longitudinal element.
Joint Modelling For Time-to-dropout
In Chapter 1 the concept of joint modelling of longitudinal and time to event data was
introduced in a general context. One advantage of this flexible method is that a longitu-
dinal outcome can also be modelled while accounting for dropout. In this case event time
is replaced by dropout time and statistical inferences can be made such that;
• Inferences about the longitudinal measurements being adjusted to compensate for
potential informative dropout based on treatment group.
• The distribution of dropout while compensating for longitudinal measurements.
• Analysis of how the model evolves with respect to the longitudinal measurements
and dropout.
The formulation specified by Henderson 2000 [10] can be used to jointly model a lon-
gitudinal outcome and dropout as described in Chapter 1, Section 4.3.
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2.3.4 Other Methods
As well as the imputation and modelling methods described in this chapter, there are
alternative ways of taking into account dropout that can be combined with any of the
above. Two of the most common are the Weighted Least Squares Method (WLSM) and
Sensitivity Analyses.
In the WLSM, weights are assigned to the complete cases with the purpose of reduc-
ing bias. All patients are allocated into subgroups based on their baseline readings and
response profiles so that each group contains patients with similar prognostic profiles re-
gardless of whether a patient completed the study. Prior to analysis, the individuals who
complete the study despite having a high probability of dropout can have a large influence
on the results using a weighting system. Greater details of how WLSM is utilised, as well
as the various proposed methods of weighting can be found in published literature. [83,84]
Alternatively, a sensitivity analysis assumes an uncertainty in the trajectory of patients
post-dropout. In a sensitivity analysis, a number of potential di↵erent scenarios are con-
sidered post dropout, and imputations are made based on these scenarios. The multiple
generated datasets are then analysed separately to determine whether the same conclusions
are reached in the di↵erent analyses, and the plausibility of each imputation is discussed.
An example of this in an RCT setting would to by generate the following 3 separate data
sets; 1) Patients that dropped out have the worst case value imputed post-dropout, 2) Pa-
tients that dropped out have the best case value imputed post-dropout, 3) Missing values
are imputed using LOCF. By observing the results from all 3 separately an uncertainty
analysis can be utilised to provoke a discussion of the overall e cacy of a treatment.
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2.4 Simulation Study
Throughout the chapter, emphasis has been made on the importance of choosing the cor-
rect method for missing data handling. Each choice of missing data handling method
should be discussed and justified extensively prior to analysis as an incorrect choice of
imputation method can lead to incorrect assessments of treatment e↵ect [69]. While the
optimal missing data handling method in an RCT is trial specific, some methods may be
more appropriate than others across a wider range of trial properties.
In the past, many reviews of missing data techniques have been conducted, although
very few of these discuss techniques in longitudinal trials exclusively. Of those that do, no
studies compare di↵erent imputation methods alongside joint modelling methods by using
real data to generate simulated datasets in a longitudinal environment. By applying impu-
tation methods to simulated datasets and comparing the results, it is possible to establish
the advantages and drawbacks of using each imputation method and look at how successful
each method is in estimating treatment e↵ect. In this section, a simulation study based
on the parameters of the MAGNETIC dataset is presented. This is something which has
not previously been published in statistical literature.
2.4.1 Simulating Data
Mimicking the MAGNETIC trial scenario, joint longitudinal and time-to-dropout data are
generated. The aim was to generate data for patients randomised to one of two treatments,
with four di↵erent percentages of dropout; 20%, 30%, 40% and 50%. By simulating data
using joint modelling methods, a higher probability of dropout can be given to patients
with a higher longitudinal profile which ensures that the data is not MCAR. 1000 datasets
were simulated for each percentage of dropout. Various imputation methods were then
employed to each data set, and separate analyses were carried out using linear mixed mod-
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els. The results were collected to establish how accurate each method was for estimating
the true treatment e↵ect  1.
Outcome data was simulated from a longitudinal mixed model with variables of time
(↵), intercept ( 0) and treatment ( 1) (see Section 1.4.3). Longitudinal timepoints were
set at 0, 60, 120, 180 and 240 hours in order to mirror the MAGNETIC follow-up time.
Event-time was simulated from the Cox proportional hazards model with a flat baseline
hazard, also based on MAGNETIC parameters [112]. This was then transformed into
dropout time, defined as the last time point prior to the event-time generated for each sub-
ject. To simulate data that mirrored the MAGNETIC trial (which will be demonstrated
in Section 2.5), we fixed ↵ =  0.0076,  0 = 5.617,  1 = 0.2 and   = 0.18.  2 =  0.5 and
the variances of (U1, U2) were set to 1.19 and 0.00003 respectively. The covariance between
the random e↵ects was set to 0 and the error variance was set at 0.5.
For these simulations, continuous outcome data was generated, as opposed to discrete
as in Magnetic, as we were interested in establishing the success of each method when mod-
elling a continuous longitudinal outcome. However, as one of the missing data handling
methods to be utilised was highest/lowest value imputation as employed in the MAG-
NETIC dataset, it was desirable for the longitudinal outcome in the simulations to be
within the range of 0 to 9. To achieve this range, values < 0 or > 9 were rounded to 0 or
9. To ensure that this modification had a negligible e↵ect on the true treatment e↵ect in
the analysis, 10000 preliminary datasets were generated and the percentage of outcomes
not in the desirable range was calculated. The average percentage of longitudinal values
not in the range of 0 to 9 was 0.072%. This was considered an acceptably low value, and
would have a negligible e↵ect on the simulated results.
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2.4.2 Methods
For each method of analysis and missing data handling technique, one of two models were
fit to the data. For complete cases and all imputation based methods, a standard longitu-
dinal linear mixed model was fitted with random slope and random intercept. The form
of this model is shown in Equation (2.1), with  1 = {↵, 0, 1} included as fixed e↵ects.
For the joint modelling analysis, a random slope and intercept joint model was fit to
the data as described in Equations (1.1) and (1.2) in Chapter 1, Section 4.3. Similarly, we
defined  1 = {↵, 0, 1} and  2 =  2 to model the hazard ratio between treatment groups.
The following descriptions detail how the missing data methods were applied:
• Complete Cases - Only patients with no missing data are included and a linear
mixed model was fit to estimate treatment e↵ect. .
• LOCF - Patients that dropped out had their last longitudinal value repeated until
the end of the study. The dataset was then modelled using the same linear mixed
model.
• High/Low Imputation - Patients with a longitudinal outcome of 4.5 or higher at
dropout had the value of 9 imputed for the remainder of the study, and likewise those
lower than 4.5 had 0 imputed. The data was analysed using linear mixed models.
• Mean Imputation - The mean value of the patients observed values were imputed
for patients that dropped out, and linear mixed models were fit.
• MICE - The missing values were multiply imputed 5 times via mixed modelling
techniques. Analysis was carried out using linear mixed models.
• Mixed Models - Only the observed values were fit using the linear mixed model.
• Joint Modelling - The parameters were estimated using the E.M. algorithm. De-
tails of how the joint model are fit have been provided previously in section 2.4.2.
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For the majority of the methods above, ready made code was available in R to carry
out the imputations. However, this was not the case for high/low imputation, so a novel
function was generated in R to employ these methods (see Appendix). To establish the
success of each method the mean estimate of  1, the mean square error (MSE), the mean
standard error and relative bias are calculated for  1. To calculate the standard error of
the parameter  1, standard methods are used for the linear models, and bootstrapping
methods are applied in the case of joint modelling. MSE is defined as
MSE =
P1000
i=1 ( ˆi1    1)2
1000
as data was simulated 1000 times in each setting, and i is the simulation number. Relative
bias is defined as the mean percentage of error in estimation of  1, with the mathematical
formula:      1    ¯i1 1
    ⇥ 100.
where  ¯i1 is the mean estimate of  1 across the simulations. The most successful methods
of estimation were those with low mean square errors and mean estimated treatment e↵ects
close to the true value.
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2.4.3 Results and Discussion
Table 2.1 displays the results for the simulations with di↵erent percentages of dropout.
The true value of  1 was 0.2. Figure 2.7 graphically shows the mean estimates of  1 and
the MSE of the treatment e↵ects for each missing data method.
Dropout Method Mean Estimate  ˆ1 MSE Standard Err. Relative Bias(%)
20% Complete Cases 0.2268 0.01147 0.1066 13.4
LOCF 0.2108 0.00967 0.0909 5.4
High/Low 0.2064 0.00931 0.0885 3.2
Mean Imp 0.2012 0.00944 0.0939 0.6
MICE 0.2028 0.00942 0.0927 1.4
Mixed Models 0.2030 0.00942 0.0921 1.5
Joint Modelling 0.2030 0.00941 0.0918 1.5
30% Complete Cases 0.2620 0.01852 0.1218 31.0
LOCF 0.2176 0.00983 0.0924 8.8
High/Low 0.2059 0.00911 0.0889 3.0
Mean Imp 0.2026 0.00994 0.0941 1.3
MICE 0.2040 0.00969 0.1054 2.0
Mixed Models 0.2048 0.00968 0.0932 2.4
Joint Modelling 0.2041 0.00966 0.0923 2.1
40% Complete Cases 0.2679 0.02105 0.1410 34.0
LOCF 0.2148 0.00992 0.0932 7.4
High/Low 0.1886 0.00860 0.0932 5.7
Mean Imp 0.1977 0.01016 0.0949 1.2
MICE 0.1970 0.00998 0.0935 1.5
Mixed Models 0.2031 0.01004 0.0951 1.6
Joint Modelling 0.2009 0.00992 0.0933 0.5
50% Complete Cases 0.2701 0.02326 0.1685 35.1
LOCF 0.2242 0.01031 0.0979 12.1
High/Low 0.1792 0.00851 0.0939 10.9
Mean Imp 0.2040 0.01035 0.1009 2.0
MICE 0.2016 0.01009 0.1002 0.8
Mixed Models 0.2046 0.01030 0.0974 2.3
Joint Modelling 0.1967 0.00995 0.0965 1.7
Table 2.1: Simulation Study Results
41
Figure 2.7: Mean treatment estimate and MSE for each missing data method
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When dropout was set to 20%, complete case analysis and LOCF methods yielded
the greatest overestimation of true treatment e↵ect. Similarly, the method of complete
case analysis has the highest MSE, indicating that this method performed the worst. The
lowest MSE resulted from a combination of highest/lowest value imputation, while mean
imputation methods displayed a mean treatment e↵ect estimate closest to the actual value.
Joint modelling methods performed well, with the second lowest MSE and a relative bias
of 1.5%. There did not appear to be a large variation in estimate of  ˆ1 for each method.
In the simulations with 30% dropout, the magnitude of overestimation of treatment ef-
fect was far greater in the complete cases than the previous simulation. The MSE was also
higher for the complete case analysis than the alternative missing data handling methods.
In general the MSE’s were higher than for the previous simulation, with the exception of
highest/lowest imputation, which had the lowest MSE. A mean imputation analysis yielded
the  1 estimate closest to the true value, while MICE, mixed models and joint modelling
methods also gave low relative biases.
In general, the high/low imputation method underestimated treatment e↵ect more than
the other methods in the simulation with 40% dropout, although this MSE was again the
lowest for these imputations. Joint modelling methods performed well, yielding the lowest
relative bias and a low MSE.  1 in a complete case analysis was on average overestimated
by 34.0%. LOCF methods resulted in higher relative biases than the other imputation
methods.
With a 50% dropout a greater range of results would be expected for the di↵erent
methods of missing data handling. However, in these simulations, MICE provided treat-
ment e↵ect estimates closest to the true value. Mixed models, joint modelling and mean
imputation methods also still performed well despite the high dropout percentage. When
observing the relative bias; a complete case analysis, LOCF and a combination of high and
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low imputation had considerably higher values than the other methods which may shows
that they performed poorly with such a high percentage of dropout.
When comparing the MSE and mean parameter estimate to the actual treatment e↵ect
(0.2), it can be observed that in general the high/low imputation methods, as used in
MAGNETIC, appeared to perform successfully with the lowest MSE across the 4 simu-
lation studies. However, in general the high/low imputation method underestimated the
treatment e↵ect for higher percentages of missing data which led to higher values of relative
bias. The slight overestimation of treatment e↵ect in general may be caused by di↵erent
percentages of patients dropping out in the treatment groups, and the fact that patients
with higher profiles were more likely to dropout. Despite the common use of the tech-
nique in many trials, complete cases as expected performed the worst, with LOCF also
performing comparatively poorly. With 30% dropout and higher, the mean estimation of
treatment e↵ect for a complete case analysis was a more than 30% overestimation of the
actual value.
Across all simulations joint models, MICE, mixed modelling methods and mean impu-
tation methods were the most consistent at estimating  1.
2.5 Application to MAGNETIC Data
As previously highlighted, the motivating dataset for this thesis came from the MAG-
NETIC trial which was introduced in detail in Chapter 1. Overall 26.7% of patients
dropped out from this trial, so a complete case analysis alone may not provide accurate
results of treatment e↵ect. In the primary analysis for MAGNETIC, ASS was found to be
significantly lower for patients randomised to magnesium at t = 60. In this section, a joint
modelling analysis is applied to MAGNETIC, which allows inferences to be made about
ASS, dropout and the relationship between these components.
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2.5.1 Exploratory Analysis
Figure 2.8 shows the mean longitudinal profiles of the ASS for the two treatment groups.
Figure 2.8: Mean Profiles of Asthma Severity Score for Magnesium (Black line), Placebo
(Red line)
The mean ASS was approximately the same between the treatment groups at baseline
(5.72 in the magnesium group, 5.75 in the placebo group), however the mean ASS became
marginally lower for patients in the magnesium group as time progressed. At the original
primary outcome of interest, t = 60, the severity score was 4.72 in the magnesium group
and 4.95 for patients randomised to placebo.
Figure 2.9 shows plots of the mean longitudinal profiles for patients that dropped out at
each time point, by treatment group.
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Figure 2.9: Mean Severity Score for Dropouts at each time point
Overall, the mean profiles showed that most patients had a decreasing ASS pre-dropout,
which indicates that the data is not MCAR. The mean ASS of patients randomised to mag-
nesium decreased prior to dropout for all time points, and magnesium randomised patients
that dropped out earlier in the study had a greater mean decrease in ASS. However, in the
placebo group, patients that dropped out at t = 20 and t = 40 had an increasing mean
ASS pre-dropout. This may be informative as treatment stopped being administered in
this study at t = 60. These results indicate that patients with a positive prognosis were
more likely to drop out.
2.5.2 Estimating the treatment e↵ect
To investigate the treatment e↵ect in the longitudinal context,  1, statistical models were
fit to the data and four separate methods of analysis were conducted; complete case, max-
imum/minimum imputation, MICE and joint modelling. For imputation methods and
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complete case analysis, the random slope and intercept linear mixed model from Equa-
tion (2.1) is fit, with the same fixed and random e↵ects parameters as described in Section
2.4.2. For maximum/minimum imputation, information was available about the reasons for
dropout from the trialists involved in this study. “9” was imputed for patients post-dropout
that withdrew due to poor prognosis, and likewise “0” was imputed for withdrawals due
to good prognosis, while patients where no details of reasons for dropout were given are
omitted from the maximum/minimum analysis
For the joint modelling analysis, the random slope and intercept model described was
fit as described in Section 2.4.2. In the dropout element, treatment e↵ect  2 was modelled
using the Cox-Proportional Hazards model. The results are presented in Table 2.2.
Model Parameter Estimate Std.Error p-value
Complete Case -  1 -0.1293 0.1112 0.2452
Maximum/minimum Imputation -  1 -0.1601 0.1107 0.1488
MICE -  1 -0.2132 0.1049 0.0332
Joint Modelling -  1 -0.2048 0.1041 0.0408
Joint Modelling -  2 0.5533 0.1789 0.0103
Joint Modelling -   -0.1823 0.0990 0.0318
Table 2.2: Analysis of MAGNETIC ASS
In the analysis, a complete case analysis and maximum/minimum imputation analysis
did not detect a significant di↵erence between the two treatments, which is not the case
when MICE and joint models are used. In both analyses with case deletion, the di↵erences
between the treatments was underestimated when compared to MICE and joint modelling.
Using joint modelling methods, it was determined that patients randomised to magnesium
had an ASS that was 0.20 points lower than in the placebo group, which was a statistically
significant outcome. The log hazard ratio was estimated at 0.55, and therefore patients
randomised to magnesium were more likely to leave the study. This appears to concur with
Table 1.1 in Chapter 1.   was also found to be significant and negative, which indicates that
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patients with a lower severity score were more likely to drop out, which is demonstrated
in Figure 2.9.
2.6 Discussion
In the simulation study, the joint model performed consistently well for all percentages of
dropout, with the MSE’s being low and the mean treatment e↵ect being approximately the
same across the simulations when compared with the other missing data methods. This
demonstrated that joint modelling can prove to be a useful tool when analysing longitudinal
data while compensating for dropout. Some missing data methods resulted in inaccurate
treatment e↵ect estimates for larger percentages of missingness. The study indicated that
a complete case analysis will often yield skewed or inaccurate results when non MCAR
data is present, particularly for higher percentages of missingness.
The diversity within the results of simulation study reinforces the importance of care-
fully selecting an appropriate missing data method in a trial. One advantage of conducting
a sensitivity analysis, in which multiple imputation mechanisms are applied to the post-
dropout data, is that the merits of each imputation method can be discussed and conclu-
sions drawn from the multiple analyses. By presenting the information from a sensitivity
analysis in an understandable way, the clinician is able to utilise the information to provide
more in depth results.
The MAGNETIC trial provided an opportunity to illustrate the joint modelling frame-
work in a trial with longitudinal data and a high percentage of dropout. The joint model fit
to the data estimated that patients randomised to magnesium had an ASS of 0.2048 points
lower than in placebo, which was a statistically significant di↵erence. However, due to the
small magnitude, the clinical significance of this result is something to be discussed by
trialists and physicians. The estimate of treatment e↵ect was found to be underestimated
48
by using a complete case analysis, and a statistically significant di↵erence was not detected.
Children randomised to magnesium were also found to be more likely to dropout from
the study. By modelling  , the negative estimate shows that patients were more likely to
leave the study if they had a lower severity score. This seems to indicate that children may
have been withdrawing from the study more frequently due to good status/the feeling that
their asthma symptoms had improved. A more detailed discussion of   interpretation is
presented in Chapter 5.
The simulation study results provide further evidence of the benefits of using joint
modelling analyses in clinical trials, as this method performed as well as imputation anal-
yses and mixed models. MAGNETIC was a perfect illustration of a trial which benefited
from an additional joint modelling analysis. By fitting this type of model, information was
gained which would have been more di cult to obtain by carrying out separate analyses.
In terms of the statistical literature, joint modelling is still a relatively new methodol-
ogy. Despite the advantages of using joint modelling some clinicians or statisticians may
be unaware of how to apply the model, and therefore it may be under-utilised in trials
which model a longitudinal outcome while some patients drop out. In the next chapter a
systematic review is carried out to establish just how often joint modelling and the other
missing data handling methods are used in trials with longitudinal measurements.
49
Chapter 3
A Review Of The Handling Of
Missing Longitudinal Outcome
Data in Clinical Trials
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3.1 Introduction
In the previous chapter, methods were presented that aim to counteract the problem of
missing data in RCTs with longitudinal measurements. In this chapter an investigation
is carried out to establish how often these methods are used in practice. The problem of
handling missing data is frequently highlighted in RCT literature [92]. In well designed
trials, measures are taken to ensure that the level of missingness is as low as possible,
however patient dropout is inevitable in most RCTs and high percentages of missing data
can prove problematic in establishing the true clinical e↵ectiveness of a treatment [71].
Since the last review of missing data handling techniques published by Wood et al. in
2005 [89], there has been significant development and progress in the area of missing data
handling. In Chapter 3, a systematic review is conducted to observe which missing data
handling methods are used in trials with longitudinal outcome data, published between
2005 and 2012. The work in this chapter has been published in the Journal of Trials [60],
and this article has been used to influence the missing data handling methods used in the
PEPTIDE randomised control trial [72].
By reviewing all trials published between July 2001 and September 2001 in four leading
journals, White, Wood and Thompson came to the conclusion that missing outcome data
was an issue that has failed to be addressed in an appropriate manner in many RCTs,
and that missing data was “often inadequately handled”. Of the papers in the study with
longitudinal outcomes, 17 out of the 37 (46%) used a complete case analysis to deal with
the missing data, which can yield misleading conclusions as demonstrated in Chapter 2.
Of the RCTs with missing longitudinal outcome data included in the study, 7 out of 37
(19%) papers used imputation methods. [89].
However, the majority of papers in the aforementioned review did not contain longi-
tudinal outcome data, and little research has been done into how missing data is handled
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specifically in RCTs with longitudinal outcomes. As establishing the reasons for missing-
ness within a trial and using appropriate methods based on this information is of utmost
importance, one of the primary focuses of this chapter is to assess the level of information
detailed about missing data within recently published RCT articles. Unlike previously
published systematic reviews of missing data handling methods, this chapter exclusively
focuses on trials with longitudinal outcome data. The results in this chapter motivate the
proposal of a four point plan in Section 3.4.2, which aims to provide a rigid guideline for
missing data handling in future RCTs.
3.2 Methods
This systematic review aims to establish how often the trialists reported the reasons for
missing data, and how the missing data was dealt with in the analysis. In particular, details
are extracted about the use of imputation methods in these trials; whether imputation was
used, and if an explanation for doing so was provided in the text.
Inclusion/Exclusion Criteria
Only papers that contained balanced repeated measures outcomes, and are described as
a “randomised control trial” in the abstract were included in this study. Papers that
were published from the years 2005 to 2012 were included and no restrictions were put
on journal. All papers that were not written in English, or had non human participants
as the subjects were excluded from the study, as well as any papers with only binary
outcomes being recorded longitudinally, as these require di↵erent techniques of missing
data handling.
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Definitions and Study Selection
For this study, dropout was defined as a patient having withdrawn from the trial, with no
more longitudinal readings until the end of the follow up period. While intermittent miss-
ing data is also an issue, the main focus of our extracted data will be on those individuals
who withdrew from each trial.
To identify potential papers for inclusion, MEDLINE (OVID interface) was searched
using the following terms; longitudinal randomi$ed controlled trial$ or repeated measure$
randomi$ed controlled trial$ or longitudinal RCT$ or the same searches with “controlled”
replaced by “control”. The papers identified also had to fall within the constraints of the
pre-specified eligibility criteria.
Of all the papers identified as eligible for this study, it was decided at the outset that
100 would be selected at random for inclusion due to time constraints. This was done in
order to ensure that there was a realistic number of papers for the time available allocated
within this thesis. This randomisation was done by ordering the papers alphabetically by
first authors surname, giving each of these papers a number, and then randomly generating
a sequence of the integers using the “random” function in the R statistical software. The
data was then extracted from each full paper in the order generated. If a paper was found
to be ineligible on closer inspection then the 101st paper in the sequence was added to the
study, and then the 102nd and so on. If less than 100 eligible papers were identified then
all papers were included.
When the extraction was carried out, 10 of the first 100 papers read were found to
be ineligible. Therefore a further 10 papers selected at random were read in full, and all
these were found to be eligible. Further details of this can be found in Section 3.3 and the
CONSORT diagram in Figure 3.1.
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Data Extraction
For each RCT, data was extracted relating to the general characteristics of the trial, as
well as more specifically the details relating to missing data handling. For the missing
data handling methods, the main focus was those used for patients that dropped out. The
nature of the longitudinal data; the number of longitudinal time points and whether a
primary longitudinal outcome was recorded were extracted. As the need for imputation
based methods is greater for larger amounts of missing data, details of the percentage of
completing patients were extracted from each trial. The imputation methods used in each
study were recorded, as well as the level of explanation for using the chosen method for
missing data handling, and whether each trial recorded reasons for dropout within a study.
As an extra analysis, an assessment was made as to whether the methods for missing
data handling used were appropriate in each paper based upon the description of the ob-
served and missing data, the justifications provided by the authors and the percentage of
missingness. In the cases where this was unclear, my first supervisor was consulted for an
additional opinion.
Additionally, the presence of a statistician as one of the authors of the study and the
software used for the analysis was also extracted. Finally, for the papers that used im-
putation, information was collected about whether a comparison was made between the
complete case and imputed datasets, as well as whether these analyses yielded di↵erent
statistical conclusions.
3.3 Results
Our search identified 882 articles, and abstracts were screened for potentially eligible pa-
pers. A total of 381 papers appeared to be eligible for inclusion from the abstract. After a
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randomisation of the order of these papers, a further 10 of the first 100 papers were found
to be ineligible due to the unbalanced nature of their longitudinal readings, after reading
the full articles. A CONSORT diagram of the progress is shown in Figure 3.1.
Figure 3.1: CONSORT diagram showing inclusion of papers in the study
Methods of Imputation
Data was collected from papers from a wide range of di↵erent medical areas in order to
investigate how missing data was handled in practice for randomised control trials with
longitudinal measurements. The most popular medical areas were mental health (13%),
cancer (11%) and rheumatology (10%). Greater detail of the properties of these trials is
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provided in Table 3.2, and Table 3.1 lists the primary method of imputation for missing
data handling within each trial.
Primary Approach to Analysis Papers
Complete Case Analysis 32 1
Mixed Models 18
Simple Imputation
LOCF/FOCB/Baseline Carried Forwards 9
Average Value either side Imputed 1
Simple Algorithmic Based Imputation 1
Mean of other patients values imputed 1
Median values imputed 1
Multiple Imputation Methods 4
Other non-imputation based methods 2 14
Exclusion based on amounts of missingness 6
Exclusion based on reasons for missingness 1
No missing data 9
Unclear 3
Table 3.1: Method of Missing Data Handling
Of the studies reviewed, 9 trials had no missing data (9%), and 3 papers in the “Un-
clear” category made no reference to missing data in their articles (3%) and therefore the
level of missingness was unclear. Out of the 100 papers, 18 had used imputation (18%)
and only 4 had used multiple imputation (4%). One paper carried out a complete case
analysis as the primary method of missing data handling, but included an analysis based
on last observation carried forward (LOCF) as a secondary method. For the papers that
only included the complete cases, the most common methods of analysis were variations
of ANOVA or ANCOVA in 13 trials (13%), mixed modelling in 6 trials (6%) , t-tests for
mean comparison in 5 trials (5%) and linear regression modelling in 4 trials (4%).
The most common method of simple imputation used was LOCF, or a variation of
1One paper which used a complete case analysis, also used simple imputation as a secondary analysis.
In Table 3.2, this paper is included in the simple imputation section.
2e.g Comparison of means, t-test, RMANOVA
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this method. LOCF was used in 8 papers (8%). The clinical topics in these papers
were QoL based on moral support in patients with depression, chronic muscle based neck
pain, chronic arm pain due to repetitive use, shoulder pain in stroke patients, outcomes
in COPD (Chronic Obstructive Pulmonary Disease), stress levels in arthritic patients,
amount of sleep in patients with chronic insomnia and number of behavioural disturbances
in patients with dementia. In one trial, the baseline value was carried forward to impute
outcome data at 2 and 6 months for patients with missing values. LOCF may be a reason-
able method if patients are in a steady state closer to the time of dropout. Of the papers
that used simple imputation as a primary method of analysis, 5 trials used t-tests for com-
parison of means (36%), 5 used linear mixed models (36%), 3 used a variation of ANOVA
(21%) and 1 used chi-squared test (7%). Of the 4 trials that used multiple imputation
methods, 2 used mixed modelling, 1 used linear regression modelling and 1 used t-tests as
the primary method of analysis.
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Explanation of the reasons for using the statistical methods for handling
missing data
It was found that 37 (42.0%) papers with missing values made comments on why they had
used their particular missing data handling method of choice. The level of explanation
ranged from one line statements about the e ciency of the chosen method, to multiple
page descriptions of di↵erent missing data methods and the merits of each.
Of the 88 papers in which missing data was present, 51 (58.0%) provided no explana-
tion of the reasons for the missingness methods used. All 4 papers that employed multiple
imputation methods provided explanation of the reasons for their use. Out of the 14 pa-
pers that used simple imputation methods, 7 (50%) gave explanation of the reasons for
their choice of imputation. 26 out of 70 (37.1%) papers without imputation explained the
reasons for the missing data handling method chosen. For the papers with no missing data,
1 of the 9 (11.1%) discussed potential missing data methods with a view to suggesting how
the missing data would be analysed if some had been present.
Was a statistician involved in the analysis?
Out of the 88 papers with missing data, 30 (34.1%) had a statistician cited as one of the
co-authors of the study. Results indicated that there was little di↵erence in the levels
of explanation of the missing data methods used when a statistician was co-authoring a
paper. 13 out of the 37 (35.1%) papers which justified their missing data methods had a
statistician present, compared to 17 out of 51 (33.3%) papers which failed to explain the
reasons for their chosen method.
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Number of Publications by Year
It was assessed whether a greater number of papers had used imputation in recent times.
Figure 3.2 shows the number of trials using imputation methods for each year.
Figure 3.2: The number of papers using each imputation method by year
No papers published before 2009 that were included in the study used methods of
multiple imputation, and the majority of simple imputation based papers were published
in the last three years. This could indicate an increase in a recognition and awareness of
the benefits of using imputation within the past few years.
The use of imputation methods based on the percentage of completing
patients within the study
With larger percentages of missing data, there is a greater potential for bias if non-
completing patients are ignored within the analysis. Figure 3.3 is presented to show the
number of patients using each missingness method based on the percentage of completing
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patients.
Figure 3.3: The number of papers using each imputation method by percentage of com-
pleting patients
Out of the papers with a clear definition of the methods for handling missing data, 12
(12.3%) did not mention the percentage of completing patients. 11(68.8%) papers with
less than 70% completing patients used no imputation methods. In general, trials with less
than 10% patients dropping out rarely used imputation methods.
Were the reasons for dropout recorded?
The level of information given for dropout in each study was assessed by putting each paper
into one of the following categories; “Yes” is defined as detailed discussion on missingness
or reason for dropout, including a record of the number of people that dropped out and the
specific reasons for dropout recorded at each time point. “Partial Information” is defined
as being less detailed with some reference to the reasons for dropout, but not necessarily
indicating the number of patients at each time point or providing specific medical reasons.
Papers in the “No” category provided no details of the reasons for missing data.
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Table 3.2 shows that 35 (39.8%) papers fell in to the “Yes” category, providing sub-
stantial and detailed reasons for the missing data of each patient. In 25 (28.4%) cases, the
details of reasons for dropout could be categorised as “Partial Information”. 28 (31.8%)
of papers failed to provide any reasons for patients dropping out. There was not found to
be an increase in the quality of missing data reporting for more recent studies with 8 out
of 29 papers (27.6%) published in 2011/2012 providing detailed reasons for missing data.
Where no reasons were recorded for missing data, 7 out of the 28 (25.0%) papers made
an attempt to explain the reasons for missing data handling method used. For the papers
that had some reference to reasons for dropout, 30 out of 60 (50%) made an attempt
to explain the reasons for their chosen method of missing data handling. However, the
majority of these papers provided a justification of the general statistical benefits of the
methods they applied, while few referenced the specific prognostic factors and potential
dropout reasons unique to the trial in question.
Assessment of the appropriateness of the missing data methods used
The reasons provided for the use of each missing data method within the 100 papers was
extracted, and the appropriateness of each method was assessed on a trial by trial basis. Of
the 37 papers that attempted to explain the reasons for the chosen missing data method,
19 (51.3%) had provided su cient detail and justification for their choice. For 5 papers,
it was unclear whether the justifications provided were enough for this systematic review
when simply observing the published paper, as the appropriateness was dependent on some
features of the specifics of the trial dataset. In 13 (35.1%) of the cases it was felt that the
justification provided was insu cient for the method used. In many of these cases, the
author provided general advantages of the missing data method, but failed to acknowledge
the specific details of the trial in question e.g. “certain relatively simple methods can be
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appropriate” referring to a complete case analysis when the trial in question has a high
percentage of missing outcome data. While this justification may be appropriate in some
trials with low percentages of missing data, despite the explanation being vague, it disre-
gards the fact that the trial in question had over 30% missing data.
Table 3.2 shows an assessment of whether the missing data handling methods used in
each RCT were appropriate. In 44 (50%) of the articles where the methods were clear, it
was established that the method used to handle missing data was appropriate, e.g. LOCF
method for missing data being used in a trial where there was a steady state outcome. It
was di cult to determine the appropriateness in 14 (15.9%) of the papers, e.g. trials where
the amount of, or nature of missing data was not recorded in the paper. In 30 (34.1%) of
the papers it was decided that the method used was not appropriate, e.g. a trial with high
percentages of missing data that used a complete case analysis.
In all cases where multiple imputation was used, this appeared to an appropriate
method. There were 13 (40.6%) which used a complete case analysis where the percentage
of missing data was too high (over 10%) to justify. It was concluded that the majority of
papers which used mixed models without imputation and simple imputation methods as a
form of missing data handling were justified in doing so.
There were some unexpected trends when observing general trial characteristics in
relation to the appropriateness of a missing data method. For example, Figure 3.4 demon-
strates whether an acceptable method was used based on the number of patients in the
trial.
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Figure 3.4: The number of papers using appropriate methods by number of patients
Overall, the categories of 0-100, 201-300 and more than 400 patients had the highest
proportions of appropriate missing data methods used. There was a disproportionately
high percentage of RCTs which used inappropriate missing data handling methods with
between 101 and 200 patients randomised. The majority of papers for which it was di -
cult to assess the quality and appropriateness of missing data handling methods had fewer
patients (between 1 and 100), while this was less of an issue for larger trials.
Figure 3.5 shows the relationship between the number of longitudinal time points, and
the acceptability of the missing data method.
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Figure 3.5: The number of papers using appropriate methods by number of longitudinal
timepoints
From Figure 3.5, it is observed that a high percentage of inappropriate missing data
handling methods were used in studies with only three time points. This may be due to tri-
alists not considering missing data methods for trials where less outcome data is presented.
This was less of an issue for the trials with 4 or more time points. The only exception was
in trials with 6 time points, although there were few studies in this category.
There appeared to be no di↵erences in preference of missing data handling method
or levels of justification for di↵erent countries of publication. In all the most popular
clinical areas of study within this review there was at least one paper which did not use
an appropriate method of missing data handling, and In the area rheumatology, 5 out of
9 (55.6%) of papers used an inappropriate missing data handling methods, as detailed in
Table 3.2.
Imputed datasets as a comparison to non-imputed data
Out of the 18 papers that used imputation methods, 11 (61.1%) made no reference to a
comparison between the complete case analysis results and the imputed dataset results.
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Of the 7 papers that made the comparison, 2 (28.6%) of them yielded di↵erent clinical
conclusions about treatment e↵ect when complete case analysis was compared to one of
the imputed datasets, although one paper only provided the details of this di↵erence for
the purpose of illustration. One of the 2 papers (mental health) had 43.2% dropout, and
reported the p-values for treatment comparison using the complete case (p=0.428), mean
imputation (p=0.360), LOCF (p=0.026), and multiple imputation (p=0.426). The treat-
ment e↵ect was significant when LOCF was used but not when other imputation methods
were used. However, in this case the authors suggested that LOCF was not an appropri-
ate method to use for missing outcome data in their trial. The authors suggested that
LOCF exaggerated the di↵erence between the treatment groups over time, due to the
“non-random pattern of missing values” [98]. Therefore no di↵erence in treatment e↵ect
was concluded. The second study, also in mental health, stated that there had been a
di↵erence in conclusion without presenting both sets of results. Both of these papers had
less than 70% of patients completing the study.
3.4 Discussion
3.4.1 The Extent of Missing Data Handling and Use Of Imputation
Methods
In the CONSORT statement, point 13b. states “for each group, losses and exclusions after
randomisation, together with reasons” should be included within the trial report [97]. De-
tails of this nature were not presented in a large proportion of articles within the study. It
is di cult to suggest a gold standard for missing data handling as the appropriateness of
a method is dependent on the unique nature of missing data within each individual trial.
However, by carrying out a complete case analysis or eliminating certain patients based
on level of missingness assumes that the data is missing completely at random. This is
rarely, if ever the case in practice [4]. Therefore it was disappointing to see that 39 out
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of 88 (44.3%) RCT analyses excluded certain patients from the analysis. As 32 out of
88 (36.4%) papers used a complete case analysis, this represents a decrease in the use of
this method since the study by Wood, White and Thompson in 2004 [89]. Greater under-
standing of the benefits and methods of multiple imputation have been developed in recent
years. However, only 4 papers within the study used multiple imputation, with the evi-
dence suggesting that statisticians are more frequently using simple imputation methods.
One positive sign is that the trends suggest that there are a greater number of papers in
the past few years using multiple imputation methods. It was also interesting to discover
that having a statistician involved within a trial investigation didn’t appear to have an im-
pact on the choice of imputation method, or the level of justification for the chosen method.
One factor in determining the optimal missing data handling method in a trial is the
percentage of missing data. The systematic review published by Wood, White and Thomp-
son [89] found that imputation was more frequently used in papers with larger amounts
of missing data. The updated systematic review in this chapter shows that while papers
with a lower percentage of dropout appeared to be less frequent in their use of imputation,
there was a large amount of papers with high levels of dropout that did not use imputation.
In particular, 11 out of the 16 (68.8%) papers with more than 30% used no imputation
methods. Additionally, 30 (33.0%) of papers used inappropriate missing data handling
methods, and 13 (35.1%) of the papers that attempted to explain the reasons behind their
choice of method provided an inadequate justification.
For the benefit of clarity, one suggested technique is to present imputed dataset results
alongside the results for just complete case analysis. This was done in 7 out of 18 (38.9%)
papers with imputation methods used. Out of these 7 papers, 2 studies yielded di↵erent
conclusions when some of the imputed results were compared to the complete case; both of
these papers had over 30% dropout. One of the two papers in particular used a multitude
of imputation methods, and a significant treatment e↵ect was given when LOCF is used.
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While LOCF was not selected as an appropriate missing data handling method of analy-
sis in this paper, this illustrates further how an incorrect choice of missing data handling
method can influence the results.
The discussions within this paper have been largely directed towards appropriate meth-
ods of statistical analysis, with a particular emphasis on the use of imputation. Missing
data becomes less of a problem when larger amounts of information can be obtained on
the patients that dropped out. When possible in trials with longitudinal measurements,
clinicians and trialists should ensure that the trial design considers the potential for miss-
ing data arising in the study and aims to take precautions to try reduce the amount of
missingness within a study.
3.4.2 Guidelines for Missing Data Handling - The Four Point Plan
As the issue of missing data in general is not addressed in great detail in the CONSORT
statement, it may be of use to suggest the following guidelines in order to formalise a
procedure of missing data handling. This is with the interest of ensuring we are obtaining
accurate prognostic conclusions by not failing to recognise the problems that come with
ignoring missing data within a trial.
• Within a trial the reasons for missing data, and more specifically the reasons for
dropout, should be reported in detail. This can be defined as each individual patient’s
reason for dropout being recorded within the study.
• After assessing these reasons for missingness, detailed discussions should be had as
to the methods that will be used for missing data handling.
• These methods should then be justified within the report, and their potential limi-
tations described.
• When the final analysis is carried out, any imputed dataset results should be pre-
sented alongside the complete case analysis results.
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3.4.3 Missing Data Handling in the MAGNETIC Trial
For an example of how missing data could be handled in a trial, the MAGNETIC trial
provides a good demonstration [47]. This trial clearly stated its aims, and the reasons for
patient dropout was recorded when possible. Once these reasons were assessed, suitable
methods were chosen and results were presented for the complete case analysis, as well
as using missing data methods. One particular method employed in this trial which was
not used in any of the papers included in this systematic review is “joint modelling of
longitudinal and time-to-event data.” The benefits of this method have been highlighted
in Chapter 2.
By following the example of the MAGNETIC trial, and the 4-point plan proposed, it
can be ensured that trialists do not allow the missing data to be a catalyst for inaccurate
conclusions within randomised control trials with longitudinal readings.
3.4.4 Limitations
Within any systematic review study there may be potential biases which we have done
our best to avoid. This potential bias may be increased by randomly selecting a subset
of papers, however we felt that this was a more informative method than selecting only
papers from high impact journals. The possibility was considered that higher impact jour-
nals may publish trials with greater detail of missing data. While little research has been
done to confirm or deny this, not putting a restriction on journal eliminated this potential
problem. Should more time have been available, it would be informative to assess the
missing data mechanisms of all 381 papers that were regarded as eligible. However, we
felt that the 100 included may have provided an accurate overview of the extent of the
problem of mishandling of missing data.
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3.5 Conclusion
This study indicates that a large proportion of papers fail to recognise the issue of missing
data, and many gave insu cient information to ensure that an accurate method of missing
data handling was used. The majority of papers failed to explain their reasons for the
method of missing data handling employed within their trial. As well as this, less than
40% of papers gave detailed reasons for the missingness. Collecting and presenting the
reasons for missing data can prove a valuable and important asset when establishing the
consistency of trials, as well as drawing accurate conclusions. There was very little con-
sistency in the levels that di↵erent trials considered the problems caused by missing data.
In general, a greater awareness is needed in order to ensure that clinical investigators can
obtain clinically accurate results from the trial in question by making informed choices and
using appropriate methods of missing data handling.
Joint modelling of longitudinal and time-to-event data was not used in any of the papers
included in this systematic review, despite the benefits highlighted in Section 1.4. Many
papers fail to address the issues caused by dropout appropriately so it could be recom-
mended that joint modelling should be employed more often. In the correct circumstances,
the amount of “guesswork” required when establishing successful handling of missing data
techniques can be reduced by using these models, and details of dropout can also be mod-
elled alongside the longitudinal outcome.
It is possible that the reason no identified papers used joint modelling is due to a lack of
awareness or understanding of the model, or that some important trial design properties for
joint models are yet to be addressed in detail in published literature. In the next chapter,
we focus on the methodological and trial design aspects of joint modelling by investigating
sample size and power calculations for the random slope and intercept joint model.
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Chapter 4
Sample Size and Power
Calculations in Joint Modelling
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4.1 Introduction
In Chapters 1 and 2, a methodology for joint models has been presented and the benefits
of applying these methods to simultaneously monitor a longitudinal outcome and dropout
has been justified for certain trial designs. In the field of joint modelling, the published
literature has focused primarily on the development of model specifications [42], [44], [10],
while the topic of trial design for joint longitudinal and event time outcomes is rarely dis-
cussed. When planning a trial to be analysed using joint modelling methods, the same
design considerations should be addressed prior to a study as with any other type of statis-
tical analysis [1]. In particular it is important to generate a sample size which ensures that
enough individuals are included in the study to detect a clinically significant di↵erence,
but that also minimises the risk of patients being unnecessarily exposed to an experimental
treatment [99].
Currently, there are several sample size formulae derived in literature for separate lon-
gitudinal and time-to-event data. A summary of the work done in the area of longitudinal
data is highlighted in Diggle (2002) [22], while Schoenfeld [100] originally derived a sample
size formula for the Cox-Proportional Hazards model in 1983, with the other developments
and specifications since presented in Therneau and Grambsch (2000) [101]. However, for
models which account for both types of data, greater considerations must be given when
deriving and estimating the power and sample size within a study.
While Chen et al (2011) [48] derived a sample size formula for the estimation of overall
treatment e↵ect in the general polynomial joint model [48], little work has been done on
the development of sample size formulae in joint modelling for other specifications. In
particular no sample size formulae or power formulae have been generated for the Hen-
derson et al. [10] random slope and intercept joint model, which is the primary focus of
this thesis. When fitting this model, there are generally three main parameters of interest;
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the longitudinal treatment e↵ect,  1, the time-to-event treatment e↵ect,  2 and the link
between the longitudinal and time-to-event outcomes,  .
The systematic review carried out in Chapter 3 showed that joint modelling of longitu-
dinal and time-to-event data is rarely used in practice. Currently, sample size calculations
for this type of modelling are done using simulations [140]. However, this may be one of the
reasons that joint modelling is not used more often. Clinicians may be unaware of how to
conduct these pre-trial simulations or be put o↵ by what they perceive to be complicated
statistical programming.
For the Henderson et al. specification of the joint model [10] , no research has focused
on how di↵erent parameters and trial properties a↵ect the power for  1,  2 and  . In
this chapter, sample size formulae for   and  2 are derived for the aforementioned random
slope and intercept joint model using the distribution of the Rao score statistic [102]. Fur-
thermore, a discussion is invoked about the potential factors a↵ecting the sample size for  1.
Using a simulation study based on the parameters of MAGNETIC, the success of the
newly generated sample size and power formulae are tested, and the properties of the power
for  1 investigated. As a final task, the power for each parameter in the MAGNETIC trial
will be calculated.
4.2 Sample Size and Power for  2
Within the specification in Section 1.4.2, the time-to-dropout is modelled using a Cox-
Proportional Hazards model, in which  2 is defined as the estimate of the the log-hazard
ratio between treatments. Schoenfeld derived a sample size formula for  2 in a standard
Cox-Proportional Hazards model, which does not model interactions with a longitudinal
outcome monitored over time, and contains no patient specific random e↵ects [100]. To
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derive a sample size formula for  2 in the joint modelling context, we apply similar methods
to those used by Schoenfeld, by using the Rao score test to establish the distribution of
the Rao test statistic.
The longitudinal element of the random slope and intercept model can be written as
Yi(t) = X1i(t) 1 +W1i(t) (4.1)
where W1i(t) = U1i + U2it. The time-to-dropout is modelled by
 i(t) =  0(t) exp{X2i(t) 2 +W2i(t)}. (4.2)
The link between the latent parameters defined as W2i(tij) =  W1i(tij). We begin by
making the assumption that U1 and U2 have no impact on the power for  2, and address
the interactions with random e↵ects later in the chapter. While X2i(t) can generally
represent the individual patient values for a collection of variables, for the derivation of
sample size we can define X2i(t) as a binary indicator indicating the treatment group
and  2 is the corresponding treatment e↵ect as Schoenfeld demonstrated that the other
independent fixed variables will have no e↵ect on the power for  2 [100]. Therefore, for the
derivation let X2i(t) and X1i(t) be the same (the treatment indicator), so we denote this
as Xi(t). As the treatment is the same at all time points for each patient i, we can denote
this as Xi. Therefore rewrite (4.2) as;
 i(t) =  0(t) exp{Xi 2 +  (U1i + U2it)} (4.3)
We assume a two arm trial and label the treatments either A or B. Define PA to be the
probability that patient i is in treatment group A. In general, the score function is defined
by:
U (✓) =
dlogL(✓|x)
d✓
(4.4)
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for the parameter of interest ✓ (in this case  2) and data x. The Fisher Information is
given by
I(✓) =  E[ d
2
d✓2
logL(X; ✓)|✓] (4.5)
where L denotes the corresponding likelihood. The statistic to test H0 : ✓ = ✓0 is then
S(✓0) =
U (✓20)
I(✓0)
. (4.6)
This is asymptotically normal when H0 is true. Rao [103] also showed that this was
mathematically equivalent to testing S⇤(✓) =
p
S(✓), which follows a normal distribution.
The power and number of events required for  2 in a trial which uses joint models can be
established by finding the distribution of S( 2). The partial likelihood for Equation (4.3)
is
Li =
(
exp( 2Xk +  (U1i + U2it))PN
k=1 I(Sk  Si) exp( 2Xk +  (U1i + U2it))
) i
(4.7)
where N is the total number of patients in the trial, Si defines the event-time for patient
i and  i is the indicator function which is equal to 1 if an event occurred and 0 other-
wise [100].
From Schoenfeld and Chen [48,100], we can define Gi for any function g(X,Y ) as;
Gi{g(X,Y )} =
PN
k=1 I(Sk   Si) exp( (U1i + U2it))g(X,Y )PN
k=1 I(Sk   Si) exp( (U1i + U2it))
(4.8)
which is related to the partial likelihood with  2 = 0. It has been shown for Cox propor-
tional hazards models [100] that the score function can be written as
S( 2) =
N 
1
2
P
i2D{Xi  Gi(Xk)}
{N 1Pi2DGi{X2k}  (Gi{Xk})2} 12 (4.9)
where i 2 D denotes the set of subjects who experienced an event, and k = 1 . . . N .
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Now we define
ei(Xk) =
PN
k=1 I(Sk   Si) exp( 2Xk +  (U1i + U2it))XkPN
k=1 I(Sk   Si) exp( 2Xk +  (U1i + U2it))
(4.10)
This can be used to rewrite S( 2) as
S( 2) =
N 
1
2
P
i2D{Xi   ei(Xk)}
{N 1Pi2DGi{X2k}  (Gi{Xk})2} 12 (4.11)
+
N 
1
2
P
i2D{ei(Xk) Gi(Xk)}
{N 1Pi2DGi{X2k}  (Gi{Xk})2} 12
N 
1
2
P
i2D{Xi ei(Xk)} is asymptotically normal with mean 0 as it is the score function
of the partial likelihood, with variance equal to N 1
P
i2D ei{X2k}   (ei{Xk}2) [48]. As
in Schoenfeld, we can treat  2 as O(n
  12 ) [100]. Therefore ei{(X2k)} ! Gi{(X2k)} when
 2 ! 0, so therefore the first term of (4.11) tends to N(0,1) as  2 ! 0 [100]. Now focusing
on the second part of the numerator N 
1
2
P
i2D{ei(Xk)   Gi(Xk)}, using a Taylor series
expansion about  2 = 0 to the second order, it can be observed that the numerator
approximates to
ei{Xk} Gi(Xk) ⇡  2{Gi{X2k}  (Gi{Xk})2}. (4.12)
By substituting this into the second term, and simplifying with the denominator, it is
found that the second term approaches
 2
(X
i2D
{Gi{X2k}  (Gi{Xk})2
) 1
2
(4.13)
Initially, we derive a sample size formula based on the assumption that V ar(U2) has no
impact on the power, and adjust for this impact post-derivation. Therefore when  2 ! 0,
we find that Gi{Xk}! E{Xk}, and therefore Gi{X2k}  (Gi{Xk})2 ! V ar(Xk) = PA(1 
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PA), where PA is the proportion of patients randomised to treatment group A. Hence S( 2)
is asymptotically normal with a mean
 2D
1
2
(
1
D
X
i2D
PA(1  PA)
) 1
2
=  2(DPA(1  PA)) 12 (4.14)
and a variance 1 where D is the number of events.
Therefore [105], for a two sided test with significance ↵ and power  ,
 2(DPA(1  PA)) 12
1
⇡ z  + z1 ↵/2
and hence the number of events required for a two sided test with significance ↵ and power
  is given by:
D =
(z  + z1 ↵/2)2
PA(1  PA) 22
. (4.15)
This derivation makes the assumption that the parameters of U1 and U2 have no impact
on the sample size formula. It has been shown that independent and fixed non time-
parameters have no influence on this sample size, so by treating U1 in this way we can
rule out the sample size formula being a↵ected by U1 values [104]. However this may
not be the case for V ar(U2) as this introduced a time influence into the Cox-Proportional
Hazards element of the model. Therefore, the simulation study in Section 4.6 investigates
the e↵ect of varying V ar(U2) on the number of required events for  2. Investigations of
the power for a Cox-Proportional Hazards model which include a patient specific random
slope component has not been carried out in published literature.
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4.3 Sample Size and Power for  
In some cases, a trial may be focused on establishing a relationship between a given
biomarker and dropout [40], which can be attained by estimating  . More details of
the nature and properties of   will be provided in Chapter 5. So far, there have been no
derivations for the number of events required to successfully estimate the   parameter for
joint models.
In this section, a sample size formula is derived for the   parameter of the Henderson
et al. [10] specification. To do so, the score statistic for the Rao score test is derived and
the distribution is established. The time-to-dropout element of the model is defined as in
Equation (4.3). For the reasons highlighted in the  2 derivation, we can take  1 and  2 to
be the parameters for the treatment e↵ects in the longitudinal and time-to-dropout model.
Therefore, substituting (4.1) into (4.3) we can write:
 i(t) =  0(t) exp{Xi(t)0 2 +  (Yi    1X1i)}. (4.16)
As in the previous derivation, we can define a formulae for Gi(g(X,Y )) and ei(g(X,Y )).
In this case, in conjunction the derivation of Equation (4.15), define
Gi{Yk(Si)   1Xk} =
PN
k=1 I(Sk   Si) exp( 2Xk)(Yk(Si)   1Xk)PN
k=1 I(Sk   Si) exp ( 2Xk)
(4.17)
and
ei{Yk(Si)   1Xk} =
PN
k=1 I(Sk   Si) exp( (Yk(Si)   1Xk) + ( 2Xk))(Yk(Si)   1Xk)PN
k=1 I(Sk   Si) exp ( (Yk(Si)   1Xk) + ( 2Xk))
(4.18)
Therefore, the partial likelihood is derived as
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Li =
(
exp{ (Yi    1Xi) +  2Xi}PN
k=1 I(Sk  Si) exp{ (Yi    1Xi) +  2Xi}
) i
(4.19)
For the simplicity, we define Qk(Si) = Yk(Si)    1Xk = U1k + U2kSi. Therefore the
score statistic for the Cox’s partial likelihood is given by
S( ) =
N 
1
2
P
i2D{Qi(Si) Gi{Qk(Si)}}
{N 1Pi2D(Gi{Qk(Si)2} Gi{Qk(Si)}2)} 12 (4.20)
The score statistic S( ) can be written as
S( ) =
N 
1
2
P
i2D{Qi(Si)  ei{Qk(Si)}}
{N 1Pi2D(Gi{Qk(Si)2} Gi{Qk(Si)}2)} 12 (4.21)
+
N 
1
2
P
i2D{ei{Qk(Si)} Gi{Qk(Si)}}
{N 1Pi2D(Gi{Qk(Si)2} Gi{Qk(Si)}2)} 12
P
i2D{Qi(Si)  ej{Qk(Si)} is the score function of the partial likelihood Li defined in
Equation (4.19). Consequently the the numerator of the first row of (4.21) is asymptotically
normal with mean 0 and a variance equal to N 1
P
i2D[ei{Qk(Si)2}  (ei{Qk(Si)})2]. As
  ! 0, ei{(Qk(Si))q}! Gi{(Qk(Si))q} where q is any integer and therefore this first term
! N(0, 1). We expand the numerator of the second term in a Taylor series about   = 0.
This demonstrates that
ej{Qk(Si)} Gi{Qk(Si)} ⇡  {Gi{Qk(Si)2}  (Gi{Qk(Si)})2} (4.22)
so the second term approaches
 
(
DX
i=1
Gi{Qk(Si)2}  (Gi{Qk(Si)})2
) 1
2
. (4.23)
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If it is assumed that each treatment group is large, then
Gi{(Qk(Si))q} =
1
N
PN
k=1 I(Sk   Si) exp (Xk 2)(Qk(Si))q
1
N
PN
k=1 I(Sk   Si) exp (Xk 2)
(4.24)
! E{I(Sk   Si)(Qk(Si))
q}
E{I(Sk   Si)} (4.25)
Sk is independent of U1 and U2 when   = 0 and I(Sk   Si) is independent of Qk(Si)
conditional on Si. Therefore
Gi{(Qk(Si))q}! Ei{(Qk(Si))q} (4.26)
In conjunction with Equation (4.23), as   ! 0:
{Gi{Qk(Si)2}  (Gi{Qk(Si)})2}! V ar{Qk(Si)} (4.27)
Hence;
 D
1
2
(
1
D
X
i2D
{Gi{(Qk(Si))2}  (Gi{Qk(Si)})2
) 1
2
(4.28)
!  D 12
(
1
D
X
i2D
V ar(Qk(Si))
)
(4.29)
The variance of Qk(Si) can be calculated as
V ar(Qk(Si)) = V ar(U1k + U2kSi) (4.30)
= V ar(U1k) + V ar(U2k)E{I(t  tf )T 2}/⌧ + 2Cov(U1k, U2k)E{I(t  tf )T}/⌧
where T is the event or censoring time, ⌧ = D/N and E{I(t  tf )T},E{I(t  tf )T 2} are
truncated moments.
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Therefore S( ) is asymptotically normal with unit variance and the mean is equal to
 {D 2s}
1
2 . D !1. Therefore [105], for a two sided test with significance ↵ and power  ,
 {D 2s}
1
2
1
⇡ z  + z1 ↵/2
and hence the number of events required for a two sided test with significance ↵ and power
  is given by:
D =
(z  + z1 ↵/2)2
 2s 
2
(4.31)
where  2s = V ar(U1k) + V ar(U2k)E{I(t  tf )T 2}/⌧ + 2Cov(U1k, U2k)E{I(t  tf )T}/⌧ .
Due to the multiplicative nature of   and {V ar(U1k), V ar(U2k)} in the model, the
values of V ar(U1k), V ar(U2k) and Cov(U1k, U2k) are required to generate the sample size.
If these values are unknown, then Bayesian techniques as described by Tsiatis et al (1995)
can be used to estimate these variances and the potential sample size [40,48]. When U1 and
U2 are independent, then in Equation (4.31)  2s = V ar(U1k)+V ar(U2k)E{I(t  tf )T 2}/⌧ .
Estimates of the truncated moments E{I(t  tf )T} and E{I(t  tf )T 2} are also re-
quired to calculate sample size. In some trials with time-to-event or survival outcomes,
it is possible to obtain an estimate for these based upon previous literature. However,
when dropout is the event of interest estimates of the truncated moments can rarely be ob-
tained from previous studies, particularly when a new treatment is being tested in an RCT.
Therefore, we propose approximating E{I(t  tf )T} and E{I(t  tf )T 2}, by assuming
a discrete uniform distribution of T for the dropouts, such that patients are equally likely
to drop out at any point in the study. While this may not be the case in practice, and
time points will not always be equally spaced, this is su cient for generating an approxi-
mate sample size formula and investigating the impact of more time points on the power
calculations.
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Firstly we derive an approximation for E{Tdrops} for patients that dropped out, based
on the expectation of the generalised discrete uniform distribution [106], which is calculated
as the average of the first and last dropout point (0 and tf   tfntms 1), where ntms is the
number of time points.
E{Tdrops} =
0 + tf   tfntms 1
2
=
tf (1  1ntms 1)
2
As this is the expectation across the dropouts only, the expectation E{I(t  tf )T}
would be
E{I(t  tf )T} = ⌧
(
tf (1  1ntms 1)
2
)
(4.32)
The second truncated moment is calculated using E{T 2drops} = E(Tdrops)2+V ar(Tdrops)
from the definition of variance. For simplicity, let d =
tf
ntms 1 denote the distance between
the longitudinal timepoints in the study. Then, by the definition of the expectation and
variance of the generalised discrete uniform distribution:
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E{T 2drops} = E(Tdrops)2 + V ar(Tdrops)
=
⇢
tf   d
2
 2
+ d2
(ntms  1)2   1
12
=
⇢
tf   d
2
 2
+ d2
✓
(ntms  1)2
12
  1
12
◆
=
⇢
tf   d
2
 2
+ d2
✓
(tf )2
12
d 2   1
12
◆
=
1
4
(tf   d)2 + 112(t
2
f   d2)
=
1
4
((tf )
2   2tfd+ d2) + 112((tf )
2   d2)
= d2
✓
1
4
  1
12
◆
  tf
2
d+ t2f
✓
1
12
+
1
4
◆
=
1
6
d2   tf
2
d+ t2f
✓
1
3
◆
By substituting d =
tf
ntms 1 back into the equation:
E{T 2drops} =
1
6
✓
tf
ntms  1
◆
  tf
2
✓
tf
ntms  1
◆
+ (tf )
2
✓
1
3
◆
= (tf )
2
 
1
6
✓
1
ntms  1
◆2
  1
2
✓
1
ntms  1
◆
+
1
3
!
and therefore
E{I(t  tf )T 2} = ⌧
(
(tf )
2
(
1
6
✓
1
ntms  1
◆2
  1
2
✓
1
ntms  1
◆
+
1
3
))
(4.33)
using the same technique as in Equation (4.32).
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Therefore, sample size for   can be approximated by
Dˆ =
(z  + z1 ↵/2)2
 2s 
2
(4.34)
where
 2s = V ar(U1k) + V ar(U2k)
(
(tf )
2
 
1
6
✓
1
ntms  1
◆2
  1
2
✓
1
ntms  1
◆
+
1
3
!)
+ 2Cov(U1k, U2k)
8<:tf
0@
⇣
1  1ntms 1
⌘
2
1A9=;
To verify and investigate formulae (4.31) and (4.34), a simulation study is carried out in
Section 4.6 to test both the derived formula based on the data, and the approximation.
4.4 Sample Size and Power for  1
In many clinical trials with longitudinal data measured, the outcome of interest will be
the treatment e↵ect over time within a repeated measures setting [107–109]. However,
estimating the power or sample size for a longitudinal treatment e↵ect over time is gener-
ally reliant on some assumptions that are untestable prior to the trial commencing. Many
di↵erent sample size formulae have been proposed for longitudinal data alone [22,110,111].
In the previous chapter, it was shown that the most common method for analysis in lon-
gitudinal studies is to analyse the complete cases [60, 89]. In these trials, the approach to
sample size is to calculate the number of patients required in total and then increase the
number of patients admitted by a figure relating to the expected percentage of dropout.
However, even in simple longitudinal trials, assumptions must be made about the within
patient correlation in order to determine sample size [22].
Further complications arise when attempts are made to calculate sample sizes for trials
that employ more sophisticated methods than a complete case analysis. The wide range
84
of possible causes of missing data presents a challenge for alternative longitudinal designs
as the pattern of missingness can have an e↵ect on sample size [4]. Patients dropping
out, staggered or intermittent missing data and missed hospital visits are among many of
the potential reasons for incomplete data sets and making predictions about the nature of
missing data can be di cult prior to a trial commencing. Approaches for assessing sample
size and power calculations for longitudinal trials with missing data have been investigated
in published literature using Bayesian methods, frequentist based algorithmic concepts and
simulation studies for testing longitudinal treatment e↵ect [48].
When considering a derivation of sample size for  1 in the joint modelling context, there
are a number of variables to be taken into account. Due to the complexities, Rizopoulos
(2010) states that simulations should be used to calculate the required sample size [140].
However, this has not been done in practice for an RCT using the joint model defined
in Section 1.4.3. Also no investigations have been made into the factors which a↵ect the
sample size of  1 in the context of joint modelling, which is one of the aims of this chapter.
As a preliminary, Diggle et. al. 2002 [22] derived the following sample size formula for
standard linear mixed models:
N =
2(z1 ↵/2   z )2(1 + (ntms  1)⇢)⇣
 1
 
⌘2 ⇥ ntms (4.35)
where ntms is the number of time points, ⇢ is the assumed correlation between the re-
peated measures and  2 is the common variance between the two groups. Observing the
above formula it can be noted that in this setting, increasing the common variance and
assumed correlation between repeated measures will result in a decrease of power. Also as
⇢ < 1, a higher number of time points would result in a higher power for the same number
of patients, due to more information being available about the outcome variable.
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As highlighted above, more complex derivations have been used to handle missing data
when greater detail is available about the nature of the missingness, however sample sizes
for longitudinal designs are reliant on information that may not be available prior to a
trial commencing. Equation (4.35) serves to provide a basic motivation to establish the
e↵ects upon power for  1 in this study. In Section 4.5, a simulation study is conducted to
establish the e↵ect of varying di↵erent parameters and trial properties on the power of  1.
4.5 Simulation Study
A power and sample size simulation study is carried out based on the parameters of the
joint model as specified in Section 1.4.3. The main aims of this study can be categorised
as
• (a) Testing the accuracy of the previously derived sample size formulae.
• (b) Establishing an approximate relationship between power of  2 and V ar(U1)
• (c) Determining the factors that e↵ect the power for the longitudinal treatment e↵ect
 1.
• (d) Establishing the e↵ect of the di↵erent number of time-points on the power for
each parameter.
• (e) Estimating the power for each parameter of the MAGNETIC data when using
joint modelling.
Simulations will be generated for various di↵erent trial properties and parameter values,
and the corresponding powers for  1,  2 and   will be calculated.
4.5.1 Methods
Data is simulated based on the parameters of the MAGNETIC dataset in the joint mod-
elling framework using the same simulation methods as in Chapter 2.4.1, to mimic a two-
arm trial. Continuous longitudinal data is simulated from Equation (1.1) in Chapter 1,
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jointly with time-to-dropout using a flat baseline hazard and a random slope and intercept
model from Equation (1.2). Dropout was modified to be the last previous time-point prior
to the simulated event times. For these simulations, parameters are set to  1 = 0.2048,
 2 =  0.5 to mirror the MAGNETIC trial, and dropout is set at 20% by varying the
baseline hazard.
Di↵erent datasets are simulated by varying the number of patients, the number of lon-
gitudinal time points, the values of   and the variances of U1 and U2. The power is defined
as the proportion of these simulated datasets that yielded a significant result at the 95%
confidence level. Data is generated for n=200, 400, 600, 800 patients total in a trial with
an equal number of simulated patients randomised to each arm. The number of timepoints
in the study is set to ntms = 4, 6, 9 and   = 0.25, 0.5, 0.75, 1 for di↵erent simulations.
The follow up time, tf , was set to 240, and longitudinal time points were generated by
dissecting the interval of [0, 240], ntms times.
Simulated data was generated for 3 di↵erent combinations of (V ar(U1), V ar(U2)),
which are set to (1.19, 0.0003), (1.19, 0.00003) and (0.6, 0.00003). The second of these
is approximately the parameters estimated in MAGNETIC, with the other two varying
V ar(U1) and V ar(U2) respectively. For the analysis where V ar(U1, U2) = (1.19, 0.00003),
we let Cov(U1, U2) =  0.001, which was the approximate covariance between the ran-
dom e↵ects in the MAGNETIC analysis. In the other analyses, the covariance was set
to be the equivalent of this value for the given variances such that the correlation be-
tween U1 and U2 was the same for all simulations. Therefore Cov(U1, U2) =  0.0032 for
the set of simulations with V ar(U1, U2) = (1.19, 0.0003) and Cov(U1, U2) =  0.0007 for
V ar(U1, U2) = (0.6, 0.00003). The error variance was set to 0.5 for all simulations. For
each combination of trial properties, simulated data was analysed using the random slope
and intercept joint model, with confidence intervals being calculated using bootstrapping
methods with 1000 iterations for  1,  2 and  . Simulations were done using the CONDOR
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computing service for R in order to minimise amount of time required.
For  2, the empirical powers are calculated from the simulations by observing the pro-
portion of significant parameter estimates for di↵erent values of V ar(U2) and  . These
are compared to the expected powers estimated by Equation (4.15). This is with a view
to testing the validity of the formula, and establishing the impact of varying the random
e↵ects and   on the power of  2.
For   the empirical power calculated is calculated from the simulations in the same
way, and these are compared to the estimated power from Equations (4.31) and (4.34).
The aim is to test the accuracy of the derived formulae based on the both the uniform
approximation to the truncated moments (4.34) and the mean empirical estimate of the
moments (4.31). We will also establish the e↵ects of varying V ar(U1), V ar(U2) on the
power for  .
For  1, the empirical power for di↵erent simulation settings are generated, and these
are compared to the power generated by using a complete case analysis; the most common
method for handling missing data according to the systematic review in Chapter 3. This is
to establish the extent to which using joint models improves the power when estimating  1.
4.5.2 Results
 2 Results
Data was simulated, and the powers of  2 were calculated for three di↵erent combinations
of V ar(U). The results presented in Tables 4.2 - 4.5 show that as the variances of U2 were
increased, the power decreased. Varying V ar(U1) seemed to have a negligible e↵ect on
power, which coincides with the hypothesis given in Section 4.2. It can also be observed
from the tables that the number of time points in a study had no impact on the power for  2.
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In general, the formula for power given in Equation (4.15), which relies on the assump-
tion that   = 0, predicted a higher power than was given in the simulations. Similarly, the
power appeared to be inversely proportional to the value of  , as when   was increased,
the power of the trial decreased in the majority of cases. To investigate this relationship
further, the mean power over the three di↵erent numbers of time points was calculated
for each combination of   and V ar(U1), V ar(U2), as ntms was found to have no e↵ect on
power. Figure 4.1 shows the relationship between   and power for  2 in each simulation
when combining the powers for the di↵erent time points. The dotted line in the plots
indicates the power as predicted by Equation (4.15).
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Figure 4.1: Plot of  2 power against   by V ar(U) combination. V ar(U1, U2) =
(1.19, 0.0003)(black), V ar(U1, U2) = (1.19, 0.00003)(red), V ar(U1, U2) =
(0.6, 0.00003)(green)
In Figure 4.1 it can be observed that there is a greater loss in power, when compared to
the derived formula in Equation (4.15), for the simulations with a higher value of V ar(U2),
while the simulations in which V ar(U1) are varied yield similar results to each other. For
higher values of  , the loss in power is also higher. Furthermore, the reduction in power
appears to be greater between   = 0.75 and   = 1 than for small   values. Figure 4.2
shows the loss in power when comparing the empirical estimates to Equation (4.15) for
each V ar(U1, U2) combination.
90
Figure 4.2: Loss in power from predicted power for each V ar(U) combination.
V ar(U1, U2) = (1.19, 0.0003)(black), V ar(U1, U2) = (1.19, 0.00003)(red), V ar(U1, U2) =
(0.6, 0.00003)(green)
Figure 4.2 indicates that when   = 0, Equation (4.15) may have given an accurate
prediction of the power for  2. However, the formula gives an overestimation when   6= 0.
To compensate for this, Hsieh and Lavori (2000) [104] introduced a variance inflation factor
(VIF) to be estimated within a trial for survival analysis with non-independent covariates.
This can be estimated as D/D⇤ where D* is the number of events in a trial, and D is the
required number of events to obtain the power of the trial without considering the e↵ect
of other parameters on the variance (in this case, from Equation (4.15)). To investigate
the relationship between  , V ar(U2) and power further, the VIF for each simulation was
calculated compared to the estimated power. As V ar(U2) and   are multiplicative within
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the trial, V ar( U2) =  2V ar(U2). Figure 4.3 shows plots of the calculated VIF against
 2V ar(U2).
Figure 4.3: Power study for  2
From Figure 4.3 it can be observed that the relationship between VIF and  2V ar(U2)
appears to be approximately linear. Therefore, we fit a linear model to the above data
to investigate the relationship. Calculating the coe cients for this model to examine the
relationship between  2V ar(U2) and V IF showed that as  2V ar(U2) increased by 0.001,
the V IF increases by 3.773. The intercept was found to be 1.00305 ⇡ 1 as expected.
From the above simulations it can be deduced that for a follow up time of 240, an
approximate formula for the number of events required in Equation (4.15) can be modified
92
to
D = V IF
(z  + z1 ↵)2
PA(1  PA) 22
(4.36)
so
D ⇡  1 + 3773.3 2V ar(U2)  (z  + z1 ↵/2)2
PA(1  PA) 22
(4.37)
for a design similar to the MAGNETIC trial.
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  Results
Data was simulated and the results of power for di↵erent trial scenarios and di↵erent  ’s
were calculated. The results are shown in Tables 4.5 - 4.7. For each table, the calculated
power is compared to the estimate from Equation (4.31) using the truncated moments as
determined by the data and the estimate from Equation (4.34) using a uniform approxi-
mation for the truncated moments. The results show that V ar(U1), V ar(U2) and number
of time points all had an e↵ect on the power for  . In general, greater variances resulted in
higher powers for the simulated data. For V ar(U1, U2) = (1.19, 0.0003), powers were found
to be high, with the majority of empirical power being estimated as 100%. Therefore Table
4.7 lists the only power values that were less than 100. In this study, for the simulations
where V ar(U2) = 0.0003 the empirical powers were found to be substantially higher than
when V ar(U2) = 0.00003. The power was also greater when V ar(U1) was higher.
The change in power appears to be sensitive to the   parameter. For the simulated
results, in the majority of cases where     0.5 the power from the simulated data was
approximately 100%. The exception was when V ar(U1, U2) = (0.6, 0.00003) with 200
patients in the study, as shown in Table 4.5. Figure 4.4 shows a comparison of the simulated
power with the two approximations of power using Equations (4.31) and (4.34) for   = 0.25.
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Figure 4.4: Powers for   = 0.25. Black = Power from simulations, Red = Power calculated
from Equation (4.34) using approximate truncated moments, Green = Power calculated
from Equation 4.31 using actual value of truncated moments. The di↵erent line types
in Figure 4.5 indicate the combinations of V ar(U1) and V ar(U2) where (1.19, 0.0003) is
represented by a solid line, (1.19, 0.00003) by dashed lines and (0.6, 0.00003) by dotted
lines.
Figure 4.4 demonstrates that as the number of time points increased, there was a slight
increase in the power for   in most cases. The graphs indicate that the approximation
formula generally acted as a good predictor for the calculated power in these simulations.
In simulations with V ar(U1, U2) = (0.6, 0.00003), the simulated power was found to be
overestimated by the derived formulae in some cases. However, the majority of predicted
powers were within 3% of the empirical estimate.
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 1 Results
The results in Tables 4.8-4.11 show that for almost all   and variance combinations, higher
numbers of longitudinal time points resulted in an increase in the empirical power of the
study. This echoes the sample size formula for linear mixed models in Equation (4.35).
This was less detectable through the simulations for trials with fewer patients and greater
variances. In particular, for the second set of simulations (Table 4.9), there are some cases
where a the relationship between time points and power is di cult to detect. However, in
Table 4.11, which demonstrate the empirical power for trials with 800 patients total, there
is shown to be a strong correlation between these two properties. The value of   was found
to have no e↵ect on the power for  1. Figure 4.5 shows the mean power across all values of
  for each combination of V ar(U1), V ar(U2) and number of patients plotted against the
number of time points used in each simulation.
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Figure 4.5: Plot of mean  1 power across  0s against ntms by V ar(U1, U2) combination.
V ar(U1, U2) = (1.19, 0.0003)(black), V ar(U1, U2) = (1.19, 0.00003)(red), V ar(U1, U2) =
(0.6, 0.00003)(green)
Figure 4.5 indicates that when V ar(U2) is increased, this has little or no e↵ect on the
power for  1. However, this is not the case for V ar(U1), which results in a decrease in
power for higher variances. This decrease can be observed for all 4 sets of simulations
with di↵erent numbers of patients. The final row of Tables 4.8 - 4.11 show the results of
the powers calculated using only a complete case analysis. The powers when using joint
modelling were found to be higher than for a complete case analysis in all simulations.
Figure 4.6 shows the mean increase in power when compared to a complete case analysis
plotted against number of timepoints for all simulation properties.
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Figure 4.6: Increase in power for  1 compared to the powers for a complete case analysis.
V ar(U1, U2) = (1.19, 0.0003)(black), V ar(U1, U2) = (1.19, 0.00003)(red), V ar(U1, U2) =
(0.6, 0.00003)(green)
In general, there was a greater increase in power for larger values of V ar(U1). On
average there appeared to be a greater increase in power for larger number of time points,
although this was not the case for all simulations. In the majority of simulations, the power
when using joint modelling was at least 4% higher than for a complete case analysis.
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Simulated Power For MAGNETIC
We estimate the power within the MAGNETIC trial for each parameter. The primary
outcome for MAGNETIC was the di↵erence in treatment after 60 minutes, for which the
power was specified as 80% in the protocol. Data was simulated with 508 patients, 27%
dropout, V ar(U1) = 1.19 and V ar(U2) = 0.00003 to go with the MAGNETIC trial anal-
ysis. From the Henderson et al. specification of the joint model, longitudinal data was
generated for 7 di↵erent time points, namely t = 0, 20, 40, 60, 120, 180, 240.
Using bootstrapping methods for the 95% confidence interval and 1000 simulations,
the power for  1,  2 and   were calculated. The power for  1 based on the simulated data
was found to be 43.4%. The corresponding powers for  2 and   were 72.5% and 74.6%
respectively. The predicted powers based on formulae (4.37) and (4.34) were 72.0% for  2
and 77.2% for  , which indicated a reasonably successful approximation.
4.6 Discussion
In this chapter, the powers for  1,  2 and   parameters were investigated. A sample size
formula for   and approximate sample size formula for  2 was derived for the random slope
and intercept joint model. The sample size for   was found to be dependent on a number
of factors, including the pre-specified power, the number of time points and the covari-
ance matrix of U . Due to the nature of the model, knowledge of the variances of these
random e↵ects are required to derive the sample size formula in an RCT. This may seem
problematic, however, in many trials preliminary studies are carried out and these can be
used to approximate V ar(U1) and V ar(U2) prior to a larger scale trial. The simulation
studies in this chapter showed that these formulae provide accurate estimation of power.
Also, the proposed approximations for the truncated moments appeared to perform well
for estimating power.
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In the case of  2 for time-to-dropout, when   = 0, the power is only related to the
magnitude of  2, the proportion of patients in each treatment group and the number of
dropouts. As   increases for random slope and intercept models, the power decreases.
Also when   6= 0, the power decreases for higher values of V ar(U2), although the power is
unrelated to V ar(U1). To account for the loss in power, to calculate the power for  2 we
can combine Equation (4.15) with a variance inflation factor, as shown in Section 4.5.2.
The relationship has been verified for the MAGNETIC trial scenario with a follow up time
of 240, however more work has to be done to investigate the relationship for di↵erent trial
designs.
When the parameter of interest is the longitudinal treatment e↵ect,  1, using joint
models over the complete case analysis will increase the power in a trial and therefore
require fewer patients. Likewise increasing the number of time points will have a positive
e↵ect on power. Despite this clarification, with all the di↵erent factors to consider, the
best method of calculating the power for  1 is to use simulation methods.
In practice, the formulae proposed in this chapter will provide a useful aid for trial
design when using joint modelling. However, in order to accurately estimate the power
for  2 and  , a more concise definition of   must be available and the properties of this
parameter should be understood. In the next chapter, a visualisation of   is provided and a
detailed examination of the relationship between   and longitudinal outcome pre-dropout
carried out.
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Chapter 5
A Visualisation of the   Parameter
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5.1 Introduction
The majority of the work in this thesis has been based around a random slope and inter-
cept joint model, which utilises a latent Gaussian process to model the progression of a
longitudinal outcome over time alongside dropout. In Chapter 4, a sample size formula
was generated for the   association parameter. However, currently knowledge about the
properties of   is limited.
It has been established that RCT analyses with a negative   estimate contain patients
that are more likely to dropout with a lower longitudinal reading, while a positive   estimate
indicates that patients with a higher longitudinal reading are more likely to dropout [10].
Although this information is useful, it makes no comment about how the magnitude of  
is related to the change in longitudinal outcome of patients prior to dropout. Currently
no details of how to interpret the magnitude of the   parameter has been described in
clinical literature, however knowledge of the relationship between the outcome of patients
pre-dropout and   can be informative in a clinical environment.
Using two simulation studies, the aim of this chapter is to provide a visualisation of the
relationship between the magnitude of change in longitudinal outcome pre-dropout and
di↵erent values of  . The first study investigates the mean dropout profiles for various  ’s
based upon the parameters of the MAGNETIC trial. The second study aims to quantify
the relationship by using simulated data based upon a wider range of trial properties and
simulation parameters. A simulation study that focuses on the relationship between   and
the longitudinal profiles of patients prior to dropout has not been previously carried out
in statistical literature.
Information provided in Chapter 4 displays a need for greater understanding and con-
text to be given to the   parameter in joint models. This study aims to provide a useful
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overview of the properties of   for statisticians and clinicians employing a random slope
and intercept joint modelling analysis.
5.2 Mathematical properties of the   parameter
A definition of the random slope and intercept joint model is provided in Section 1.4.3,
with the longitudinal and time-to-event elements of the model defined in Equations (1.1)
and (1.2) respectively.
In this model, there are no multiplicative interactions considered between the fixed and
random e↵ects. Di↵erentiating the longitudinal element of the model yields:
dyi
dt
= ↵+ U2i. (5.1)
Therefore the change in longitudinal outcome for each patient is only estimated by ↵
and the subject specific slope random e↵ect. For this simulation study, the focus will be
models with no fixed time variable (↵). In this instance, change in longitudinal outcome
over time is only dependent on the U2 random slope parameter. In this case, U2i can be
defined as the mean increase in longitudinal outcome for each increase in unit time for
patient i.
Therefore, for the aforementioned specification, we can substitute U2i = y0i into the
time-to-event component of the model:
 i(t) =  0(t) exp{x2i(t)0 2 +  (U1i + y0it)} (5.2)
In the semi-parametric Cox-Model, the baseline hazards are uniquely calculated, and
are di↵erent depending on the trial dropout characteristics [112]. If the baseline hazard
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function is constant, the formula above indicates that as time increases by one unit, the
hazard for that patient increases by a proportion of e y
0
i . This means that the higher
the value of  , the more likely a patient with higher outcomes (values of U1 + U2t) are
to dropout. Similarly, a negative   indicates patients with decreasing outcomes are more
likely to dropout. As the nature of dropout is changing on an exponential scale,   is sensi-
tive. For example a   value of 5 will result in patients with the same positive values of U1
and U2 being
e5(U1+U2)
eU1+U2
= e4(U1+U2) times more likely to dropout as time progresses to t=1,
than if   = 1 and all other properties were the same. As another illustrative example, if U1
and U2 were both equal to 1, this would equate to a patient being approximately e5 ⇡ 148
times more likely to drop out at t = 1 than at t = 0.
As the both longitudinal and time-to-event outcomes are dependent on some random
e↵ects U1 and U2, the properties of the distributions of the latent variables have a direct
impact on the estimated value of  .
Due to the finite number of patients in a study and discrete time points, for higher
variances there are inevitably values of   which fail to make clinical or statistical sense.
For example it may be di cult to estimate in a trial of 500 people that a patient is
e10 ⇡ 22, 026 times more likely to leave a study as time increases by a unit time interval
(i.e. when   = 10), as there may not be enough patients to accurately determine this value.
Calculating the exact continuous mean profiles for patients that dropped out would require
an infinite number of time points, which is understandably not practical. Therefore, the
more time-points and patients available, the more accurate the estimate of  . Also, the
Gaussian and mean 0 nature of U1 and U2 will restrict the possible longitudinal values
pre-dropout for combinations of  , V ar(U1) and V ar(U2) as in the formula proposed by
Henderson et al [10], there is a multiplicative relationship between   and a combination
the random Gaussian variables.
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In order to understand the magnitude of  , the profiles of patients that dropped out,
the variance of U1, U2 and the percentage of dropout must all be taken into consideration.
The last of these is largely defined by the baseline hazard.
5.3 Simulation Study 1 - Methods and Results
The aim of simulation study 1 is to obtain a visual appreciation for the relationship be-
tween change in outcome pre-dropout and   parameter. For the first simulation study,
data is generated for a longitudinal outcome that also records an event. The event-time in
this simulation study is defined as dropout to remain consistent with the rest of this thesis.
Data is generated using the random slope and intercept Henderson joint model specifica-
tion outlined in Chapter 1.4.3, using similar techniques as in Chapter 2.4.1. Dropout was
generated from the Cox-proportional hazard based event-time and then transformed to the
last time point which was non-missing. As in the previous simulation study, the baseline
hazard was generally set to be flat unless stated otherwise and continuous longitudinal
outcome data was used.
In simulation study 1 datasets are generated by varying the   parameter while  1,  2,
V ar(U1), V ar(U2) and the percentage of dropout are fixed. For each combination of trial
properties, 1000 data sets are simulated. Data is generated based on the two arm MAG-
NETIC trial in order to discover and highlight the di↵erences in longitudinal profiles prior
to dropout depending on  .
For this simulation,  0 = 5.613 as the intercept and  1 =  0.2 are fixed, which were the
approximate parameter estimates for the MAGNETIC data. Similarly the variances of U1
and U2 were fixed at 1.19 and 0.00003 respectively. We set  2 = 0.5, dropout equal to 20%
by varying the flat baseline hazard and simulations are generated for   = 0, 0.25, 0.5, 0.75
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and 1. There was no necessity to simulate data for negative   as this would result in the
same magnitude of change in outcome prior to dropout as the corresponding positive value,
but with decreasing profiles. The error variance was set to 0.5.
The review in Chapter 3 demonstrated that 92% of the sample of the balanced longi-
tudinal RCTs had less than 8 time points recorded [60]. Therefore, simulated datasets are
generated for the common trial scenarios of 4,5 and 6 time points as well as 9 longitudinal
time points. The MAGNETIC trial had a follow up time of 240. To mirror this, time
points are generated by dissecting this into ntms = 4, 5, 6, 9 equal intervals. 1000 data sets
are simulated for each combination of   and number of time points for 500 patients per
group. Comparisons are made by observing the backwards longitudinal dropout plots for
all patients that left the study, with a view to identifying the key areas of variation in the
dropout profiles. This way the general trends of patients just before they left the study
could be clearly visualised.
Figure 5.1 shows the mean longitudinal profiles prior to dropout for the simulations
where   = 0, 0.25, 0.5, 0.75, 1 for 4,5,6 and 9 timepoints respectively.
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4 time points 5 time points
6 time points 9 time points
Figure 5.1: Longitudinal dropout profiles based on simulations;   = 0 (black),   = 0.25
(blue),   = 0.5 (red),   = 0.75 (green),   = 1 (yellow), Dropout = 20%
Figure 5.1 indicates that the magnitude of increase in longitudinal outcome prior to
dropout is proportional to the value of  . When   = 0, there is no discernible change in
patient profiles before leaving a study, while all other mean profiles show an increase over
time. The graphs representing simulations with a higher number of timepoints had greater
levels of longitudinal profile variation for di↵erent   values in the moments leading up to
dropout. For example, in the plot for ntms = 9 there is very little di↵erence between the
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dropout profiles shown for   = 0.75 and   = 1 before t =  90. The di↵erence between
the dropout profiles is also more evident for lower values of  , with the di↵erence in slope
between   = 0 and   = 0.25 being larger than between   = 0.75 and   = 1.
One key area of variation that should be investigated further is the di↵erence in lon-
gitudinal outcome in the last 2 timepoints leading up to dropout, for di↵erent ntms. In
Figure 5.2 the di↵erences between the last two time points for each group of simulations
are plotted.
Figure 5.2: Di↵erence in mean profile between last two time points
Figure 5.2 appears to show a clear pattern when observing longitudinal outcome change
immediately prior to dropout for di↵erent   values. The graphs demonstrate a larger
di↵erence in the change in longitudinal outcome between   = 0 and   = 0.25, than
for higher values of  . As   increased the di↵erences in change in longitudinal outcome
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decreased. This was the case for all variations of di↵erent timepoints. To compare the
results from each simulation for varying ntms, the normalised mean change in longitudinal
outcome per unit time was calculated by dividing the change in longitudinal outcome by
the distance between these last two points.
Figure 5.3: Di↵erence in mean profile between last two time points prior to dropout. The
di↵erent coloured dots represent the simulated data for di↵erent numbers of time points;
ntms = 4 (black), ntms = 5 (red), ntms = 6 (green), ntms = 9 (blue)
The graph in Figure 5.3 represents the mean change in longitudinal outcome per unit
time for each   for the last two recorded timepoints. The mean profile immediately prior
to dropout is approximately the same for the majority of simulations with di↵erent ntms.
However, a higher mean change in outcome is observed in the simulation with ntms = 9
and   = 1. While this di↵erence has a magnitude of approximately 0.0002, it is important
to note that accurately estimating higher values of   may require greater amounts of infor-
mation, and higher numbers of time points will result in more accurate   estimates. This
di↵erence also suggests that the normalised change in outcome is dependent on ntms
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To provide a greater context to the simulations carried out in this section, confi-
dence intervals of the longitudinal dropout profiles were calculated with patients n =
100, 200, 400, 500 per treatment group. 1000 simulations were generated with ntms = 5
for each number of patients and the 95% C.I.s calculated. Figure 5.4 shows the confidence
intervals for the mean dropout profiles for varying sample sizes and 5 time points.
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Figure 5.4: Dropout profiles with confidence intervals for di↵erent values of   and numbers
of patients per treatment group;   = 0 (black),   = 0.25 (blue) ,   = 0.5 (red),   = 0.75
(green),   = 1 (yellow)
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For the simulations with 400 and 500 patients in each group (160 and 200 dropouts),
there is a significant di↵erence between the dropout profiles for each value of  . In simu-
lations with 100 and 200 patients per group (40 and 80 dropouts) there was some overlap
in the mean confidence intervals, although the overall mean profiles were very similar for
each number of patients.
In this study, visualisations of di↵erent   parameters in terms of change in longitudi-
nal outcome are presented based upon the framework of MAGNETIC. In summary, these
simulations identified that the greater the change in mean longitudinal outcome prior to
dropout, the higher the estimate of  . Also, there is a greater di↵erence in longitudinal
dropout profiles between smaller values of  . This di↵erence can be observed by looking
at change in longitudinal outcome between the last two time points prior to dropout, how-
ever more accurate estimates of   are given in RCTs with a higher number of timepoints.
Traditionally for this type of statistical modelling, the majority of parameters included
in the model to describe the outcome variable have no interaction with time. Therefore,
focusing on the change in mean longitudinal outcome over time for dropouts may be the
most successful approach for approximating  .
5.4 Simulation Study 2 - Methods and Results
In the second simulation study, the aim is to gain a greater understanding of this rela-
tionship between y0 and   by allowing more flexible simulation settings. To explore the
properties of di↵erent   values, data is simulated for the simplistic scenario of a trial with
longitudinal data measured at 5 di↵erent time points at unit intervals, with a view to
quantifying the relationship between   and change in longitudinal outcome pre-dropout
for this trial design. This study should provide a basis for future investigations into the
properties of   for alternative trial scenarios.
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Simulation study 1 provides a simple visualisation for dropout profiles, however this
only investigated the profiles for fixed variances of U1, U2 and a fixed percentage dropout.
In the second simulation study, the variances of U1, U2 and the percentage of dropout will
also be varied along with the   parameter. The initial focus of the study will be on joint
modelling data with a flat baseline hazard.
Before considering this new trial scenario, an exploratory analysis is carried out to
observe the relationship between V ar(U2) and the dropout profiles for fixed  , using the
MAGNETIC parameters from simulation study 1. Joint longitudinal and dropout data
is simulated with   = 0.5, dropout percentage equal to 20%. V ar(U2) is varied and the
dropout profiles are plotted. For all simulations in this study, the error variance was set
to 0.5. The corresponding dropout profiles are shown in Figure 5.5;
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Figure 5.5: Mean dropout profiles for di↵erent values of V ar(U2) when V ar(U1) = 1.19,
dropout percentage = 20% and   = 0.5
Figure 5.5 shows that there is a relationship between magnitude of y0 for drop outs and
V ar(U2) when   is fixed. For larger values of V ar(U2), there is a greater change in longi-
tudinal outcome pre-dropout. This implies that for the same y0, the parameter estimate
for   becomes smaller as V ar(U2) increases. By the model definition, if   was negative
these results would be mirrored, as joint modelling concerns a multiplicative relationship
between   and U2.
We now attempt to model the relationship between change in outcome pre-dropout and
  for the trial scenario where there are 5 di↵erent time points at unit intervals. To quantify
change in outcome pre-dropout, we define this as the di↵erence in mean dropout profile
between the last two time points leading up to dropout. Data is again simulated from the
linear mixed model and Cox-proportional hazards model for the longitudinal and dropout
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elements respectively. To assess the raw properties of the   parameter, it is important to
ensure this simulation study’s results are as general as possible. By setting  0 = 0,  1 = 0
and  2 = 0 in the simulations, a more general solution can be obtained for the relationship
between   and y0. For all simulations, 1000 data sets are generated with 500 patients in
each treatment group. After plots have been generated to investigate the relationship, by
using linear modelling techniques to generate approximate mathematical formulae we can
establish the extent to which V ar(U1), V ar(U2) and change in outcome a↵ect  . This will
provide a basis for understanding this relationship when considering other trial scenarios.
Once a formula has been established, standard diagnostic techniques are used to check the
validity of the model.
The e↵ect of varying U1 on change in longitudinal outcome, y0, is now investigated using
our newly described trial scenario. We set V ar(U2) = 0.25,   = 0.5, 1, percentage dropout
= 20% and simulate for di↵erent values of V ar(U1). Two plots are shown in Figure 5.6;
the first is the di↵erence in the mean longitudinal outcomes at 1 time-point before dropout
and at dropout, while the second is a plot of the mean change in outcome between the last
2 longitudinal readings pre-dropout when excluding patients that dropped out at t = 0.
This was to test whether high baseline values for patients that dropped out immediately
were distorting our interpretation of y0.
119
Figure 5.6: Di↵erence in longitudinal profiles pre dropout for di↵erent V ar(U1)’s including
patients that dropped out at t=0 (left) and disregarding those patients (right)
The left panel of Figure 5.6 represents the di↵erence in the last two longitudinal out-
comes pre dropout from all patients including those that dropped out at t=0. This graph
appears to show an increase in change of longitudinal outcome for higher variances of U1.
However these results are clearly skewed by the patients that dropped out after only one
longitudinal reading, as the graph on the right indicates no significant di↵erence in change
of outcome pre-dropout when these patients are excluded from the analysis.
To ensure that the influence of V ar(U1) does not provide misleading results, hence-
forth all graphs and references to graphs of mean dropout profiles exclude the patients
that dropped out at t = 0. We denote the mean di↵erence in longitudinal value between
the last 2 timepoints pre-dropout as  y. To provide a visualisation of the mean dropout
profiles with t = 0 dropouts excluded, Figure 5.7 shows the simulated mean dropout pro-
files for varying  ’s with V ar(U1) = 1, V ar(U2) = 1 and percentage dropout equal to 20%.
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Figure 5.7: Mean dropout profiles with with V ar(U1) = 1, V ar(U2) = 1 and percentage
dropout equal to 20%.
After observing the relationship between V ar(U2),   and y0, the next stage is to quantify
this relationship. The percentage of dropout is set as 10%, 20%, 30%, 40% and 50% and
1000 simulated dataset are generated for each combination of  , V ar(U2) and dropout
percentage. V ar(U1) is set equal to 1 for all simulations as this will have no impact on  y.
The di↵erence in mean longitudinal outcome between the last two time points pre-dropout
is calculated for each outcome. Figure 5.8 shows plot of  y against V ar(U2) for each  .
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Figure 5.8: Plots of  y against V ar(U2). gamma=0 (black), gamma=0.1 (red),
gamma=0.25 (green), gamma=0.5 (dark blue), gamma=0.75 (light blue), gamma=1 (pur-
ple)
For simulations with   = 0, the change in longitudinal outcome is approximately 0 for
all values of V ar(U2). This follows from the formula in which longitudinal outcome and
dropout time are unrelated if   = 0. When   6= 0, the change in longitudinal outcome
increases as the variance of U2 increases. However, the magnitude of this increase becomes
smaller for higher variances. The higher the value of   the greater the reduction in outcome
change as V ar(U2) increases. It would also appear that this deceleration is more noticeable
for higher percentages of dropout.
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For the simulations with 40% and 50% dropout, the values of  y were similar for higher
 , V ar(U2). As the percentage of dropout was increased,  y decreased for fixed   and
V ar(U2). This demonstrates that the relationship between  y and   is dependent on the
baseline hazard.
Due to   and V ar(U2) working on an exponential scale in the time-to-event component
of the joint model, it can be di cult to identify a di↵erence in longitudinal outcome pre-
dropout as there are only a finite number of dropout points and a fixed level of dropout.
For a reasonable amount of patients and time points recorded in a study, there will always
be an upper threshold which   can not exceed without the inclusion of unrealistic trial
properties. This is particularly evident in the simulations with higher values of  .
Figure 5.9 presents the simulation results in terms of change in longitudinal outcome
plotted against  .
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Figure 5.9: Plots of  y against  .
In general, when V ar(U2) and dropout percentage was fixed, there was an increase in
longitudinal outcome as   increased. However, by pinpointing the results where this is
not the case, simulations that used inappropriate combinations of  , V ar(U2) and percent-
age dropout can be identified. This was less problematic in the simulations with 10 and
20% dropout, however the following combinations provided misleading results due to the
aforementioned factors:
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% Dropout   V ar(U2)
30% 1 5
40% 1 4
40% 1 5
50% 1 3
50% 0.75 4
50% 1 4
50% 0.75 5
50% 1 5
Table 5.1: Situations where change in longitudinal outcome is di cult to estimate accu-
rately
When aiming to find a relationship between  , change in outcome and V ar(U2) for this
trial design, it is important to find a model which identifies the results of these particular
simulations as underestimated.
Figures 5.8 and 5.9 show that there is an interaction between   and V ar(U2) when
modelling  y. To investigate this further, Figure 5.10 shows plot of change in  y against
  ⇥ V ar(U2) with di↵erent   values identified.
125
Figure 5.10: Plots of  y against   ⇥ V ar(U2). For gammas; black = gamma 0, red = 0.1,
green = 0.25, dark blue = 0.5, light blue = 0.75, purple = 1
The relationship between  y0 and  ⇥V ar(U2) can be clearly observed from Figure 5.10.
The di↵erent colours highlight the di↵erent values of   in the simulations. As  ⇥V ar(U2)
increases,  y increases. However, this level of increase is proportional to the value of  ,
and is smaller for higher   values.
Model Fitting
As an attempt to quantify the relationship between  y and   for this particular trial design,
a mathematical formula is fit to the simulated data. A requirement for this formula is that
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when   = 0 the change in longitudinal outcome must be approximated as 0. Also the
formula must be capable of taking into account   ⇥ V ar(U2) and   as separate outcomes
when estimating  y.
A mathematical model of the form
 y = !ˆ1  + !ˆ2 V ar(U2) + !ˆ3 
2V ar(U2) + ✏ (5.3)
was fit to the data using standard modelling techniques. Models were fit separately
for each percentage of dropout where  y denotes the di↵erence in longitudinal outcome
between the last two time points. The following table shows the estimates of !ˆ1, !ˆ2 and
!ˆ3 for each dropout percentage;
% Dropout !ˆ1 !ˆ2 !ˆ3
10 0.4050 2.2752 -1.5558
20 0.3450 1.8738 -1.3093
30 0.3053 1.5984 -1.1490
40 0.2848 1.3703 -1.0318
50 0.2541 1.1701 -0.9231
Table 5.2: Mathematical Model Parameter Estimates
Diagnostic plots for the parameters of each of the above models are included in the
appendix. From observing the q-q plots of each model, the residuals appear to be evenly
distributed. A Shapiro-Wilk test of normality was employed and the values were signif-
icant at the 95% confidence level for each model above. The q-q plots appear to incite
a successful model fit in all cases, particularly for lower percentages of dropout with the
majority of points being on y = x. A higher number of outcome values are underestimated
for higher percentages of dropout, with all simulation results highlighted in Table 5.1 being
shown as underestimated in the q-q plot (in particular points 30 and 31 in the q-q plots of
40 and 50% correspond to the 2nd, 3rd, 7th and 8th rows in Table 5.1). The fact that these
points were identified to be underestimating the change in longitudinal profile pre-dropout
127
within the model is a positive attribute.
In order to test the above models, data was simulated 1000 times for 500 patients
per group for 5 di↵erent scenarios. One of the aims stated in Section 5.4 was to com-
pare the results for flat baseline hazard simulations to alternative baseline hazard profiles.
Therefore, three di↵erent variations of the simulations were carried out in order to test
the appropriateness of the model. Data was simulated with a flat baseline hazard, an
increasing baseline hazard and a decreasing baseline hazard drawn from the Gompertz dis-
tribution [113]. The mean longitudinal outcome change in the last two time points prior to
dropout was recorded and the results compared to the approximated value from Equation
5.3. Table 5.3 shows these results;
% Dropout   V ar(U2) Pred.  y Sim.  y (flat) Sim.  y (inc) Sim.  y (dec)
10 3 0.0002 1.2135 1.2129 1.2350 1.2006
20 0.3 0.0395 0.1211 0.1212 0.1254 0.1201
30 6 0.0002 1.8254 1.8221 1.8334 1.7991
40 0.07 6 0.5651 0.5623 0.5625 0.5611
50 1.2 0.8 0.7193 0.7190 0.7186 0.7179
Table 5.3: Model Verification
All the simulated values with a flat baseline were within 0.03 of the predicted change
in longitudinal outcome pre-dropout, indicating a good model fit. However, the estimates
were less accurate for a non flat baseline. It can be observed that when the baseline dropout
risk was decreasing over time, the mean change in longitudinal outcome also decreased.
The opposite was the case for an increasing baseline hazard, further demonstrating that the
approximation for   is also dependent on baseline properties. Despite this, the estimates
were all within 0.03 of the correct dy for all verification simulations.
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Classifying the   parameter
One of the aims of this study was to provide a formula which could be used to observe the
relationship between  ,  y, V ar(U2) and percentage of dropout for the trial scenario in
simulation study 2. The model established appears to provide a useful approximation to
this relationship. In order to provide an approximate estimate for   based on  y, Equation
(5.3) can be rearranged.
As
 y = !ˆ1  + !ˆ2 V ar(U2) + !ˆ3 
2V ar(U2)
it follows that
0 = !ˆ1  + !ˆ2 V ar(U2) + !ˆ3 
2V ar(U2)   y (5.4)
0 = !ˆ3V ar(U2) 
2 + (!ˆ1 + !ˆ2V ar(U2))     y (5.5)
Equation (5.5) has the following roots;
  =
 (!ˆ1 + !ˆ2V ar(U2))±
p
(!ˆ1 + !ˆ2V ar(U2))2 + 4!ˆ3V ar(U2) y
2!ˆ3V ar(U2)
(5.6)
This leads to the following approximation formulae for each percentage dropout, with
the smallest positive value being the estimate of   due to the quadratic nature of the
approximation and the di culty in estimating  y for higher values of  .
10% Dropout
  =
(0.4050 + 2.2752⇥ V ar(U2))±
p
(0.405 + 2.2752⇥ V ar(U2))2   6.2232⇥ V ar(U2) y
3.1116⇥ V ar(U2)
(5.7)
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20% Dropout
  =
(0.3450 + 1.8738⇥ V ar(U2))±
p
(0.3450 + 1.8738⇥ V ar(U2))2   5.2372⇥ V ar(U2) y
2.6186⇥ V ar(U2)
(5.8)
30% Dropout
  =
(0.3053 + 1.5984⇥ V ar(U2))±
p
(0.3053 + 1.5984⇥ V ar(U2))2   4.5960⇥ V ar(U2) y
2.2980⇥ V ar(U2)
(5.9)
40% Dropout
  =
(0.2848 + 1.3703⇥ V ar(U2))±
p
(0.2848 + 1.3703⇥ V ar(U2))2   4.1272⇥ V ar(U2) y
2.0636⇥ V ar(U2)
(5.10)
50% Dropout
  =
(0.2541 + 1.1701⇥ V ar(U2))±
p
(0.2541 + 1.1701⇥ V ar(U2))2   3.6924⇥ V ar(U2) y
1.8462⇥ V ar(U2)
(5.11)
It is important to note that the above formulae are not capable of approximating for
all   values, however the majority of plausible combinations are accounted for. Data has
mainly been simulated in this chapter for trial scenarios where longitudinal readings are
made at unit intervals over time. It is sometimes the case that there are larger gaps be-
tween equidistant timepoints, longer follow up times and di↵erent definitions of   in joint
modelling analyses. For these trials, the simulation study in this chapter should act as a
guide for future   estimation studies.
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5.5 Conclusions
By using simulation methods, graphical representations of the relationship between   and
change in outcome pre-dropout are presented in this chapter. With the right level of
information available this could provide useful to a clinician in estimating  , as there are
benefits to having knowledge about the properties of this value prior to the commencement
of a study. From the results of the simulation study, it was established that the parameter
estimate for   is dependent on:
• The estimated percentage of dropout and baseline hazard
• The variance of the random slope U2
• The change in longitudinal outcome pre-dropout.
The simulation study showed that the higher the values of   and V ar(U2), the greater
the change in longitudinal outcome pre dropout, and that these two variables had multi-
plicative properties. Contrarily the change in longitudinal outcome was less prominent for
higher percentages of dropout.
When considering the power and sample size of a longitudinal trial, the estimated per-
centage of dropout is usually taken into account during the planning phase [114]. Similarly,
statistical methods exist for estimating the variance of the slope and intercept in a random
e↵ects model, as well as the possibility that details of such a variance can be estimated by
using historical data in previously conducted trials. Using these factors it is possible to
estimate   using simulation methods as demonstrated in simulation study 2.
A clear example of how this can be done was demonstrated in simulation study 2.
By simulating data sets for di↵erent dropout percentages and values of  , V ar(U1) and
V ar(U2) we were capable of establishing an approximate relationship between change in
longitudinal outcome and   estimate for the trial design described in Section 5.4. As the
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design of a trial is generally discussed prior to the randomisation of patients, similar meth-
ods can be applied to any given trial design to approximate  . As a guide, the R code based
upon the joineR software [46] used for simulating data in the second simulation study is
included in the Appendix.
Until now, there has been little discussion of diagnostic methods used in joint modelling,
however some methods are available for this framework. In Chapter 6, joint modelling
diagnostic procedures are introduced, and software is developed to carry out these methods
in R.
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Chapter 6
Diagnostics of Joint Modelling
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6.1 Introduction
In Section 1.4, a history of the development of joint modelling was presented. Research
in the area of joint modelling of longitudinal and time-to-event data is ongoing and many
di↵erent specifications of the joint model have been proposed and implemented in pub-
lished articles [49, 115, 116]. While a lot of progress has been made in this area, the focus
of research has largely been based around model generation and procedures for parameter
estimation. Therefore, there still are a large number of research questions which need to
be addressed to develop a stronger and more complete framework in Joint Modelling [140].
The appropriateness of using joint modelling analyses are dependent on some untestable
assumptions, however there are procedures available which can be used to assess the appli-
cability of joint models being fit to a given dataset, and to identify outliers once a model
has been fit [119,120]. Although many diagnostic procedures exist for separate longitudinal
and time-to-event analyses [87,117,118], the development of diagnostics for joint modelling
is still in the early stages, and few papers have been published which discuss the progress
of diagnostics in this area [140].
There are two main articles concerning the development of joint modelling diagnostic
procedures. Dobson and Henderson 2003 [119], proposed a selection of diagnostic methods
for the joint models described in Henderson et al., whereas Rizopoulos 2007 focused on the
area of residual analysis for joint models with a parametric time-to-event component [120].
Since the development of these diagnostic procedures, they have not been used in clinical
trial analysis in published literature, and no statistical packages or software currently ex-
ist to carry out the methods proposed in the former paper. In this chapter, code in the
statistical program R is developed to carry out a variation of the sequential discrimination
method described in the original paper [119], and for the calculation of Cook’s distance for
the random slope and intercept joint model as specified in Section 1.4.3. These methods
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are illustrated using the MAGNETIC analysis from Section 2.5.
As we have only discussed the semi-parametric Cox model in the thesis up until this
point, in the final section of the chapter a relative risk model with Weibull baseline function
is introduced with a view to illustrating the multiple imputation residual analysis procedure
as described in Rizopoulos, 2007 [140]. Utilisation of the relative risk model and subsequent
residual analysis will be demonstrated using the MAGNETIC dataset [47].
6.2 Sequential Discrimination
6.2.1 Methods
Graphs of Sequential Discrimination
As shown in the systematic review in Chapter 3, joint modelling has been a method rarely
used in recent clinical trials [60]. While this may be due to joint modelling being a relatively
newly developed procedure, fitting joint models is also more complicated than using stan-
dard linear mixed modelling techniques. By using sequential discrimination, it is possible
to establish whether a longitudinal analysis alone is su cient, or whether there are intrinsic
di↵erences between the patients that remained in the study and those that dropped out
which fail to be accounted for by using separate analyses [119]. In these cases, joint mod-
elling is a more appropriate method of analysis. Sequential discrimination provides both
a visual demonstration and quantification of the prognostic di↵erences between patients
that dropped out and continued at each time point.
To distinguish a di↵erence in longitudinal profiles between patients that left the study
after a given time point and patients that continued, Dobson and Henderson propose
a technique based on Diggle (1989) [122]. The method tests the di↵erence in between
dropouts and non dropouts at all longitudinal time points by initially categorising patients
still active in the trial at each time point, dj , into groups, ⌫d, depending on their dropout
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status at that time point. We define the risk set Rd to be all patients that could drop
out at a given time point. For example, when testing for the di↵erences between dropouts
and non-dropouts at time t = 20, define ⌫20 = 1 for each individual that had no more
longitudinal readings after t = 20 and ⌫20 = 2 for the patients that continued in the trial.
A standard linear mixed e↵ects model, as described in Section 2.3.3, is then fit to the
observed longitudinal data. In the original method described by Dobson et al., a linear
model with a time parameter is fit to the residuals up until time point dj for each individual
still in the trial at this time. The parameter estimates for the residual slope are plotted
against the parameter estimates of the residual intercept for each individual, and those
that dropped out are distinguished from the non-dropouts.
However, in this thesis a variation of the original method is proposed in an attempt
to establish a procedure which is both more understandable and easier to interpret for
clinicians.
To carry out this variation of the original sequential discrimination, define
Ri = Yi   x01i 1 (6.1)
as the vector of residuals for each subject, i, and classify those patients who are at risk of
dropping out at each time point d into a risk set Hd. A subset of the residuals Ri is then
generated, denoted Rid which contains all the residuals for patients with a complete set of
measurements prior to timepoint d.
We define the slope of the residuals as the di↵erence between the residual at the given
time point and the previous time point. A correlation matrix for the 2 dimensional sum-
maries of the residuals and slope of residuals at each time point can be generated as these
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summaries would be complete and balanced. For each separate time point, the slopes of
the residuals are plotted against the residuals for patients in the risk set and separated
into the pre-specified groups dependent on dropout profile.
By observing the graphs, any obvious di↵erences between the patients that dropped
out and stayed in at each time point can be identified by observing the distribution of
residuals and change in residuals from the previous time point (denoted here as the slope
of the residual). While the originally proposed method in Dobson and Henderson [119]
is dependent on the historical profiles of patients, this newly proposed method focuses on
the most recent longitudinal outcomes prior to dropout. This way any radical changes in
outcome can be identified in the graphs and any profile di↵erences in longitudinal outcome
for patients that dropped out can be observed clearly. If there appears to be a clustering
of patients in one group away from the other at various time points then this may indicate
a di↵erence in dropout profiles and that joint modelling methods may be reasonable to use.
Full details of the joint modelling analysis of MAGNETIC are provided in Chapter
2.5.2. To carry out the sequential discrimination for MAGNETIC, Equation 2.1 in Chap-
ter 2 was fit to the data with  1 = {↵, 0, 1} where ↵ is the parameter for time,  0 is a
fixed intercept and  1 is the treatment e↵ect. The residuals and slope of residuals were
calculated for each time point.
In Section 6.2.2, two pre-joint modelling sequential assessments are carried out to es-
tablish the appropriateness of using joint modelling in the MAGNETIC trial using this
newly proposed variation of the original method. The first aims to establish whether there
were any intrinsic di↵erences in the residual profiles between dropouts and non-dropouts
at each time-point as described above. However, an additional analysis was also carried
out to investigate the di↵erence between the patients that dropped out due to good status,
other dropouts and the patients that remained in the study using graphical methods. The
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details of patients that dropped out due to good status was recorded by the trialist in
MAGNETIC.
Quantifying Sequential Discrimination
While graphs can provide a visual overview of the di↵erences in each group, it can some-
times be di cult to establish the extent of the general di↵erences between dropouts and
non-dropouts at each time point. To generate a p-value to test the di↵erence in profiles
between the groups, two-dimensional summaries of Rid denoted by pid = (⌫id1, ⌫id2) are
generated for each dropout group, with these ⌫i referring to the aforementioned residuals
and slope of the residuals. The di↵erences between the two dimensional summaries for the
di↵erent dropout groups at each timepoint are then tested using a discriminant analysis
based on the Mahalanobis distance [123], defined as
Mqr = (p¯qd   p¯rd)0Var(pid) 1(p¯qd   p¯rd) (6.2)
where p¯gd is the sample mean of group g subjects. This generates a value for the Maha-
lanobis distance between the two groups for each dropout point. To test the significance of
this Mahalanobis distance, p-values are generated by permuting the patients in each group,
calculating the corresponding Mahalanobis distances for 10,000 di↵erent permutations of
the group indicator and then comparing the value Mjk to these generated values.
For an analysis of the MAGNETIC data set, the Mahalanobis distance was calculated
for the plots described in this section, and the p-values calculated. This was initially
done to compare the dropouts to non-dropouts at each timepoint, and subsequently non-
dropouts with patients that dropped out due to good status and other dropouts. Original
R code developed for generation of the graphs, calculation of Mahalanobis distances and
p-values is included in the appendix.
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6.2.2 Results
An analysis was carried out to assess whether there was a di↵erence in the profiles between
dropouts and non dropouts in MAGNETIC. A linear mixed e↵ects model was fit to the
ASS score. The following are plots of the slopes of the residuals against the residuals for
time points t = 40 onwards, due to the low number of dropouts before this time.
Figure 6.1: Sequential Plots showing patients that dropped out (red crosses) at each time
point compared to those who did not (grey triangles). The values to the left of the graphs
indicate the Mahalanobis distance and the p-value at each time point.
Due to the few fixed e↵ect covariates included in the model and the discrete nature of
the outcome, it was di cult to assess whether there were any intrinsically di↵erent charac-
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teristics in the profiles of those patients that dropped out at each time point compared to
those that did not simply by observing the graphs. Higher values on the y-axis indicates an
increase in the residual from the previous time point, while higher x-axis values indicate a
higher than expected longitudinal outcome. At t = 40, a large proportion of patients that
dropped out had negative values for the slope of residuals, although the individual with
the highest residual profile also dropped out at this timepoint. At t = 60, it would appear
that there were a higher proportion dropouts with a negative residual than non-dropouts,
and therefore lower longitudinal values than expected. The range of the slope residuals was
higher for patients that remained in the study, with the majority of slope values ranging
between -2 and 2 for patients that dropped out at each time point.
When observing the p-value of the Mahalanobis distance, it can be seen that there is
a significant di↵erence in the profiles of the two groups at t = 40 and t = 60. The Maha-
lanobis distance at t = 120 and t = 180 was not found to be significant. It is interesting
to note that patients stopped receiving treatment at t = 60, after which the longitudinal
profiles showed no significant di↵erence for dropouts compared to continuers in the trial.
These results suggests that a joint modelling analysis may be appropriate, as the Maha-
lanobis distance is significant at some time points.
In the analysis of the MAGNETIC trial, the results (as listed in Section 2.5.2, Table
2.2) suggested that patients with were more likely to dropout due to good status. Details
of some of the reasons for dropout were collected by trialists, of which some patients were
dismissed due to good status. However, other patients that left the study had no recorded
reasons for dropout. We now compare the profiles of non-dropouts at each time point to
both those that dropped out due to good status and other dropouts. Figure 6.2 shows the
of slope of residuals plotted against the residuals.
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Figure 6.2: Sequential Plots showing patients that dropped out non-informatively (red
crosses) at each time point compared to those who dropped out due to low severity score
(blue crosses) and those who did not dropout(grey triangles). The values to the left of
the graphs indicate the Mahalanobis distance and the p-value at each time point between
groups. Group 1 = Non dropouts, Group 2 = Dropouts not due to good status, Group 3
= Dropouts due to good status.
The graphical di↵erences in the residual properties of those patients that dropped out
due to negative status compared to the other patients in the study is clearly observed
from Figure 6.2. Analysing this quantitively, it was found that there is a highly significant
di↵erence in the profiles of those that dropped out due to good status at all time points
when compared to non-dropouts. There was only found to be a significant di↵erence
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between patients that dropped out for alternative reasons and continuers in the trial at
t = 40.
6.3 Case Influence
6.3.1 Methods
Once the model has been fit, the influence di↵erent subjects have on the regression param-
eters ✓ = ( 1, 2,  ) can be analysed. The standard method of calculating this is using the
Cook’s distance [130] . Implementation of this method can be more complicated in joint
modelling procedures than standard estimation due to additional parameters required for
estimation. To calculate the Cook’s distances, patient i is excluded from the analysis, the
model is refit and the parameters without individual i, ✓ˆ(i) are calculated for each sub-
ject [131]. These can then be substituted into the following formula which calculates the
Cook’s Distance for patient i:
CDi = (✓ˆ(i)   ✓ˆ)0V ar(✓ˆ)(✓ˆ(i)   ✓ˆ) (6.3)
Original code for calculating the Cook’s Distances of a joint modelling data set has
been included in the appendix. It has been suggested in the past, that calculating the
correct Cook’s Distance can be impractical and time consuming [119]. However, due to
the increase in computing power and e ciency, this is no longer the case.
However, to test an alternative approach, we also propose an approximation to Cook’s
Distance as proposed in Dobson et al. 2003:
✓ˆ(i)   ✓ˆ =  I 1(i) (✓ˆ)U(i)(✓ˆ) (6.4)
which utilised the negative of the observed score multiplied by the information. The suc-
cess of this approach will be tested in this chapter. Code for calculating the observed score
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and information is included in the JM package [121].
The methods of case influence described above are applied to the MAGNETIC data set.
The aims of this are to firstly identify any outliers in the MAGNETIC analysis for further
investigation and secondly to compare the results of using the true Cook’s distance for each
patient and the approximated Cook’s distance using the estimation in equation 6.4. After
identifying the most influential patients, the longitudinal profiles of these will be plotted
and discussed. While Cook’s distance can be used to focus on specific parameters, here we
apply it to the full model fit and therefore define ✓ = {↵, 0, 1, 2,  }. Outliers are more
frequently identified by observation rather than application of a mathematical definition,
due to the diverse range of potential specifications of an outlier. In this study, we define
outliers as any patients with a Cook’s distance that is both considerably higher than both
the majority of patients, and greater than 3 times the mean of the Cook’s distances.
6.3.2 Results
After the model was fit, a case influence was carried out based on the Cook’s distance to
highlight any influential patients. Figure 6.4 shows the true Cook’s distance for the 508
patients.
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Figure 6.3: Cook’s Distance for each patient
It can be observed from the graph that the most influential patients were those with
ID’s equal to 176, 373, 174 and 125. Patient 176 has a considerably greater influence
on parameter estimates than anyone else, and this was therefore identified as an outlier.
Figure 6.4 shows the longitudinal responses for the four most influential patients.
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Figure 6.4: Plots showing the severity profiles of the most influential patients
The graph shows that the most influential patient was randomised to Magnesium. Un-
like the majority of patients, the most influential individual (176) had an initial increase
in severity score. In the first 60 minutes since randomisation, the ASS for this patient
increased from 6 to 9, the maximum severity, indicating a deterioration in the condition.
While the majority of patients given Magnesium recorded lower ASS scores, this patient
had the maximum recorded on two separate occasions. Also, the   estimate indicated that
patients with a lower ASS were more likely to dropout, however patient 176 dropped out
from the study with an ASS of 8, which is categorised as severe.
Patient 373, randomised to placebo, initially showed improvements in their condition.
However, their ASS increased from 6 to 9 within the last 60 minutes of follow up before
they dropped out from the study due to poor status. This high score at the time of drop
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out may have been the reason for the high influence of this patient. Patient 174 was also
randomised to placebo, and entered the study with a high severity of asthma. After 60
minutes of treatment, this patient dropped out without any indication of an improvement
in ASS. Unlike the other influential cases, patient 125 did not dropout, however their ASS
was consistently high despite being randomised to magnesium.
Analysis of case influence using the true Cook’s distances was then compared to the
results of the approximation, to test the e↵ectiveness. The results are shown in Figure 6.5
Figure 6.5: Approximate Cook’s Distance using First Order Estimate
The Pearson’s correlation coe cient between the correct Cook’s distance and the ap-
proximate Cook’s distance was found to be 0.79. However, while patient 176 was identified
as the most influential, the 2nd and 3rd most influential patients identified above were
di↵erent to those in Figure 6.4. Therefore, while the approximation can provide similar
results to the actual Cook’s distance, it can be observed that the patients identified as
influential are not always consistent across the two methods.
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6.4 Residual Analysis using Multiple Imputation Methods
6.4.1 Methods
When carrying out separate longitudinal and time-to-event analyses of a data set, there
are a multitude of available methods for residual analysis [87, 117, 118]. In a longitudinal
context with a linear mixed model, the subject specific residuals or marginal residuals can
be calculated to assess the model fit.
These can be used to carry out a residual analysis based solely on the observed longi-
tudinal data. However, there may be assumptions within the standard definitions of these
residuals that distort the accuracy of the model verification [140]. In particular, joint mod-
elling is reliant on the assumption that the occurrence of dropout is potentially related to
the subject-specific longitudinal profiles, and is therefore non-random. Therefore, residual
analysis from the observed data alone may not be applicable, as the residuals may not
display the typically associated properties (i.e. independence, mean zero etc.) [120].
To account for some of these issues caused by the nature of a non random dropout
structure within a dataset for a residual analysis of the joint modelling longitudinal pro-
cess, multiple imputation methods can be utilised [120, 126, 127]. However, this method
requires a complete likelihood specification, and therefore has only been described in the
literature as a method to be used for joint models with a parametric time-to-event com-
ponent. While this method may therefore not be applicable to the main model utilised
throughout this thesis, it is important to include details of this residual analysis as a) It
is useful to demonstrate how alternative joint modelling specifications can be applied to a
dataset, b) a demonstration may be beneficial for those who wish to fit a joint model with
a parametric time-to-event component and c) to discuss the issues associated with merely
carrying out a residual analysis based on the observed data only.
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The aim of this method is to impute longitudinal data under the assumptions of the
complete data model. These imputations are designed to replicate what may have hap-
pened if each patient had not dropped out, and therefore induce a complete dataset.
Software for this type of modelling and residual analysis has been developed in the JM
package in R [121].
To demonstrate this residual analysis, we fit a relative risk model with Weibull baseline
hazard. The longitudinal component of the model is as given in Equation (1.1) from
Chapter 1. The time-to-event element is modelled using the form:
 (t) =  0(t) exp{x02i 2 +  mi(t)} (6.5)
where mi(t) is the true unobserved longitudinal trajectory obtained by excluding the
measurement error,  2 = { , 2} where   is an intercept for the time-to-event element of
the model, and   is the association parameter. The baseline function is modelling by
 0(t) =  tt
 t 1 (6.6)
where  t is the shape parameter. The residuals can be defined by
Ri(tij) = {yi(tij)  x01i 1(tij) W1i}/ ˆy (6.7)
To carry out these imputations, joint modelling must be considered in a Bayesian
context. Samples are taken from the posterior distribution of the longitudinal outcome
ymis, where mis refers to the missing data, which is averaged over the posterior of the
other parameters. The density of the distribution can be expressed as
p(ymisi |yobsi , Ti, di) =
Z
p(ymisi |yobsi , Ti, di; ✓)p(✓|yobsi , Ti, di)d✓i (6.8)
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where yobsi is the observed data for a patient, Ti is the time of observation, and di is
the dropout time. Let Ui = {U1i, U2i} be the set of random e↵ects for each patient i.
Rizopoulos [140] showed that
p(ymisi |yobsi , Ti, di; ✓) =
Z
p(ymisi |Ui; ✓)p(Ui|yobsi , Ti, di; ✓)d✓i (6.9)
and Cox and Hinckley [133] showed that {✓, yobsi |, Ti, di} can be approximated using ✓ ⇠
N (✓ˆ,Var(✓ˆ)). Therefore, the following procedure was proposed to generate the missing
data;
• For imputation number l = 1, ..., L draw the fixed parameters ✓(l) ⇠ N (✓ˆ,Var(✓ˆ))
• Draw random e↵ects U li ⇠ {Ui|yobsi , Ti, di, ✓(l)}
• Generate the imputed values by drawing ymis(l)i (tij) ⇠ N{mˆ(l)i (tij),  ˆy2,(l)}.
In the first and last steps, samples are taken from the multivariate normal distribution.
Step 2 in the above algorithm can prove to be computationally di cult as it is based on the
posterior distribution of the random e↵ects, and is in a non specified form. Therefore the
Metropolis-Hastings algorithm, based upon proposals from the multivariate t distribution
centred around Bayes estimates of Ui with a scale matrix Var(Ui), is employed to carry
out this sampling method. [120,128,140]
Once calculated, the value of the residuals are plotted against the fitted values and the
LOESS smoothing [129] is used to plot a curve for the residuals of the observed data and the
potential full data set with multiply imputed values. If the smoothed line is approximately
equal to 0 for most fitted values, then this suggests a good fit. These residuals will be
calculated for the model fit to MAGNETIC, as described in this section. Code for these
procedures can also be found in the JM package for R [121].
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6.4.2 Results
The Weibull relative risk model was fit to the ASS score in MAGNETIC, with the results
of the model fit shown in Table 6.1.
Component Parameter Estimate SE 95%Lower 95%Upper
Longitudinal (Intercept) 5.6281 0.0743 5.483 5.775
time -0.0077 0.0003 -0.0083 -0.0070
 1 -0.2115 0.0489 -0.4069 -0.0161
Survival  2 0.5202 0.1881 0.1515 0.8889
Association   -0.0920 0.0884 -0.2652 0.0812
Table 6.1: Results of joint model fit to ASS for Weibull baseline
With this alternative model fit, the ASS score in the magnesium group was found to be
significantly lower than in the placebo group. Furthermore, the results show that patients
in the magnesium group were significantly more likely to dropout, so fitting the relative
risk model with Weibull baseline yielded the same conclusions of treatment e↵ect as the
random slope and intercept joint model (Section 2.5). However, based on this di↵erent
definition of  , the association parameter was found not to be significant.
To check the success of the joint model, marginal residuals were plotted against the
fitted values. To obtain an accurate estimation of the residual values, 50 imputations were
used, which is standard in joint modelling literature [140]. Two LOESS smoothed curves
are fit to the plot to assess the mean residual profiles. This was fit for both the observed
values only, and the observed coupled with the multiply imputed values. The results are
displayed in Figure 6.3.
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Figure 6.6: Plot of residuals against fitted values. The black circles indicate the observed
residuals, with the grey points showing the multiply imputed values. LOESS smooth func-
tion for observed residuals (red), LOESS smooth function for both observed and imputed
residuals (blue).
While the functional values at y = 3.55, are greater than 0, which decreases to below 0
at around y = 4.45, there is no large variation in the mean standardised marginal residuals.
Observing the graph, the LOESS smooth functions for the observed values and the full
imputed data set both maintain a trajectory close to y = 0. This indicates a good model
fit for the joint model of MAGNETIC data.
6.5 Discussion
Due to the time constraints within a clinical trial, it is necessary to ensure that the most
e cient and accurate method of analysis is carried out, and overcomplicated or inappropri-
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ate analyses can lead to time being wasted. While the benefits of joint modelling have been
highlighted throughout this thesis, this method requires a greater level of computational
power than some standard methods which focus solely on longitudinal data. Sequential
discrimination is used to check whether di↵erences in profiles exist between dropouts and
non-dropouts, which may indicate the need for joint modelling. The newly updated vari-
ation of sequential discrimination proposed in this thesis serves the same purpose as the
original method, while simultaneously allowing for an easier interpretation of the plots for
clinicians; as the emphasis is on the longitudinal outcomes immediately prior to dropout.
While the original code generated for the diagnostic methods and included in the appendix
is specific to MAGNETIC trial, more user-friendly functions for all the above will be in-
cluded in the next release of joineR for R [46]. In the MAGNETIC data set, there was
found to be a significant di↵erence in profiles between dropouts and non dropouts at the
earlier time-points in the study. Therefore a longitudinal analysis alone may not have
accounted for the dropouts in a reasonable way, so it was appropriate to use a joint mod-
elling analysis. This seems to concur with the analysis of ASS score in Section 2.5.2, which
showed a significant   estimate. One drawback to be considered within the analyses in this
chapter, is that the ASS score is a discrete outcome, and therefore the di↵erences between
dropouts and non-dropouts were di cult to observe using graphical methods alone for
sequential discrimination (see Figure 6.1). In a trial with continuous scores being taken,
clusters of patients within the di↵erent dropout groups would be more evident.
To establish the existence of outliers and identify influential patients in a study using
joint models, the Cook’s distance for each patient is calculated. In the MAGNETIC trial,
the 4 most influential patients were identified, all of which had considerably higher longitu-
dinal profiles for ASS than the majority. However, the same patients were not identified as
most influential when using an approximation to the Cook’s distance. Historically, calcu-
lating Cook’s distance was a lengthy procedure, however this is no longer the case for the
majority of datasets. The code in the appendix demonstrates how this was approached for
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the MAGNETIC trial. A more general original function capable of calculating the Cook’s
distance for other datasets and trial designs will also be included in the next release of
joineR [46].
Standard methods of residual analysis may not account for dropouts e↵ectively when
applied to joint models, so a residual analysis based on multiple imputation methods was
proposed for joint models with a parametric time-to-event component. This was used to
check a relative risk Weibull model fit to the MAGNETIC dataset. The results from the
residual analysis appeared to indicate a good model fit. While this method may also be
capable of assessing model fit for multiple outcomes, no current method of residual analysis
is available for the model proposed in Section 1.4.3 which is based upon the complete data.
In this thesis, methods have been described for joint modelling analysis, formulae for
sample size estimation has been derived and code has been generated for diagnostic meth-
ods. However, these have mainly been applied to the MAGNETIC ASS analysis or sim-
ulations based upon MAGNETIC. The next chapter demonstrates applicability of joint
modelling to a wider range of studies.
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Chapter 7
Applications
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7.1 Introduction
In Chapter 3, a systematic review highlighted that in longitudinal trials, joint modelling is
used rarely in practice [60]. In some studies, having additional information about the rela-
tionship between an outcome and dropout or an event can be informative when evaluating
drug e↵ectiveness [134] - [138]. For example, in trials where a significant number of patients
have a deterioration in outcome pre-event, further investigations can be carried out to eval-
uate the reasons for this pattern. Joint modelling is a feasible option for these studies. [140]
So why is joint modelling not used more frequently? This could be for a number of
reasons. Firstly joint modelling is a relatively new methodology with the greatest advances
in model development having been made in the past 15 years, and therefore the theoretical
elements are still being developed. Consequently many trialists may be unaware of the
methods of joint modelling. With sample size formulae usually reliant on simulations [140]
and the majority of the methods being described in Chapter 6 not having been applied
in practice, there are few examples of how joint modelling can be utilised for clinical trial
data. In this Chapter, the methods described and developed in this thesis are applied
to other clinical trial data sets. This is with a view to demonstrating the flexibility of
the methodology and newly written software, providing examples of how joint modelling
methods can be formally applied in RCTs. A secondary aim of this chapter is to gain
a greater insight into the results of the MAGNETIC trial by analysing the data of the
subcomponents [37, 47].
In this Chapter, the joint modelling methods outlined in this thesis will be used to
analyse the subcomponents of the MAGNETIC trial, a trial for patients with minor mental
health problems [46] and a trial involving treatment for patients with liver cirrhosis [56].
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7.2 The Subcomponents Of ASS In The MAGNETIC trial
The methods described in this thesis have been demonstrated by being applied to the ASS
outcome of the MAGNETIC trial [47], which is described in detail in Section 1.3. The
conclusion drawn from investigating the properties of the ASS score is that joint modelling
was an appropriate method of analysis for this dataset (See Section 2.4, Section 6.2). The
model fit in Chapter 2 showed that ASS was significantly lower in the magnesium treat-
ment group, patients randomised to magnesium were more likely to drop out and patients
with lower severity scores dropped out more frequently in this trial. ASS is made up of
three components measured at each time point; wheeze score, heart rate and muscle score
rated from 0-3. Descriptions of the criteria for each can be found in Yung et al (1996) [38].
By analysing the subcomponents data, it may be possible to establish whether magne-
sium had a direct impact on one of the subcomponents more than the others and therefore
obtain an understanding for the pharmacodynamic e↵ect of magnesium on the body when
treating acute severe asthma [139]. The analysis in Section 2.4 also demonstrated that
patients with an improving prognosis were more likely to stop receiving treatment. By
estimating   for the subcomponents in MAGNETIC, we can hypothesise about which in-
dicators may have been used by patients and healthcare professional to establish whether
individuals had recovered.
Prior to a joint modelling analysis, sequential discrimination as described in Chapter
6.2.1 is applied to determine whether joint models are required for each subcomponent by
initially fitting a linear mixed model for the longitudinal part. Mahalanobis distance [123]
is calculated based on two dimensional summaries of the residuals and slope of the residuals
for each time point, and the p-values are generated. In the cases where joint modelling
may be appropriate, the model described by Equations (1.1) and (1.2) in Chapter 1 are fit
to wheeze score, heart rate and muscle score data separately. For this analysis, we define
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 1 = {↵, 0, 1} and  2 = { 2}. After model fitting, Cook’s Distances are calculated to
identify outliers [119], and the outcome profiles of these patients are examined.
Wheeze Score
For this analysis, the wheeze score data was treated as independent of the overall severity
score analysis. This meant that as some patients had wheeze score available at some time
points but not severity score, time-to-dropout was defined as the first time point at which
a patient was missing a wheeze score measurement. Overall, 17.13% of children had at
least one missing value for wheeze score, which was measured at baseline and 20, 40, 60,
120, 180 and 240 minutes post randomisation. Figure 7.1 shows the mean dropout profiles
for patients randomised to Magnesium and Placebo.
Figure 7.1: Mean Dropout Profiles for Wheeze Score are each time point
In the Magnesium group, the mean profiles of wheeze score for the patients that dropped
out before t = 60 was either decreasing or constant. This is in contrast to patients that
dropped out after t = 120, which displayed increasing mean profiles. In the placebo group,
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the patients who had their final measurement at t = 20, t = 40 and t = 180 had increasing
mean profiles. At all other time points, there was a decrease pre-dropout. The overall
mean change in outcome pre-dropout was found to be negative.
The diverse range of mean profiles caused di culty in establishing if a joint modelling
analysis is appropriate for wheeze score. Therefore, sequential discrimination is used to
check any di↵erences in profile between dropouts and non-dropouts. Figure 7.2 shows the
plots of sequential discrimination for times t = 40, 60, 120, 180. A plot for t = 20 is not
included as there too were few dropouts to detect an informative di↵erence in profiles.
Figure 7.2: Sequential Discrimination for non-dropouts (grey triangles) v. dropouts (red
crosses) at each time point
Figure 7.2 demonstrates that the range of values of the residual slopes for dropouts
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was smaller than patients who remained in the trial. An analysis of Mahalanobis distance
showed no significant di↵erence in profiles at t = 60, 120 and 180. However, the low p-value
at t = 40 suggests that early stage dropouts had di↵erent profiles to continuers. Therefore,
mixed linear modelling techniques alone may not be su cient to accurately model the
longitudinal outcome, and joint models are fit to the data. The results of model fit are
shown in Table 7.1.
Component Parameter Estimate SE 95%Lower 95%Upper P-Value
Longitudinal (Intercept) 1.365 0.0368 1.291 1.424
time -0.0031 1.7⇥ 10 4 -0.0035 -0.0028 < 0.001
 1 -0.1370 0.0489 -0.216 -0.0354 0.005
Survival6  2 0.628 0.208 0.250 1.063 0.003
Association   -0.255 0.283 -0.996 0.271 0.368
Variance U1 -0.332 0.0249 0.275 0.371
U2 7.4⇥ 10 6 1.6⇥ 10 6 4.6⇥ 10 6 9.0⇥ 10 6
Table 7.1: Results of joint model fit to wheeze score for MAGNETIC
A joint model fit determined that children randomised to magnesium had on average
a wheeze score of 0.1370 lower than the placebo group, with 95% certainty that this value
was between 0.035 and 0.216. Therefore this was found to be a significant di↵erence
(p=0.005). Also patients randomised to magnesium were more likely to dropout, with the
95% confidence interval for the log-hazard ratio of [0.250,1.063]. The parameter estimate
for   indicates that a lower score may be linked to dropout, however this result was not
significant (p=0.368). In order to assess the presence of outliers, the Cook’s distances are
calculated to identify any patients with a high influence. This plot is shown in Figure 7.3.
6 2 is reported on the log-hazard scale throughout the chapter
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Figure 7.3: Plot of Influence for Each Patient
From Figure 7.3, patients 174 and 439 were identified as highly influential and we
judged these to be outliers. Patient 174 was also identified as one of the most influential
patients when modelling the overall ASS score. Figure 7.4 shows the longitudinal wheeze
score profiles for the outliers in this model.
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Figure 7.4: Longitudinal Profiles of Most Influential Cases
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Both influential patients had the maximum wheeze score prior to dropout, which was
considerably higher than average. While in general the wheeze score over time was decreas-
ing for the dataset, no change in outcome was observed prior to dropout for these patients.
The negative estimate for   suggests that patients with lower outcomes were more likely
to drop out, which was not the case for the outlying patients.
Heart Score
In the following section, the heart score data for MAGNETIC is analysed. For the heart
score subcomponent, 18.5% of patients had at least one missing value. The mean dropout
profiles for heart score are shown in Figure 7.5.
Figure 7.5: Mean Dropout Profiles for Heart Score are each time point
The group of patients that dropped out at t = 60 had a mean increasing heart rate in the
magnesium treatment group. However, the mean dropout profile at the other time points
had a decreasing score prior to the time of withdrawal. The average dropout profile in the
placebo group for patients at t = 40 show a comparatively large increase in heart score prior
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to withdrawal. Otherwise the mean profiles were decreasing. In general, heart scores were
found to be higher than wheeze and muscle use scores, and there was less variation in the
dropout profiles for heart score. To investigate the need for joint modelling further, Figure
7.6 shows the sequential discrimination at each time point = 40, 60, 120, 180, calculated by
fitting a linear mixed model.
Figure 7.6: Sequential Discrimination for non-dropouts (grey triangles) v. dropouts (red
crosses) at each time point
Overall the variation of residuals and residual slopes for heart score was less spread
out than for wheeze score. The di↵erences in profiles at t = 60, t = 120 and t = 180 was
not found to be significant, despite a larger Mahalanobis distance at t = 60. However, the
results of the sequential discrimination indicated a significant di↵erence in residual profiles
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for dropouts at t = 40, so joint modelling may be necessary for analysing the heart score
data in MAGNETIC. A joint model is fitted to estimate  ,  1 and  2, and the results are
detailed in Table 7.2.
Component Parameter Estimate SE 95%Lower 95%Upper P-Value
Longitudinal (Intercept) 2.751 0.0262 2.684 2.786
time -0.0010 1.3⇥ 10 4 -0.0013  8⇥ 10 4 < 0.001
 1 -0.0102 0.0361 -0.0798 0.0634 0.778
Survival  2 0.456 0.218 0.0402 1.028 0.033
Association   -0.394 0.236 -0.850 0.0438 0.095
Variance U1 0.124 0.0144 -0.0943 0.154
U2 3.1⇥ 106 5.0⇥ 10 7 2.4⇥ 10 6 4.1⇥ 10 6
Table 7.2: Results of joint model fit to heart score for MAGNETIC
By analysing the joint model applied to heart score, it is observed that the longitudinal
di↵erence in heart score between the two groups is not found to be significant (p=0.778).
The estimate for  1 is -0.0102. This represents approximately one hundredth of a heart
score point, which is clinically negligible. Patients with lower heart scores were more likely
to drop out in this study although this was not significant, as indicated by the   parameter
(p=0.095), with a confidence interval of [-0.850,0.044]. The  2 parameter was found to be
significant in this study (p=0.033). Figure 7.7 shows the Cook’s distances for each patient.
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Figure 7.7: Plot of Influence for Each Patient
From the influence diagnostic, we classified patient’s 250 and 258 as outliers and the
most influential values. Longitudinal profiles for these patients are presented in Figure 7.8.
Figure 7.8: Longitudinal Profiles of Most Influential Cases
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Both influential patients had a constant heart score of 1 over time, despite the estimate
of the intercept for the heart score being 2.751. Both patients were randomised to mag-
nesium, which on average had patients with lower heart scores, which may be the reason
patients 250 and 258 were identified as outliers.
Muscle Score
For muscle score, the percentage of patients with missing values was 21.7%, which is higher
than for the heart and wheeze scores. The mean muscle score in both treatment groups
was found to be lower than the other subcomponents. Figure 7.9 shows a plot of the mean
dropout profiles in each group.
Figure 7.9: Mean Dropout Profiles for Muscle Score are each time point
For magnesium, all dropout groups had a decreasing muscle profile with the exception
of those patients that dropped out at t = 20. For the placebo, all mean dropout profiles
were decreasing prior to withdrawal - with the exception of dropouts at t = 40. There did
not appear to be a substantial di↵erence in the mean dropout profiles between treatments,
however patients with a lower longitudinal profile appeared to be more likely to dropout.
165
Figure 7.10 shows a plot of the sequential discrimination to analyse the di↵erence between
dropouts and non dropouts.
Figure 7.10: Sequential Discrimination for non-dropouts (grey triangles) v. dropouts (red
crosses) at each time point
From the plots, a di↵erence in residual profiles is observed at t = 40, with the majority
of dropouts having a negative residuals or negative change in residuals, and the Maha-
lanobis distance was significant. No significant di↵erence was found between dropouts and
continuers at the other time points. However, due to the residual di↵erences at t = 40,
joint modelling methods may be appropriate. Table 7.3 details the results of the joint
model fit.
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Component Parameter Estimate SE 95%Lower 95%Upper P-Value
Longitudinal (Intercept) 1.496 0.0421 1.418 1.575
time -0.0034 1.8⇥ 10 4 -0.0038 -0.0031 < 0.001
 1 -0.0764 0.0520 -0.169 0.0246 0.142
Survival  2 0.674 0.190 0.305 1.111 < 0.001
Association   -0.369 0.192 -0.772 -0.0428 0.047
Variance U1 0.400 0.0308 0.335 0.449
U2 8.0⇥ 10 6 9.4⇥ 10 7 6.2⇥ 10 6 9.4⇥ 10 6
Table 7.3: Results for joint model fit to the MAGNETIC muscle score
Fitting the joint model did not show a significant longitudinal treatment e↵ect (p=0.142),
although on average patients randomised to magnesium had a lower muscle score (a param-
eter estimate of -0.0764). Dropout was significantly higher in the magnesium treatment
group (p¡0.001), as was the case with both heart score and wheeze score. The significant
  estimate indicated that patients with lower muscle scores were more likely to drop out
from the study. With 95% certainty the value of   was found to be within [-0.772,-0.0428].
The following plot in Figure 7.11 shows the Cook’s distances to identify influential cases.
Figure 7.11: Plot of Influence for Each Patient
When observing the plot of Cook’s distance, no obvious outliers were identified. The
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most influential patient was number 373, who was also one of the most influential when
the model fit in Section 2.5.2 was applied to ASS.
MAGNETIC Summary
In Chapter 2, an analysis of Asthma Severity Score for MAGNETIC yielded results which
showed that patients randomised to magnesium generally had a lower severity score than
in the placebo group. Patients randomised to Magnesium were also more likely to drop
out than the placebo patients and individuals with lower severity scores were more likely
to drop out. For the longitudinal outcomes of subcomponents, children in the magnesium
group were found to have a significantly lower wheeze score than in the placebo group.
However, the di↵erence in outcome for individuals randomised to magnesium was not sig-
nificant for the other components. In particular the parameter estimate for  1 was only
-0.01 for heart score. These results would suggest that adding magnesium to the standard
nebuliser has a clinical impact on the ability of children’s breathing abilities, but has very
little e↵ect on the heart rate.
When modelling wheeze score and heart score, the   parameter was not found to be
significant. However,   was significant and negative for muscle use. As many children
dropped out of the MAGNETIC trial due to a good prognostic outcome, the joint model
results may imply that this is due to an observable improvement in muscle use abilities
for certain patients. However, the magnitude of the   parameter estimate was similar for
each subcomponent, which does not support this hypothesis.
7.3 Mental Health Trial Data
In the MAGNETIC trial, a longitudinal outcome was modelled alongside time-to-dropout
and all patients that completed the measurement schedule were treated as censored. How-
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ever, in many trials the primary interest is not exclusively time-to-dropout, but time to a
given clinical event or informative dropout. In the mental dataset as found in the joineR
package in R [46], a longitudinal continuous outcome and time to informative dropout are
recorded with censoring for patients that dropped out for non-informative reasons.
The data is taken from a trial involving mental health patients, in which 150 patients
with chronic mental health issues were randomised to either placebo or one of two active
interventions (denoted Treatment 2 and Treatment 3) with 50 patients in each treatment
group. A continuous mental health score was recorded at baseline, as well as at 1,2,4,6
and 8 weeks post randomisation, and time to informative dropout was also recorded. In
total, 63 (42.0%) of patients informatively dropped out from the study. To illustrate the
applicability of these methods to balanced longitudinal data with an event outcome and
intermediate censoring, the mental data set is analysed using methods similar to those
described in Section 7.2.
Initially, a linear mixed model is fit to the longitudinal data and plots of sequential
discrimination generated, as shown in Figure 7.12.
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Figure 7.12: Sequential Discrimination for patients that remained in the trial (grey trian-
gles) v. informative dropouts (red crosses) at each time point
Due to the continuous nature of the outcome, a di↵erence in profiles between dropouts
and non-dropouts is easier to observe than for the discrete data of the MAGNETIC anal-
yses. From observing graphs, there appears to be a di↵erence between dropouts and non-
dropouts at most of the time points, with dropouts generally having both higher residuals
on average and a higher residual slope than the patients who remained in the trial. An
analysis of the Mahalanobis distance shows that there is a highly significant di↵erence at
t = 1 and t = 4, and a significant di↵erence at t = 2 and t = 6. Therefore, joint models can
be fit to the data. This initially incorporated a time variable, ↵, in the model. However
this was not found to be significant, so another model was fit excluding this variable. Joint
modelling was used to compare the two active treatments with placebo.  1,1 refers to the
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longitudinal comparison between placebo and treatment 2, while  1,2 is the longitudinal
comparison between placebo and treatment 3. Likewise for  2,1 and  2,2. Table 7.4 shows
the results of the model fit.
Component Parameter Estimate SE 95%Lower 95%Upper P-Value
Longitudinal (Intercept) 55.710 1.866 51.140 58.921
 1,1 -1.322 2.571 -6.705 3.568 0.607
 1,2 -4.780 2.346 -9.309 -0.357 0.042
Survival  2,1 -0.522 0.402 -1.415 0.245 0.194
 2,2 -0.924 0.509 -2.156 -0.0771 0.070
Association   0.0949 0.0186 0.06870 0.141 < 0.001
Variance U1 89.686 11.514 63.631 107.111
U2 3.429 0.8846 1.846 5.658
Table 7.4: Results of joint model fit to the mental trial
In the model, the two active treatments were compared to placebo. It was found that
the longitudinal treatment e↵ect for treatment 3 was a significant improvement on placebo
(p=0.042); with the treatment e↵ect being within [-9.303,-0.357]. However, treatment
2 was not found to be significant (p=0.607). There was not found to be a significant
di↵erence between treatment groups when modelling the hazard (p=0.194, 0.070), although
patients in the placebo group dropped out informatively more frequently than in the active
treatment groups, with parameter estimates of the log hazard ratio of -0.522 and -0.924
respectively. The estimate of   was positive and significant (p¡0.001), demonstrating that
patients with higher mental scores were more likely to experience a clinically informative
drop out, which concurs with the plot in Figure 7.12. The confidence interval for   showed
that with 95% certainty the value of   was within [0.069,0.141]. Figure 7.13 shows the
influence of di↵erent patients in the trial.
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Figure 7.13: Plot of Influence for Each Patient
From the Cook’s distance it can clearly by observed that patients 80, 94 and 116
have a higher influence than the other patients, and these are identified as outliers. The
longitudinal profiles for the three most influential patients are shown in Figure 7.14.
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Figure 7.14: Longitudinal Profiles of Influential Cases
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The influential nature of patient 80 with regard to the model is easy to observe from
the graph of longitudinal outcome. While the majority of patients had a lower mental
score in treatment group 3 than the other groups, patient 80 had a mental score increasing
to 92, which was the highest outcome in the whole dataset. The outcome is consistently
increasing after t = 1 up until the time of dropout. The influence of patients 94 and 116
may have been higher than other patients due to patient 94 having an increasing outcome
from baseline despite being in an active treatment group, and patient 116 completing the
measurement schedule and having a decreasing outcome despite being in the placebo group.
Analysis of Mental Health Trial Summary
In general, there was found to be no significant di↵erence in mental score or hazard for
patients in treatment group 2 when compared to placebo. However, patients in treatment
group 3 had a significantly better outcome than the placebo group. This was an improve-
ment of 4.78 points on average. Patients randomised to treatment 3 were also less likely
to experience an informative dropout. The positive value of   indicates that patients with
higher mental scores were more likely to drop out informatively. This may seem intuitive
as higher values imply a worse prognosis.
7.4 Liver Trial Data
To avoid the problem of missing data, some longitudinal trials have an unbalanced for-
mat [22]. In many trials, longitudinal readings are collected at di↵erent times for di↵erent
patients [141] - [143]. This was not the case for MAGNETIC or the mental health trial,
however joint modelling methods can be adapted and applied to this type of data. Un-
balanced joint longitudinal and survival data is taken from a liver trial that was originally
analysed in a non-joint modelling context [56].
In this trial, 488 patients with liver cirrhosis were randomised to either placebo or
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prednisone and a measure of liver function, prothrombin index, was taken at baseline and
then at di↵erent times for each patient. Prothrombin index is a discrete indirect marker
of severe liver fibrosis [144] . The maximum time after randomisation that a patient’s pro-
thrombin index was measured in this trial was 11.1 years. Survival time was also measured
and modelled as the time-to-event outcome.
Before the methods described in 7.2, 7.3 were applied to the liver trial, an exploratory
data analysis was initially carried out. Prothrombin index scores ranged from 6 to 170 for
each patient with a mean of 5.07 readings taken per subject, and the median follow up
time for the study was 2.6 years. Of the 488 patients recruited to the study, there were
292 deaths (59.8%) and the median survival time was 2.1 years. An exploratory histogram
of the survival times is plotted in Figure 7.15.
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Figure 7.15: Plot of Censored Survival Times
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In the trial, 37.0% of patients that experienced an event did so in the first year, and
21.6% within the first 6 months. The median survival in the placebo group was 1.773
years, while this was longer in the prednisone group (2.319 years). Figure 7.16 shows the
LOESS smoothed function of prothrombin index for patients randomised to placebo and
prednisone prior to death.
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Figure 7.16: Placebo = Black line, Prednisone = Red Line
The mean change in prothrombin index was decreasing in both treatment groups prior
to dropout, which appears to verify that the outcome is a successful biomarker. Rapid
decreases in prothrombin index appears to occur at around 2 years prior to death in the
prednisone group and 20 months in the placebo group. Also the index was found to be
higher in general in the prednisone group for patients that died than the placebo group.
Analysis of the outcome for censored patients showed that the mean prothrombin score
was 88.369, which can be observed from Figure 7.16 as higher value than for the patients
that died.
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In Figures 7.2, 7.6, 7.10 and 7.12, sequential discrimination was used for each timepoint
to observe the di↵erence in residual profiles for patients that experienced an event and the
ones that did not experience an event. In an unbalanced longitudinal trial, the time points
are not pre-specified or the same for each patient. Therefore we propose an amendment to
this method for unbalanced trials. To carry out the sequential discrimination, initially fit
a linear mixed model to the data as described in Chapter 6.2.1. For all patients who had
at least two longitudinal readings taken, calculate the residual for their last longitudinal
reading prior to death/being censored and also the change in residual from the previous
measurement. These can then be plotted and the patients that experienced death identified
graphically. Mahalanobis distance will again be used to quantify the di↵erence in residual
profiles for the censored and non-censored patients. Figure 7.17 shows this plot.
Figure 7.17: Sequential Discrimination Plot; Censored = Black (o), Died = Red (x)
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The residual profiles and slope of residuals for patients that died seems to be lower
on average than for the censored observations, with the majority of censored observations
having positive values for both elements. An analysis of Mahalanobis distance showed that
the di↵erence between the two groups was highly significant (a p-value of 0.0022), therefore
implying joint modelling may be appropriate.
Initially a random slope and intercept joint model was fit with time and treatment vari-
ables in the longitudinal component, and treatment in the survival component. However,
the time variable was not found to be significant. Therefore another joint model was fit
without ↵, and the results are given in Table 7.5.
Component Parameter Estimate SE 95%Lower 95%Upper P-Value
Longitudinal (Intercept) 69.990 1.264 67.274 72.623
 1 6.929 1.817 2.916 10.431 < 0.001
Survival  2 -0.0962 0.140 -0.363 0.173 0.492
Association   -0.0416 0.00397 -0.0504 -0.0345 < 0.001
Variance U1 354.498 26.57 303.001 406.220
U2 16.809 4.052 11.010 25.372
Table 7.5: Results of joint model fit to liver data
Table 7.5 shows that patients randomised to prednisone had on average a prothrom-
bin index of 6.929 higher than in the placebo group, which was found to be a significant
di↵erence(p¡0.001). The treatment e↵ect was estimated to be within the 95% confidence
interval of [2.616, 10.431]. The log hazard ratio between the treatment groups was not
found to be significant (p=0.492), although on average patients randomised to the placebo
group were more likely to experience death in this study (a log hazard ratio of -0.0962).
Patients with a lower prothrombin index were also more likely to experience death, as  
was found to be significant and negative (p¡0.001). The parameter of   was estimated to
be within [ 0.050, 0.035] with 95% certainty.
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Methods of Cook’s distance as described in 6.2.3 can be applied to this model despite
the unbalanced format. Figure 7.18 shows the results of these diagnostics to identify
outliers.
Figure 7.18: Plot of Influence for Each Patient
From calculating the influence it was determined that patients 342 and 398 were out-
liers, as they had Cook’s distances greater than 3 times the mean of the Cook’s distance
for all patients. Figure 7.19 shows the longitudinal profiles for these patients.
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Figure 7.19: Longitudinal Profiles of Influential Cases
Both outliers were randomised to prednisone. Patient 342 died in the 6th year after
randomisation, which is approximately 4 years over the median for a subject prescribed to
prednisone. Also, observing Figure 7.17 we can see that this patient had a prothrombin
index profile lower than the mean for patients in prednisone. The patient’s liver function
fluctuated greatly between 2 and 6 years with a swift decline in prognosis detected at the
start of year 3 before a temporary recovery.
At baseline patient 398 had a very low prothrombin index which remained below 35
for the first 2 years. However, after this time the patient experienced an improvement in
liver function, with the prothrombin index reaching a peak of 69 before the patient was
censored in the 7th year post randomisation. It may be expected that a patient with such
a low prothrombin index at baseline would have a low probability of survival, particularly
as on average the prothrombin index for all patients was decreasing over time.
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Liver Data Discussion
By fitting the random slope and intercept joint model to the liver data set, conclusions
can be easily drawn from the results of the model fit which may have required a multi-
tude of more time consuming analyses to establish. In general, prednisone increased the
prothrombin index for patients and therefore their liver function. Patients randomised
to prednisone had a smaller hazard of death, but this was found not to be significant.
The analysis revealed that patients with a lower prothrombin index were at greater risk
of death, which can be verified by Figure 7.20. This confirms the success of prothrombin
index for liver cirrhosis patients as a biomarker for death.
7.5 Discussion
In this chapter, the methods discussed throughout this thesis have been applied to a more
diverse range of data sets in order to display their versatility. The hope is that the reader
will gain an understanding of how these methods can be used to draw conclusions in RCT
analyses. It was demonstrated that sequential discrimination methods are an e↵ective tool
for establishing a need for joint modelling. These methods were particularly useful for
continuous outcome data as graphical methods were easier to interpret. In section 7.4, a
method for using sequential discrimination in an unbalanced trial design was proposed.
This method established a significant di↵erence between patients that died and the cen-
sored observations, suggesting joint modelling methods would be appropriate. This turned
out to be the case as   was found to be highly significant once a joint model had been fit.
Now that joint modelling has been presented in detail, a summary of these investiga-
tions, drawbacks and ideas for future work are presented in Chapter 8.
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Chapter 8
Discussion
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8.1 Introduction
The focus of this thesis has been on the development of research in the area of joint mod-
elling of longitudinal and time-to-event data, and the aim of the research was to develop
a greater understanding of how these methods can be applied. The joint model as spec-
ified by Henderson [10] uses latent Gaussian variables to monitor a longitudinal outcome
alongside the time to an event. In many clinical trials with longitudinal outcomes, there
will inevitably be patients that dropout or fail to complete the measurement schedule, and
in these cases analysing data by utilising joint models is an e cient method. However,
the systematic review conducted in Chapter 3 showed that joint modelling of longitudinal
and time-to-event data is rarely used in practice, which may be a result of a lack of under-
standing or awareness of these techniques when conducting a trial and analysing trial data.
The research conducted within this thesis should provide a greater understanding of the
joint modelling framework to the reader, and aid with the development and application
of joint modelling when conducting an RCT. This thesis provides practical examples of
when joint modelling is utilisable in a trial, derived power and sample size formulae for
studies involving joint models, an understanding of the association between longitudinal
and event time outcome and development of software to implement diagnostic methods for
joint models.
8.2 Topics Covered
In Chapter 1, an overview of conducting an RCT was presented and the importance of
good trial design was highlighted. Methods of randomisation, blinding, sample size cal-
culation and the measurement schedule all should be discussed in the planning stage of
a trial, both for RCTs where standard analyses are used and for trials that employ joint
modelling. One major issue to be addressed in the trial design is how to handle missing
data, as a mishandling of the outcomes for patients that drop out from a trial can result
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in misleading results. The joint modelling framework was also introduced in this chapter
as a method for missing data handling, and the MAGNETIC trial was introduced, which
was the main motivation behind this thesis.
A description of some commonly used methods for handling missing data were dis-
cussed in Chapter 2, as well as the potential advantages and disadvantages of employing
such methods in a longitudinal data context. A unique simulation study was carried out
to compare the performance of existing missing data handling and imputation methods
to joint modelling for estimating the treatment e↵ect ( 1). When the missingness is not
MCAR, it was concluded that joint modelling performed consistently well for data with
20, 30, 40 and 50% dropout. Joint modelling was more successful for estimating  1 than
complete case and LOCF based methods, and showed a similar level of accuracy to the
multiple imputation methods used. Joint modelling results also showed a relative bias for
 1 of under 2.1% in all cases.
A practical application of the random slope and intercept joint model was also demon-
strated by using the MAGNETIC data, in which we aimed to test the benefit of adding
magnesium nebuliser solution to the standard treatment for children with acute sever
asthma. When applying joint models, this analysis indicated that adding magnesium neb-
uliser solution to the standard severe asthma treatment resulted in a significantly lower
ASS score, and that children randomised to magnesium dropped out more than in the
placebo group. This di↵erence was not detectable when using a complete case analysis
alone, which highlighted the benefit of joint models in this scenario. The association pa-
rameter,  , was estimated to be -0.18. This indicates that patients with lower ASS profiles
were more likely to leave the study, which may have been due to these children feeling
better, and hence being ready to be discharged from the hospital.
A systematic review was carried out in Chapter 3 to establish what methods were
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used for missing data handling in trials with longitudinal outcome data between 2005 and
2012 [60]. This study showed that many papers fail to acknowledge the issue of missing
data handling, and that the most commonly used method of missing data handling was
a complete case analysis. Of the trials with missing data, 31.8% made no references to
the reasons for dropout in the article. Imputation methods were used in 18.0% of trials.
On a positive note, the results indicate that missing data problems have been addressed
more in recent years. To encourage transparency in trial reporting of missing data, a Four
Point Plan was proposed to trialists as guidelines for missing data handling. This plan
contained missing data reporting standards that should be adhered to, encouraged the in-
clusion of a discussion of the pros and cons of the missing data methods used in each trial
and suggested that all results for imputed data should be presented alongside a complete
case analysis. This study also highlighted that few RCTs employ joint modelling, as no
studies in this systematic review used these methods.
In Chapter 4, an investigation into the sample size formulae for the joint model param-
eters  1,  2 and   was conducted, and sample size formulae for   and  2 were derived for
the random slope and intercept joint model. For the joint model specification by Hender-
son [10], no published work has currently focused on sample size and power calculations.
It is suggested that this may be one of the reasons that joint modelling is rarely used for
primary analyses in clinical trial literature. For  1, simulations demonstrated that increas-
ing the number of time points and lower values of V ar(U1) results in higher powers. The
e↵ect of varying   and V ar(U2) on power was found to be negligible for  1, although it was
found that the power when using joint models was significantly higher than for a complete
case analysis. A sample size formula was derived for  2 in the case where   = 0 using
the Rao score statistic. This formula was then adjusted for   6= 0, as it was discovered
that   and V ar(U2) have an impact on the number of required events. Specifically the
simulation study showed that as   increases, the power for  2 decreases and the magnitude
of this change is proportional to  2V ar(U2). Similarly, a sample size formula for   was
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derived using the Rao score statistic. The power for   is dependent on the truncated mo-
ment for the distribution of dropout, V ar(U1), V ar(U2) Cov(U1, U2). An approximation
to the truncated moment required to estimate the sample size is proposed based upon
the uniform distribution, which takes into account the number of longitudinal time points
when calculating power. The simulation study showed that the this approximation per-
formed well, and that the number of time points in a study had an impact on the power
for  . Although the derived sample size formulae rely on knowledge of variances of the
random e↵ects, for many phase III trials with time-to-event data, preliminary studies are
undertaken to assess potential side e↵ects and success of the treatments. By applying joint
models to the preliminary data, it is possible to approximate values for V ar(U1),V ar(U2)
and Cov(U1, U2) prior to a larger scale trial. Using these estimates, sample sizes for the
  and  2 parameters for joint models can be approximated using the formulae derived in
Chapter 4.
Despite the discussions and reliance upon the   parameter in joint models, an investi-
gation of the properties of   has not been conducted in published literature, beyond the
definition for a negative and positive value. Properties of di↵erent magnitudes of   and
a visualisation for di↵erent   values is provided in Chapter 5 using simulated data. This
work showed that   is dependent on the change in longitudinal outcome pre-dropout, the
percentage dropout (baseline hazard) and V ar(U2). This is demonstrated through the
development of an approximation formula to model relationship between   and change in
outcome pre-dropout for a commonly used trial design.
Another area in which little work has been done in joint modelling is diagnostic proce-
dures. Only two papers have proposed diagnostic methods for joint modelling [119, 120],
and these methods have not been used in practice to analyse trial data. In Chapter 6, soft-
ware was developed in R to apply appropriate diagnostic methods to the random slope and
intercept joint model, and the self-made functions for sequential discrimination and Cook’s
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distance will be included in the next update of joineR. A new variation of sequential dis-
crimination which focuses solely on the longitudinal profiles immediately prior to dropout
was proposed for testing the appropriateness of joint modelling by observing di↵erences
in longitudinal profiles between patients that left the study and those that completed the
measurement schedule at each time point. Using this new method, a pre-analysis sequen-
tial discrimination for the MAGNETIC trial data indicated that di↵erences between these
two groups of patients existed, and therefore joint modelling methods were appropriate in
this instance. Cook’s distance in joint modelling was used to identify the subjects with
the greatest influence. For joint models with a parametric time-to-event specification,
a residual analysis based upon multiple imputation can be used to assess model fit. A
demonstration of this is also provided in the chapter.
In Chapter 7, the applicability of joint modelling to many di↵erent trial scenarios was
illustrated. This work provides a guide for using and interpreting joint models to trial-
ists and statisticians. However, for someone who is more interested in the methodological
elements of joint modelling, the derivations in Chapter 4 and formulation in Chapter 5
provides greater context to the work.
The work presented in this thesis emphasised that joint modelling can be a useful
tool for modelling both a longitudinal outcome and dropout simultaneously. In many tri-
als there are clinical benefits for assessing and comparing the time-to-dropout between
treatment groups, and also estimating the relationship between longitudinal outcome and
dropout. To obtain this information, without using joint models, would be a time con-
suming procedure, requiring graphical representations to coincide with multiple model fits.
With literature available on model formulation, the work in this thesis on   parameter
visualisation, sample size calculations and software development will contribute to the un-
derstanding of how to use this type of modelling, and therefore encourage trialists to apply
joint models when appropriate.
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8.3 Limitations
Within this work, the MAGNETIC trial has acted as a motivating dataset and in Chapter
7 the methods described were applied to a wider range of trial scenarios. However, this is
still only a limited number of datasets to test the proposed methods. Unfortunately the
nature of missing data in a longitudinal trial will always have elements of uncertainty, and
some patients will inevitably have intermittent missing values. The simulation studies in
this thesis have not taken into account the e↵ect of missing intermittent data as this would
complicate the analyses and interpretations.
In Chapter 3, a systematic review was carried out and data extracted from 100 pa-
pers selected at random due to time constraints. While this provides a snapshot of the
frequency that each missing data method is used, to obtain the most accurate data all
papers highlighted by the search could have data extracted and analysed. Therefore while
no papers within the sample were found to have used joint modelling of longitudinal and
time-to-event data, it is possible that the ones that did were not part of the random se-
lection. For this work to be done in the future, a full list of the 381 papers is available
on request, although it is advised than an updated systematic review is carried out with
papers included from 2012 onwards.
In Chapter 4, sample size formulae were generated for the   and  2 parameters in joint
modelling based upon knowledge or approximations of  , V ar(U1) and V ar(U2), which
may be di cult to estimate prior to a trial commencing. In this case, Bayesian methods
can be used to calculate sample size and V ar(U1), V ar(U2) which can prove to be a dif-
ficult and time consuming task for trialists [40, 48]. Also for  1, due to complexity, the
sample size and power calculations must be carried out using simulations. The majority
of the work in this chapter is based upon approximations and is calculated using datasets
with equally spaced time points. In practice, time points are not also equally spaced which
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may decrease the accuracy of the approximate sample size formulae.
As discussed in Chapter 5 Section 1, when visualising the relationship between   and
change in outcome prior to dropout, knowledge of V ar(U2) is required. While in many
trials an approximation to this value is available from preliminary studies, this may not
always the case. Also due to the nature of the gaussian variables within model means there
are limitations on certain   values for a given V ar(U2), and higher magnitudes of   can
be di cult to simulate.
Finally, for the newly developed variation of sequential discrimination, it can be di cult
to see the di↵erences in profiles from the plots alone when a longitudinal outcome is
discrete, as can be observed in Figure 6.1. In order to overcome this, a 3 dimensional
graphical representation of the results could possibly be used to indicate the number of
data points on each discrete value. This is something to consider for the future, as a
standard 3 dimensional graph may appear convoluted and di cult to discern. However,
this discrete data does not reduce the e↵ectiveness of using Mahalanobis’ distances to
generate a p-value.
8.4 Future Work
While this thesis has contributed to the understanding of the joint modelling framework
proposed by Henderson et al. [10] as well as the trial design considerations, there is still a
wide range of possibilities for further research. As highlighted in Section 8.3, the simulated
datasets fail to include intermittent missing data or unbalanced datasets. The e↵ect of in-
termittent data caused by patients missing visits is a common occurrence that has not yet
been addressed in literature for joint modelling. To investigate the e↵ect of adjusting for
intermediate missing data in a trial we can begin by analysing the MAGNETIC dataset, in
which intermediate missingness was present, using three separate methods; the standard
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analysis which treats dropout as time to first missing value as described in Chapter 2.4 of
this thesis, an analysis which imputes values for the intermittent missing data before fitting
joint models and a third analysis which treats MAGNETIC as an unbalanced study design
with each individuals longitudinal measurements being taken at di↵erent time points for
di↵erent patients. We can compare the results and establish whether the conclusions are
the same for each analysis. To investigate this further, a simulation study can be used in
which di↵erent patterns of intermittent missingness are used for simulated datasets from a
joint model. The aforementioned analyses are then employed and the di↵erences in param-
eter estimates and confidence intervals are assessed. This way, we can also assess di↵erent
methods of multiple imputation for imputing the intermittent values.
In terms of the sample size formula and power for  1, an accurate approximation is
yet to be derived in the literature despite many trials having the analyses of an outcome
observed over time as the primary goal in a study. Currently simulations are the most
accurate method of estimation. One of the main di culties with deriving such a formula
and calculating the power is that the patterns of missing data will have an e↵ect on the
power, and the research on this topic has not been covered extensively. The missingness
patterns and properties within a trial can be assessed during the analysis, and these pat-
terns will not be known in the design stage. However, in the case where time to dropout
is analysed, this becomes less of a problem as the number of missing values will follow a
less complicated pattern. The simulation study in Section 4.5 illustrated that   has no
impact on the power of  1. Therefore patterns of dropout would be the focus of this work.
A sample size formula for a linear mixed model is proposed in Hedeker et al (1999) [110]
which is also appropriate for the  1 parameter in Joint Models. However this calculates
the total number of patients required to be remaining in the study at each time point. This
may not seem appropriate for a trialist, as predicting the number of dropouts or events
at each time point prior to a trial commencing requires some guesswork. To address this
problem, I would propose a more extensive simulation study. Building on the simulations
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carried out in Chapter 4.5, by using a greater variation of trial properties, the aim would
be to establish a simpler sample size approximation formula that can be used by trialists
in the design stage of a trial. In such a study the median length of follow up, the distribu-
tion of dropout times, percentage of missingness across treatment groups, number of time
points and V ar(U1), V ar(U2) could be varied. With these large numbers of di↵erent trial
properties, it may be possible to accurately approximate the sample size in a longitudinal
trial with time-to-dropout included for  1.
Additionally, further simulations can be carried out to assess the best method of ap-
proximating the V IF for the power of  2. In Chapter 4 an approximation for the V IF
was calculated for the MAGNETIC trial design, but this approximation formula may not
be valid for all trial designs. A further simulation study based on the work done in this
Chapter can be used to test this relationship for di↵erent RCT scenarios. Currently, no
work of this nature has been carried out in published literature, and no sample size formula
which includes a patient specific random slope to model the hazard has been derived.
In the MAGNETIC dataset, the ASS score was recorded for children over the period
of 240 minutes at 7 di↵erent time points. At each time point the physician rated the
children’s ability to breathe, their heart rate and their muscle function out of 3, and the
combined scores make up the ASS. In Section 7.2, these three components were analysed
individually and it was discovered that the wheeze score was significantly di↵erent in the
treatment groups. However,   was found to be significant only in the analysis of the heart
rate data. In practice, we are aware of how these three separate variables compose together
to make the ASS score. However, we are unaware of how the wheeze score correlates with
heart score/muscle score without performing separate correlation analyses which may fail
to take into account certain elements of the joint model. Therefore it would be of great
benefit to develop a joint modelling framework capable of monitoring multiple outcomes
over time in a multivariate setting for the Henderson specification of the joint model. Fiews
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and Verbeke (2004) [145] discussed some of the pitfalls of using random e↵ects to estimate
multivariate longitudinal profiles and this paper can provide a guide and motivations to
establish a multivariate joint modelling based upon the Henderson specification of the joint
model [10]. Some work has been done in this area [52,146], but the majority of the litera-
ture focuses on Bayesian methods [49, 51]. Frequentist multivariate joint modelling is yet
to be investigated to the point where most trialists feel comfortable using the methods.
More recently, Verbeke et. al (2014) [147] presents a random e↵ects model for longitu-
dinal multivariate data which takes into account the marginal cross correlations between
mean zero random e↵ects within each longitudinal outcome. The aim for the multivariate
joint model development would be to establish a way to jointly use this model alongside the
Henderson specification of the joint model, for which all outcomes will have the same event
times. This way, multiple  ’s could be estimated and details of the correlations between
longitudinal joint model estimates investigated. While this model is yet to be developed, I
would propose the use of 3-dimensional latent mean zero Gaussian variables as a basis to
connect the separate components of this multivariate joint model.
8.5 Concluding Remarks
Joint modelling of longitudinal and time-to-event data is an under-utilised methodology
that allows conclusions to be drawn about longitudinal treatment e↵ect, dropout and de-
tails of patient prognosis prior to dropout. It has been shown that in appropriate situations,
this methodology can prove to be an e cient and accurate statistical tool. However, re-
search in this area is currently in the developmental stage. The work presented in this
thesis has provided a contribution to the understanding of this topic, and will encourage
researchers to explore joint modelling further.
191
Bibliography
[1] Moher, David et al. “CONSORT 2010 Explanation and Elaboration: Updated Guide-
lines for Reporting Parallel Group Randomised Trials.” BMJ: British Medical Journal.
340 (2010): c869.
[2] Little, Roderick J., et al. “The prevention and treatment of missing data in clinical
trials.” New England Journal of Medicine. 367.14 (2012): 1355-1360.
[3] Gabriel, Andre P., and Charles P. Mercado. “Data retention after a patient withdraws
consent in clinical trials.” Open Access Journal of Clinical Trials 3 (2011): 15.
[4] Carpenter, James R., and Michael G. Kenward. “Missing data in clinical trials: a
practical guide.” National Institute for Health Research, Publication RM03/JH17/MK:
Birmingham (2008).
[5] Fayers, Peter M., Desmond Curran, and David Machin. “Incomplete quality of life data
in randomized trials: missing items.” Statistics In Medicine 17.5:7 (1998): 679-696.
[6] Rubin, Donald B. “Multiple imputation after 18+ years.” Journal of the American
statistical Association 91.434 (1996): 473-489.
[7] Schafer, Joseph L. “Multiple imputation: a primer.” Statistical Methods In Medical
Research 8.1 (1999): 3-15.
[8] Tseng, Yi-Kuan, Fushing Hsieh, and Jane-Ling Wang. “Joint modelling of accelerated
failure time and longitudinal data.” Biometrika 92.3 (2005): 587-603.
192
[9] Williamson, P. R., et al. “Joint modelling of longitudinal and competing risks data.”
Statistics In Medicine 27.30 (2008): 6426-6438.
[10] Henderson, Robin, Peter Diggle, and Angela Dobson. “Joint modelling of longitudinal
measurements and event time data.” Biostatistics 1.4 (2000): 465-480.
[11] Stanley K. “Evaluation of randomized controlled trials.” Circulation 115.13
(2007):1819-22.
[12] Chalmers, Thomas C., et al. “A method for assessing the quality of a randomized
control trial.” Controlled Clinical Trials 2.1 (1981): 31-49.
[13] Collins, Joseph F. “Clinical Trials Protocols.” Encyclopedia of Biostatistics (2005).
[14] Sackett, David L., et al. “How to practice and teach EBM.” Edinburgh: Churchill
Livingstone (2000).
[15] Matthews, John NS. “Introduction to randomized controlled clinical trials.” CRC
Press (2006).
[16] Harper, Diane M., et al. “Sustained e cacy up to 4-5 years of a bivalent L1 virus-
like particle vaccine against human papillomavirus types 16 and 18: follow-up from a
randomised control trial.” The Lancet 367.9518 (2006): 1247-1255.
[17] Kendall, J. “Designing a research project: randomised controlled trials and their
principles.” Emergency Medicine Journal: EMJ 20.2 (2003): 164.
[18] Kayne, G. Gregory. “The use of sanocrysin in the treatment of pulmonary tuberculo-
sis:(Section of Medicine).” Proceedings of the Royal Society of Medicine 28.11 (1935):
1463.
[19] Friedman, Lawrence M., Curt Furberg, and David L. DeMets. “Fundamentals of clin-
ical trials. Vol. 4.” New York: Springer (2010).
193
[20] NHS, “Clinical Trials and Medical Research - Phases of trials”,
http://www.nhs.uk/Conditions/Clinical-trials/Pages/Phasesoftrials.aspx, 14th
September 2014.
[21] Smeaton, Laura M., “Introduction to Clinical Trial Design - Presentation”,
http://dsg.harvard.edu/courses/hst951/Spring02/951-23.pdf, 11th March 2015
[22] Diggle, Peter, Kung-Yee Liang, and Scott L. Zeger. “Longitudinal data analysis.”
(1994).
[23] Jackson, Dan, Ian R. White, and Morven Leese. “How much can we learn about
missing data?: an exploration of a clinical trial in psychiatry.” Journal of the Royal
Statistical Society: Series A (Statistics in Society) 173.3 (2010): 593-612.
[24] Laird, Nan M. “Missing data in longitudinal studies.” Statistics In Medicine 7.1:2
(1988): 305-315.
[25] Blehar, Mary C., et al. “Enrolling pregnant women: issues in clinical research.”
Women’s Health Issues 23.1 (2013): 39-45.
[26] Drane, James F. “Competency to give an informed consent: a model for making
clinical assessments.” Jama 252.7 (1984): 925-927.
[27] Lachin, John M. “Introduction to sample size determination and power analysis for
clinical trials.” Controlled Clinical Trials 2.2 (1981): 93-113.
[28] Jones, B., et al. “Trials to assess equivalence: the importance of rigorous methods.”
BMJ : British Medical Journal 313.7048 (1996): 36-39.
[29] Christensen, Erik. “Methodology of superiority vs. equivalence trials and non-
inferiority trials.” Journal of Hepatology 46.5 (2007): 947-954.
[30] Suresh, K. P. “An overview of randomization techniques: an unbiased assessment of
outcome in clinical research.” Journal of Human Reproductive Sciences 4.1 (2011): 8.
194
[31] Torgerson D., “Allocation Methods - Presentation”, www-
users.york.ac.uk/ djt6/NIcourse/randomisation.ppt, 14th March 2015.
[32] Hahn, Seokyung. “Understanding noninferiority trials.” Korean journal of Pediatrics
55.11 (2012): 403-407.
[33] McCulloch, Charles E., and John M. Neuhaus. Generalized linear mixed models. John
Wiley & Sons, Ltd, 2001.
[34] Higgins, Julian PT, ed. “Cochrane handbook for systematic reviews of interventions.”
Vol. 5. Chichester, England: Wiley-Blackwell, 2008.
[35] Chan, An-Wen, and Douglas G Altman. “Identifying Outcome Reporting Bias in
Randomised Trials on PubMed: Review of Publications and Survey of Authors.” BMJ:
British Medical Journal 330.7494 (2005): 753.
[36] British guideline on the management of asthma; Scottish Intercollegiate Guidelines
Network - SIGN (Oct 2014)
[37] Powell CVE, Kolamunnage-Dona R, Lowe J, et al. ; on behalf of the MAGNETIC
study group “MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo-
controlled trial and economic evaluation of nebulised magnesium sulphate in acute
severe asthma in children.” Southampton (UK): NIHR Journals Library; 2013 Oct.
(Health Technology Assessment, No. 17.45.)
[38] Yung, M., M. South, and T. Byrt. “Evaluation of an asthma severity score.” Journal
Of Paediatrics And Child Health 32.3 (1996): 261-264.
[39] Rizopoulos, Dimitris. “Joint models for longitudinal and time-to-event data: With
applications in R.” CRC Press, 2012.
[40] Tsiatis, A. A., Victor Degruttola, and M. S. Wulfsohn. “Modeling the relationship of
survival to longitudinal data measured with error. Applications to survival and CD4
195
counts in patients with AIDS.” Journal of the American Statistical Association 90.429
(1995): 27-37.
[41] Lin, D. Y., M. A. Fischl, and D. A. Schoenfeld. “Evaluating the role of
CD4:lymphocyte counts as surrogate endpoints in human immunodeficiency virus clin-
ical trials.” Statistics In Medicine 12.9 (1993): 835-842.
[42] Wulfsohn, Michael S., and Anastasios A. Tsiatis. “A joint model for survival and
longitudinal data measured with error.” Biometrics (1997): 330-339.
[43] Tsiatis, Anastasios A., and Marie Davidian. ”Joint modeling of longitudinal and time-
to-event data: an overview.” Statistica Sinica 14.3 (2004) : 809-834.
[44] Faucett, Cheryl L., and Duncan C. Thomas. “Simultaneously modelling censored sur-
vival data and repeatedly measured covariates: a Gibbs sampling approach.” Statistics
In Medicine 15.15 (1996): 1663-1685.
[45] Sousa, Ines. ”A review on joint modelling of longitudinal measurements and time-to-
event.” Revstat 9.1 (2011): 57-81.
[46] Philipson, Pete, Ines Sousa, and Peter J. Diggle . “joineR: Joint mod-
elling of repeated measurements and time-to-event data.”, http://cran.r-
project.org/web/packages/joineR/index.html. (2012).
[47] Powell, C, Kolamunnage-Dona R, Lowe J, Boland A, Petrou S, Doull I, Hood K,
Williamson P. “Magnesium sulphate in acute severe asthma in children (MAGNETIC):
a randomised, placebo-controlled trial.” The Lancet Respiratory Medicine 2013, 1 (4):
301-308.
[48] Chen, Liddy M., Joseph G. Ibrahim, and Haitao Chu. “Sample size and power deter-
mination in joint modeling of longitudinal and survival data.” Statistics In Medicine
30.18 (2011): 2295-2309.
196
[49] Ibrahim, Joseph G., Ming-Hui Chen, and Debajyoti Sinha. “Bayesian methods for
joint modeling of longitudinal and survival data with applications to cancer vaccine
trials.” Statistica Sinica 14.3 (2004): 863-884.
[50] Chi, Yueh Yun, and Joseph G. Ibrahim. “Joint models for multivariate longitudinal
and multivariate survival data.” Biometrics 62.2 (2006): 432-445.
[51] Xu, Jane, and Scott L. Zeger. “Joint analysis of longitudinal data comprising re-
peated measures and times to events.” Journal of the Royal Statistical Society: Series
C (Applied Statistics) 50.3 (2001): 375-387.
[52] Song, Xiao, Marie Davidian, and Anastasios A. Tsiatis. “A Semiparametric Likelihood
Approach to Joint Modeling of Longitudinal and Time-to-Event Data.” Biometrics 58.4
(2002): 742-753.
[53] Dempster, Arthur P., Nan M. Laird, and Donald B. Rubin. “Maximum likelihood
from incomplete data via the EM algorithm.” Journal Of The Royal Statistical Society.
Series B (methodological) (1977): 1-38.
[54] Little, Roderick JA. “Modeling the drop-out mechanism in repeated-measures stud-
ies.” Journal of the American Statistical Association 90.431 (1995): 1112-1121.
[55] Shizgal, B. (1981). “A Gaussian quadrature procedure for use in the solution of the
Boltzmann equation and related problems”. J. Comp. Phys. 41: 309?328.
[56] Andersen, P. K., O. Borgan, and R. D. Gill. N. Keiding. “Statistical Models Based on
Counting Processes.” Springer Science & Business Media (2012)
[57] Breslow, Norman. “Odds ratio estimators when the data are sparse.” Biometrika 68.1
(1981): 73-84.
[58] Wothke, Werner. “Longitudinal and multigroup modeling with missing data.” (2000).
[59] Little, Roderick JA, and Donald B. Rubin. “Statistical analysis with missing data.”
John Wiley & Sons, 2014.
197
[60] Powney, M., Williamson, P., Kirkham, J., & Kolamunnage-Dona, R. “A review of the
handling of missing longitudinal outcome data in clinical trials”. Trials, 15.1 (2014):
1-19.
[61] Rubin, Donald B. “Inference and missing data.” Biometrika 63.3 (1976): 581-592.
[62] Pigott, Therese D. “Methods for handling missing data in research synthesis.” The
Handbook of Research Synthesis 4.10 (1994).
[63] Dziura, James D., et al. “Strategies for dealing with missing data in clinical trials:
from design to analysis.” The Yale Journal of Biology and Medicine 86.3 (2013): 343.
[64] “Missing Completely At Random (MCAR).” http://missingdata.lshtm.ac.uk/missing-
completely-at-random-mcar 14th April 2014
[65] Brown, Helen, and Robin Prescott. “Applied mixed models in medicine.” John Wiley
& Sons, 2015.
[66] “Missing At Random (MAR).” http://missingdata.lshtm.ac.uk/missing-at-random-
mar. 14th April 2014
[67] “Missing Not At Random (MNAR).” http://missingdata.lshtm.ac.uk/missing-not-at-
random-mnar. 14th April 2014
[68] Daniels, Michael J., and Joseph W. Hogan. “Missing data in longitudinal studies:
Strategies for Bayesian modeling and sensitivity analysis.”CRC Press, 2008.
[69] Musil, Carol M., et al. ”A comparison of imputation techniques for handling missing
data.” Western Journal of Nursing Research 24.7 (2002): 815-829.
[70] Wood, Angela M., Ian R. White, and Simon G. Thompson. “Are missing outcome
data adequately handled? A review of published randomized controlled trials in major
medical journals.” Clinical Trials 1.4 (2004): 368-376.
198
[71] Acuna, Edgar, and Caroline Rodriguez : “The treatment of missing values and its
e↵ect on classifier accuracy. Classification, Clustering, and Data Mining Applications.”
Springer Berlin Heidelberg (2004). 639-647
[72] Alghannam, Abdullah F., et al. “Post-Exercise Protein Trial: Interactions between
Diet and Exercise (PEPTIDE): study protocol for randomized controlled trial.” Trials
15.1 (2014): 459.
[73] Desai, Manisha, et al. “The use of complete-case and multiple imputation-based anal-
yses in molecular epidemiology studies that assess interaction e↵ects.” Epidemiologic
Perspectives & Innovations 8.1 (2011): 5.
[74] Davey, Adam. “Statistical power analysis with missing data: A structural equation
modeling approach.” Routledge (2009).
[75] Fitzmaurice, Garrett M., Nan M. Laird, and James H. Ware. “Applied longitudinal
analysis.” Vol. 998. John Wiley & Sons, 2012.
[76] “Joint Modelling in SAS.” http://www.hsph.harvard.edu/fitzmaur/lda/Ch14-
program.pdf. 3rd January 2016
[77] Molenberghs, Geert, et al. “Analyzing incomplete longitudinal clinical trial data.”
Biostatistics 5.3 (2004): 445-464.
[78] Wood, Angela M., et al. “Comparison of imputation and modelling methods in the
analysis of a physical activity trial with missing outcomes.” International Journal of
Epidemiology 34.1 (2005): 89-99.
[79] Higgins, Julian PT, Ian R. White, and Angela M. Wood. “Imputation methods for
missing outcome data in meta-analysis of clinical trials.” Clinical Trials 5.3 (2008):
225-239.
[80] Rubin, Donald B. “Multiple imputation for nonresponse in surveys.” Vol. 81. John
Wiley & Sons, 2004.
199
[81] Enders, Craig K. “Applied missing data analysis.” Guilford Publications, 2010.
[82] Van Buuren, Stef, and Karin Oudshoorn. “Flexible multivariate imputation by
MICE.” Leiden, The Netherlands: TNO Prevention Center (1999).
[83] Heyting, A., J. T. B. M. Tolboom, and J. G. A. Essers. “Statistical handling of drop-
outs in longitudinal clinical trials.” Statistics in Medicine 11.16 (1992): 2043-2061.
[84] Robins, James M., Andrea Rotnitzky, and Lue Ping Zhao. “Analysis of semiparametric
regression models for repeated outcomes in the presence of missing data.” Journal of
the American Statistical Association 90.429 (1995): 106-121.
[85] Meng, Xiao-Li. “Multiple-imputation inferences with uncongenial sources of input.”
Statistical Science (1994): 538-558.
[86] Royston, Patrick. “Multiple imputation of missing values: further update of ice, with
an emphasis on categorical variables.” Stata Journal 9.3 (2009): 466.
[87] Verbeke, Geert, and Geert Molenberghs. “Linear mixed models for longitudinal data.”
Springer Science & Business Media, 2009.
[88] Rubin, D; “Inference and Missing Data.” Biometrika 1976, 63 (3): 581-592.
[89] Wood AM, White, IR, Thompson SG : “Are missing outcome data adequately han-
dled? A review of published randomized controlled trials in major medical journals.”
Clin Trials 1.4 (2004): 368-376
[90] Sterne, Jonathan AC, Ian R. White, John B. Carlin, Michael Spratt, Patrick Royston,
Michael G. Kenward, Angela M. Wood, and James R. Carpenter : “Multiple imputation
for missing data in epidemiological and clinical research: potential and pitfalls.” BMJ:
British Medical Journal 338 (2009): b2393.
[91] Hedeker D, Gibbons RD : “Missing Data in Longitudinal Studies.” Longitudinal Data
Analysis, Wiley 2006, 279-312,
200
[92] Rubin D: “Multiple Imputation for Nonresponse in Surveys.” Wiley 1987
[93] Schafer JL: “Analysis of incomplete multivariate data.” Chapman and Hall 1997
[94] Van Buuren, Stef, and Karin Oudshoorn : “Flexible multivariate imputation by
MICE.” (1999): 1-20.
[95] Lin, Danyu Y., and Lee-Jen Wei. ”The robust inference for the Cox proportional
hazards model.” Journal of the American Statistical Association 84.408 (1989): 1074-
1078.
[96] McCleary L: “Using multiple imputation for analysis of incomplete data in clinical
research.” Nurs Res. 51.5 (2002):339-43.
[97] Schulz KF, Altman DG, Moher D. and the CONSORT Group : “CONSORT 2010
Statement: updated guidelines for reporting parallel group randomised trials.” BMC
Medicine 8.18 (2010)
[98] Power, Michael J., and C. Freeman. “A randomized controlled trial of IPT versus
CBT in primary care: With some cautionary notes about handling missing values in
clinical trials.” Clinical psychology & psychotherapy 19.2 (2012): 159-169.
[99] Charan, Jaykaran, and Tamoghna Biswas. “How to calculate sample size for di↵er-
ent study designs in medical research?.” Indian journal of psychological medicine 35.2
(2013): 121.
[100] Schoenfeld, David A. “Sample-size formula for the proportional-hazards regression
model.” Biometrics (1983): 499-503.
[101] Therneau, Terry M., and Patricia M. Grambsch. “Modeling survival data: extending
the Cox model. Springer Science & Business Media, 2000.
[102] Rao, C. Radhakrishna. “Tests of significance in multivariate analysis.” Biometrika
(1948): 58-79.
201
[103] Rao, C. Radhakrishna. “Linear statistical inference and its applications.” John Wiley
& Sons. (2009):22
[104] Hsieh, F. Y., and Philip W. Lavori. “Sample-size calculations for the Cox proportional
hazards regression model with nonbinary covariates.” Controlled Clinical Trials 21.6
(2000): 552-560.
[105] Snijders, Tom AB. “Power and sample size in multilevel linear models.” Encyclopedia
of Statistics in Behavioral Science 3 (2005): 1570?1573
[106] “Properties of the Discrete Uniform Distribution.”
http://www.milefoot.com/math/stat/pdfd-uniformdisc.htm 14th February 2015
[107] Karow, A., et al. “PANSS syndromes and quality of life in schizophrenia.” Psy-
chopathology 38.6 (2005): 320-326.
[108] Chappell, Lucy C., et al. “E↵ect of antioxidants on the occurrence of pre-eclampsia
in women at increased risk: a randomised trial.” The Lancet 354.9181 (1999): 810-816.
[109] Arinaitwe, Emmanuel, et al. “Artemether-lumefantrine versus dihydroartemisinin-
piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan
children.” Clinical Infectious Diseases 49.11 (2009): 1629-1637.
[110] Hedeker, Donald, Robert D. Gibbons, and Christine Waternaux. “Sample size estima-
tion for longitudinal designs with attrition: comparing time-related contrasts between
two groups.” Journal of Educational and Behavioral Statistics 24.1 (1999): 70-93.
[111] Overall, John E., and Suzanne R. Doyle. “Estimating sample sizes for repeated mea-
surement designs.” Controlled Clinical Trials 15.2 (1994): 100-123.
[112] Bender, Ralf, Thomas Augustin, and Maria Blettner. “Generating survival times
to simulate Cox proportional hazards models.” Statistics In Medicine 24.11 (2005):
1713-1723.
202
[113] “Garg, Mohan L., B. Raja Rao, and Carol K. Redmond. ”Maximum-likelihood esti-
mation of the parameters of the Gompertz survival function.” Applied Statistics (1970):
152-159.
[114] Auleley, Guy-Robert, et al. “The methods for handling missing data in clinical trials
influence sample size requirements.” Journal of Clinical Epidemiology 57.5 (2004): 447-
453.
[115] Sweeting, Michael J., and Simon G. Thompson. “Joint modelling of longitudinal and
time-to-event data with application to predicting abdominal aortic aneurysm growth
and rupture.” Biometrical Journal 53.5 (2011): 750-763.
[116] Li, Ning, et al. “Joint modeling of longitudinal ordinal data and competing risks
survival times and analysis of the NINDS rt:PA stroke trial.” Statistics In Medicine
29.5 (2010): 546-557.
[117] Santos Nobre, Juvencio, and Julio da Motta Singer. “Residual analysis for linear
mixed models.” Biometrical Journal 49.6 (2007): 863-875.
[118] Cox, David R., and E. Joyce Snell. “A general definition of residuals.” Journal of the
Royal Statistical Society. Series B (Methodological) (1968): 248-275.
[119] Dobson, Angela, and Robin Henderson. “Diagnostics for joint longitudinal and
dropout time modeling.” Biometrics 59.4 (2003): 741-751.
[120] Rizopoulos, Dimitris, Geert Verbeke, and Geert Molenberghs. “Multiple Imputation
Based Residuals and Diagnostic Plots for Joint Models of Longitudinal and Survival
Outcomes.” Biometrics 66.1 (2010): 20-29.
[121] Rizopoulos, Dimitris. “JM: An R package for the joint modelling of longitudinal and
time-to-event data.” Journal of Statistical Software 35.9 (2010): 1-33.
[122] Diggle, Peter J. “Testing for random dropouts in repeated measurement data.” Bio-
metrics (1989): 1255-1258.
203
[123] De Maesschalck, Roy, Delphine Jouan-Rimbaud, and Dsir L. Massart. “The maha-
lanobis distance.” Chemometrics and intelligent laboratory systems 50.1 (2000): 1-18.
[124] Williams, James D., et al. “On the distribution of Hotelling’s T2 statistic based on
the successive di↵erences covariance matrix estimator.” Journal of Quality Technology
38 (2006): 217-229.
[125] Verbeke, Geert, Geert Molenberghs, and Caroline Beunckens. “Formal and informal
model selection with incomplete data.” Statistical Science (2008): 201-218.
[126] Gelman, Andrew, et al. “Multiple imputation for model checking: completed data
plots with missing and latent data.” Biometrics 61.1 (2005): 74-85.
[127] Van Buuren, Stef, and C. G. M. Oudshoorn. “Multivariate imputation by chained
equations.” MICE V1. 0 user’s manual. Leiden: TNO Preventie en Gezondheid (2000).
[128] Chib, Siddhartha, and Edward Greenberg. “Understanding the metropolis-hastings
algorithm.” The American Statistician 49.4 (1995): 327-335.
[129] Cleveland, William S., and Susan J. Devlin. “Locally weighted regression: an ap-
proach to regression analysis by local fitting.” Journal of the American Statistical As-
sociation 83.403 (1988): 596-610.
[130] Cook, R. Dennis. “Assessment of local influence.” Journal of the Royal Statistical
Society. Series B (Methodological) (1986): 133-169.
[131] Kim, Choongrak. “Cook’s distance in spline smoothing.” Statistics & Probability
Letters 31.2 (1996): 139-144.
[132] Condor Liverpool, http://condor.liv.ac.uk. 23rd September 2013
[133] Cox, David Roxbee, and David Victor Hinkley. “Theoretical statistics.” CRC Press.
1979.
204
[134] Fukuoka, Masahiro, et al. “Biomarker analyses and final overall survival results from
a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/pa-
clitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia
(IPASS).” Journal of Clinical Oncology 29.21 (2011): 2866-2874.
[135] Sorensen, A. Gregory, et al. “A “vascular normalization index” as potential mecha-
nistic biomarker to predict survival after a single dose of cediranib in recurrent glioblas-
toma patients.” Cancer Research 69.13 (2009): 5296-5300.
[136] Turner, Bruce C., et al. “BAG-1: a novel biomarker predicting long-term survival in
early-stage breast cancer.” Journal of Clinical Oncology 19.4 (2001): 992-1000.
[137] Scher, H. I., et al. “Evaluation of circulating tumor cell (CTC) enumeration as an
e cacy response biomarker of overall survival (OS) in metastatic castration-resistant
prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized,
double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-
dose prednisone (P) post docetaxel.” ASCO Annual Meeting Proceedings. 29.18 (2011).
[138] Casamassima, Addolorata, et al. “C-reactive protein: a biomarker of survival in
patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2
based immunotherapy.” The Journal of Urology 173.1 (2005): 52-55.
[139] McFadden Jr, E. R. “Acute severe asthma.” American Journal of Respiratory and
Critical Care Medicine 168.7 (2003): 740-759.
[140] Rizopoulos, Dimitris, Geert Verbeke, and Geert Molenberghs. “Multiple Imputation
Based Residuals and Diagnostic Plots for Joint Models of Longitudinal and Survival
Outcomes.” Biometrics 66.1 (2010): 20-29.
[141] Anota, Amlie, et al. “Time to health-related quality of life score deterioration as a
modality of longitudinal analysis for health-related quality of life studies in oncology:
do we need RECIST for quality of life to achieve standardization?.” Quality of Life
Research 24.1 (2013): 5-18.
205
[142] Solfrizzi, Vincenzo, et al. “Dietary intake of unsaturated fatty acids and age-related
cognitive decline: a 8.5-year follow-up of the Italian Longitudinal Study on Aging.”
Neurobiology of Ageing 27.11 (2006): 1694-1704.
[143] Lim, Eric, et al. “Longitudinal study of the profile and predictors of left ventricu-
lar mass regression after stentless aortic valve replacement.” The Annals of Thoracic
Surgery 85.6 (2008): 2026-2029.
[144] Croquet, Vincent, et al. “Prothrombin index is an indirect marker of severe liver
fibrosis.” European Journal of Gastroenterology & Hepatology 14.10 (2002): 1133-1141.
[145] Fieuws, Ste↵en, and Geert Verbeke. “Joint modelling of multivariate longitudinal
profiles: pitfalls of the random-e↵ects approach.” Statistics In Medicine 23.20 (2004):
3093-3104.
[146] Fieuws, Ste↵en, and Geert Verbeke. “Pairwise fitting of mixed models for the joint
modeling of multivariate longitudinal profiles.” Biometrics 62.2 (2006): 424-431.
[147] Verbeke, Geert, et al. “The analysis of multivariate longitudinal data: a review.”
Statistical Methods in Medical Research 23.1 (2014): 42-59.
206
Appendix
Publications
The work carried out in Chapter 3 was published in Trials with the following citation:
Powney, M., Williamson, P., Kirkham, J., & Kolamunnage-Dona, R. (2014). A review of
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Chapter 5 - Diagnostic Plots of Model Fit
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Chapter 2
#The f o l l ow ing func t i on imputes High/Low va lues f o r miss ing l o n g i t ud i n a l data based on MAGNETIC
f o r a datase t in wide format .
highlow< f unc t i on ( s e t ){
subj=dim( s e t ) [ 1 ]
vars=dim( s e t ) [ 2 ]
f o r ( i in 1 : subj ){
f o r ( j in 2 : vars ){
i f ( i s . na ( s e t [ i , j ] ) == TRUE && se t [ i , j  1] > 4 . 5 ) {
s e t [ i , j ] = 9
}
i f ( i s . na ( s e t [ i , j ] ) == TRUE && se t [ i , j  1] <= 4 . 5 ) {
s e t [ i , j ] = 0
}
}
}
s e t
}
Chapter 5
#The f o l l ow ing func t i on i s used to s imulate data f o r s imu la t i on study 2 . This i s a modi f i ed
ve r s i on o f the s im jo in t func t i on in the jo ineR package such that a l l p a t i en t s p r i o r to the
end o f f o l l ow up exper i enced an event , and post f o l l ow up these were censored . As we were
i n t e r e s t e d in the va r i ance s o f u1 and u2 , but not the covar iance   t h i s was s e t to 0 .
‘ s imjo int ‘ < 
f unc t i on (n = 500 , model = c (” i n t s l o p e ” , ” i n t ” , ”quad ”) , s epas soc = FALSE,
ntms = 5 , b1 = c (0 . 0 5 , 0 . 05 , 0 . 03 ) , b2 = c (1) , gamma = c (0 . 04 , 0 . 1 ) , s igu ,
vare = 0 .5 , theta0 =  3, theta1 = 1 , censo r ing = TRUE, censlam = exp( 3) ,
t runcat i on = FALSE, trunct ime = max(ntms ) , g r i d s t ep = 0 .01 , u1=1.19 , u2=0.00003)
{
model <  match . arg (model )
s i gu=matrix ( c (u1 , 0 , 0 , u2 ) , nrow=2, nco l=2)
#I f a model i s o f an unrecogn i sed type then g ive then pr in t ”Unknown model”
i f (model !=” i n t s l o p e”&&model !=” in t”&&model !=”quad ”)
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{ stop ( paste (”Unknown model ” , model ) )}
#I f i n t model , s e t ran to 1 , f o r i n t s l o p e s e t ran to 2 , i f quad model s e t ran to 3
ran=2
i f (model==”in t ”){ ran=1}
i f (model==”quad ”){ ran=3}
#Set l a t to ran
l a t=ran
#I f s epas soc i s f a l s e then s e t l a t = 1
i f ( ! s epas soc ){ l a t=1}
#i f the number o f a s s o c i a t i o n parameters dont match the model cho i c e then pr in t an e r r o r message
i f ( l ength (gamma) != l a t ){
cat (”Warning : Number o f a s s o c i a t i o n parameters do not match model cho i c e \n”)}
#se t gamma = gamma repeated with the number o f t imes being dependent on the model cho i c e
gamma=rep (gamma, l ength=ran )
#I f s i gu i s not s p e c i f i e d in the f un c t i ona l c a l l then s e t s i gu to be a matrix with one element
being equal to ran
i f ( miss ing ( s i gu ) ){ s igu< diag ( ran )}
#I f the cov i a r i an c e matrix does not have the same number o f ho r i z on t a l e lements as the model
cho i c e squared then f l a g up as an e r r o r .
i f ( l ength ( s i gu ) !=ran ˆ2){
#cat (”Warning : Dimension o f covar iance matrix does not match chosen model\n”)
i f ( l ength ( s i gu )>ran ˆ2){ s i gu=s igu [ 1 : ran , 1 : ran ]}
e l s e { s i gu=diag ( ran )⇤ s i gu [ 1 ]}}
#I f var iance s i gu i s l e s s than 0 then g ive e r r o r message ”Variance must be p o s i t i v e
i f (model==”in t ”){ i f ( s igu <0){ stop (” Variance must be p o s i t i v e ”)}}
#Error message appears i f s i gu i s not symmetric
e l s e { i f ( ! isSymmetric ( s i gu ) ){
stop (” Covariance matrix i s not symmetric ”)}
#i f the e i g enva lu e s or the determinant o f the covar iance matrix are negat ive or i f the
determinant i s zero then i t i s not p o s i t i v e semi d e f i n i t e , so return an e r r o r message .
i f ( any ( e igen ( s i gu ) $values <0) | | ( det ( s i gu )<=0)){
stop (” Covariance matrix must be p o s i t i v e semi d e f i n i t e ”)}}
#The f o l l ow ing func t i on
”getD1”< f unc t i on (q , arg )
{
D< matrix (0 , q , l ength ( arg ) )
f o r ( i in 1 : q ){D[ i , ]= arg ˆ( i  1)}
D
}
” simdat”< f unc t i on (n , model , sepassoc , ntms , b1 , b2 , gamma, s igu , vare , theta0 , theta1 , censor ing , censlam ,
truncat ion , trunctime , g r i d s t ep )
220
{#Binar i s e func t i on i s used to s e t the treatment groups to e i t h e r 0 or 1 .
b ina r i s e< f unc t i on ( a ){
i f ( a<0){
a=0
}
e l s e { a=1
}
}
#Generate n va lues f o r ( i in 1 : n){
binx< r un i f (n,  sq r t (3 ) , s q r t (3 ) )
f o r ( i in 1 : n) {
binx [ i ] = b i n a r i s e ( binx [ i ] )
}
#Combine these va lues in a data frame X2
X2< cbind ( binx )
#Give each i nd i v i dua l va lues a unique id number
id< 1:n
#repeat t h i s dependent on the number o f t imes value inputted in the funct ion , repeat f o r the
other c reated va lues .
i d l< rep ( id , each=ntms )
binxl< rep ( binx , each=ntms )
#se t time va lues ranging from 0 to ntms 1, which c r e a t e s n⇤ntms e n t r i e s
time< rep ( seq (0 , ntms 1,by=1) , l ength=n⇤ntms )
#combine these in to a data s e t which i n c l ude s an i n t e r c e p t o f 1 f o r a l l va lues and the time
func t i on
X1< cbind ( i n t e r c e p t =1, binxl , l t ime=time )
#Generate n va lues U from the multvar ia te normal d i s t r i b u t i o n with mu being a l t e r n a t i n g from 0 to
ran ( which i s based on model cho i c e ) , and var iance s i gu .
U< mvrnorm(n ,mu=rep (0 , ran ) , Sigma=s igu )
#Put a l l d e t a i l s o f U in to a separate func t i on Ul ntms times
Ul< U[ rep ( 1 : n , each=ntms ) , ]
#Generate matrix from the func t i on getD1 above based on model cho i c e
D< getD1 ( ran , time )
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#Create Matrix DU of time va lues mu l t i p l i ed by random generated va lues from mvrnorm
DU< t (D)⇤Ul
#This b i t was rounded in the j o i n t model l ing ana l y s i s
Y< X1%⇤%b1+rowSums(DU)+sq r t ( vare )⇤rnorm (n⇤ntms )
sk=dim(Y) [ 1 ]
#In t e r c ep t va lues are ext rac ted
u0< U[ , 1 ]
#i f s l ope model chosen then s l ope va lues are ext rac t ed
i f (model==”i n t s l o p e ”){u1=U[ , 2 ] }
e l s e {u1=rep (0 , n)}
#The f o l l ow ing c a l c u l a t e s p r e d i c t i v e va lues
b2x< X2%⇤%b2
cens< rep (1 , n)
i f ( ! s epas soc ){gamma=rep (gamma [ 1 ] , ran )}
i f (model !=”quad ”){
i f (model==”in t ”){gamma=c (gamma [ 1 ] , 0 ) }
uu< r un i f (n)
#In each model , the s u r v i v a l t imes are simply generated from the Cox Propor t i ona l Hazards model
with Gompertz ba s e l i n e us ing the f o l l ow ing code .
i f (model==”in t ”)
{
survtime<  l og (uu) /exp ( theta0+b2x+gamma [ 1 ] ⇤ u0 )
}
e l s e {
i i < 1⇤(( theta1+gamma [ 2 ] ⇤ u1 )<0)&(uu<exp ( exp ( theta0+b2x+gamma [ 1 ] ⇤ u0 ) /( theta1+gamma [ 2 ] ⇤ u1 ) ) )
survtime< rep (0 , n)
survt ime [ i i ]<  I n f
survt ime [ ! i i ]< 1⇤( l og (1 ( theta1+gamma [ 2 ] ⇤ u1 [ ! i i ] ) ⇤ l og (uu [ ! i i ] ) /exp ( theta0+b2x [ ! i i ]+gamma [ 1 ] ⇤ u0 [ !
i i ] ) ) /( theta1+gamma [ 2 ] ⇤ u1 [ ! i i ] ) )
}}
e l s e {
tau< trunct ime
tgr id< seq ( r un i f (1 , 0 , g r i d s t ep ) , tau , g r i d s t ep )
lam0< exp ( theta0+theta1⇤ t g r i d )
hazt< g r i d s t ep ⇤exp ( b2x )%⇤%lam0
gD2< gamma⇤getD1 ( ran , t g r i d )
hmat< exp (U%⇤%gD2)⇤hazt
uu< matrix ( r un i f ( l ength (hmat) ) ,n , l ength ( t g r i d ) )
tmat< matrix ( tgr id , n , l ength ( t g r i d ) , byrow=T)
tmat [ hmat<uu]< tau
survtime< apply ( tmat , 1 , min )
cens [ survt ime==tau ]=0}
#I f there are censored values , then generate them randomly as a func t i on o f the uniform
d i s t r i b u t i o n with parameter n .
i f ( c enso r ing ){ censt ime= l og ( r un i f (n) ) / censlam}
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#Otherwise , s e t the censored time as a very smal l time a f t e r the f i n a l time point (0 .000000001) ,
as the f i r s t time point i s at t=0.
e l s e { censt ime=rep (ntms 0.999999 ,n)}
#I f us ing an i n t e r c ep t or i n t e r c ep t with s l ope model with t ranca t i on then censored time i s the
minimum of the p r ev i ou s l y de f ined censored time and t runcat i on time .
i f (model !=”quad ”){ i f ( t runcat i on ){ censt ime=pmin ( censtime , trunct ime )}}
#The f o l l ow ing code gene ra t e s a percentage o f i n d i v i du a l s who exper i enced an event /dropout .
i i< censtime<survt ime
survt ime [ i i ]< censt ime [ i i ]
cens [ i i ]< 0
l s< rep ( survtime , each=ntms )
Y< Y[ l s>time ]
X1< X1 [ l s>time , ]
i d l< i d l [ l s>time ]
time< time [ l s>time ]
cat (100⇤sum( cens ) /n,”% exper i enced event\n”)
l i s t ( longdat=data . frame ( id=id l ,Y, time ,X1) , survdat=data . frame ( id , survtime , cens ,X2) )
}
sim< simdat (n , model , sepassoc , ntms , b1 , b2 , gamma, s igu , vare , theta0 , theta1 , censor ing , censlam ,
truncat ion , trunctime , g r i d s t ep )
l i s t ( l o n g i t ud i n a l=sim$longdat , s u r v i v a l=sim$survdat )
}
###############################################################################
# Write some bespoke func t i on s to t e s t f l e x i b l e l i n e a r random e f f e c t s code #
# Make an i f statement f o r each model we wish to t e s t #
# Mess ier but saves time ra the r than wr i t i ng a gene ra l func t i on to cover a l l #
###############################################################################
” s imjo in t W1 i s ” < 
f unc t i on (n = 500 , ntms = 5 , b1 = c (1 , 1 , 1 , 1) , b2 = c (1 , 1) , gamma = rep (1 , 3) ,
s igu , vare = 0 .1 , theta0 =  3, theta1 = 1 , censo r ing = TRUE, censlam = exp( 3) ,
t runcat i on = FALSE, trunct ime = max(ntms ) ,
model=c (”HDD9” , ”HDD10” , ”C8” , ”C9” , ”C10” , ”C11”) )
{
ran <  2
i f ( miss ing ( s i gu ) ){ s i gu <  diag ( ran )}
i f ( any ( e igen ( s i gu ) $va lues < 0) | | ( det ( s i gu ) <= 0) ){
stop (” Covariance matrix must be p o s i t i v e semi d e f i n i t e ”)}
”getD1” <  f unc t i on (q , arg )
{
D <  matrix (0 , q , l ength ( arg ) )
223
f o r ( i in 1 : q ){D[ i , ] = arg ˆ( i  1)}
D
}
” s imda t f l e x ” <  f unc t i on (n , ntms , b1 , b2 , gamma, s igu , vare , theta0 , theta1 , censor ing , censlam , truncat ion
, trunctime , model )
{
binx <  r un i f (n,  sq r t (3 ) , s q r t (3 ) )
X2 <  cbind ( binx )
id <  1 : n
i d l <  rep ( id , each=ntms )
b inx l <  rep ( binx , each=ntms )
time <  rep ( 0 : ( ntms 1) , l ength=n⇤ntms )
X1 <  cbind ( i n t e r c e p t =1, binxl , l t ime=time )
U <  mvrnorm(n ,mu=rep (0 , ran ) , Sigma=s igu )
Ul <  U[ rep ( 1 : n , each=ntms ) , ]
D <  getD1 ( ran , time )
DU <  t (D)⇤Ul
Y <  X1%⇤%b1+rowSums(DU)+sqr t ( vare )⇤rnorm (n⇤ntms )
#Inc lude step here to change s c a l e from 1 to 9 ( d i s c r e t e va lues )   check f o r gamma d i f f e r e n c e .
u0 <  U[ , 1 ]
u1 <  U[ , 2 ]
b2x <  X2%⇤%b2
cens <  rep (1 , n)
uu <  r un i f (n)
i f (model == ”HDD9”){
i i < (( theta1+gamma [ 3 ] ⇤ u1 )<0)&(uu<exp ( exp ( theta0+b2x+(gamma[1]+gamma [ 3 ] ) ⇤u0+gamma [ 2 ] ⇤ u1 ) /( theta1+
gamma [ 3 ] ⇤ u1 ) ) )
survtime< rep (0 , n)
survt ime [ i i ]<  I n f
survt ime [ ! i i ]< 1⇤( l og (1 ( theta1+gamma [ 3 ] ⇤ u1 [ ! i i ] ) ⇤ l og (uu [ ! i i ] ) /exp ( theta0+b2x [ ! i i ]+(gamma[1]+
gamma [ 3 ] ) ⇤u0 [ ! i i ]+gamma [ 2 ] ⇤ u1 [ ! i i ] ) ) /( theta1+gamma [ 3 ] ⇤ u1 [ ! i i ] ) )
}
e l s e i f (model == ”HDD10”)
{
i i < (( theta1+gamma [ 2 ] ⇤ u1 )<0)&(uu<exp ( exp ( theta0+b2x+gamma [ 1 ] ⇤ u1+gamma [ 2 ] ⇤ u0 ) /( theta1+gamma [ 2 ] ⇤ u1 )
) )
survtime< rep (0 , n)
survt ime [ i i ]<  I n f
survt ime [ ! i i ]< 1⇤( l og (1 ( theta1+gamma [ 2 ] ⇤ u1 [ ! i i ] ) ⇤ l og (uu [ ! i i ] ) /exp ( theta0+b2x [ ! i i ]+gamma [ 1 ] ⇤ u1 [ !
i i ]+gamma [ 2 ] ⇤ u0 [ ! i i ] ) ) /( theta1+gamma [ 2 ] ⇤ u1 [ ! i i ] ) )
}
e l s e i f (model == ”C8”)
{
i i < (theta1<0)&(uu<exp ( exp ( theta0+b2x+gamma [ 1 ] ⇤ u0 ) / theta1 ) )
survtime< rep (0 , n)
survt ime [ i i ]<  I n f
survt ime [ ! i i ]< 1⇤( l og (1  theta1⇤ l og (uu [ ! i i ] ) /exp ( theta0+b2x [ ! i i ]+gamma [ 1 ] ⇤ u0 [ ! i i ] ) ) / theta1 )
}
e l s e i f (model == ”C9”)
{
i i < (theta1<0)&(uu<exp ( exp ( theta0+b2x+gamma [ 1 ] ⇤ u1 ) /( theta1 ) ) )
survtime< rep (0 , n)
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survt ime [ i i ]<  I n f
survt ime [ ! i i ]<  l og (1  theta1⇤ l og (uu [ ! i i ] ) /exp ( theta0+b2x [ ! i i ]+gamma [ 1 ] ⇤ u1 [ ! i i ] ) ) / theta1
}
e l s e i f (model == ”C10”)
{
i i < (theta1<0)&(uu<exp ( exp ( theta0+b2x+gamma [ 1 ] ⇤ ( u0+u1 ) ) /( theta1 ) ) )
survtime< rep (0 , n)
survt ime [ i i ]<  I n f
survt ime [ ! i i ]<  l og (1  theta1⇤ l og (uu [ ! i i ] ) /exp ( theta0+b2x [ ! i i ]+gamma [ 1 ] ⇤ ( u0 [ ! i i ]+u1 [ ! i i ] ) ) ) / theta1
}
e l s e
{
i i < (theta1<0)&(uu<exp ( exp ( theta0+b2x+gamma [ 1 ] ⇤ u0+gamma [ 2 ] ⇤ u1 ) /( theta1 ) ) )
survtime< rep (0 , n)
survt ime [ i i ]<  I n f
survt ime [ ! i i ]< 1⇤( l og (1  theta1⇤ l og (uu [ ! i i ] ) /exp ( theta0+b2x [ ! i i ]+gamma [ 1 ] ⇤ u0 [ ! i i ]+gamma [ 2 ] ⇤ u1 [ ! i i
] ) ) / theta1 )
}
i f ( c en so r ing ){ censt ime= l og ( r un i f (n) ) / censlam}
e l s e { censt ime=rep (ntms 0.999999 ,n)}
i f ( t runcat i on ){ censt ime=pmin ( censtime , trunct ime )}
i i< censtime<survt ime
survt ime [ i i ]< censt ime [ i i ]
cens [ i i ]< 0
l s< rep ( survtime , each=ntms )
Y< Y[ l s>time ]
X1< X1 [ l s>time , ]
i d l< i d l [ l s>time ]
time< time [ l s>time ]
cat (100⇤sum( cens ) /n,”% exper i enced event\n”)
l i s t ( longdat=data . frame ( id=id l ,Y, time ,X1) , survdat=data . frame ( id , survtime , cens ,X2) )
}
sim< s imda t f l e x (n , ntms , b1 , b2 , gamma, s igu , vare , theta0 , theta1 , censor ing , censlam , truncat ion ,
trunctime , model )
l i s t ( l o n g i t ud i n a l=sim$longdat , s u r v i v a l=sim$survdat )
}
############################################
# Now some s imu la t i on s to t e s t s p l i n e f i t s #
############################################
” s im j o i n t s p l i n e ” < 
f unc t i on (n = 500 , ntms = 5 , b1 = c (1 , 1 , 1 , 1) , b2 = c (1 , 1) , gamma = rep (1 , 3) ,
s igu , vare = 0 .1 , theta0 =  pi , theta1 = 0 .01 , c enso r ing = TRUE,
censlam = exp( 3) , t runcat i on = FALSE, trunct ime = max(ntms ) , tau = 5 , cp = 2 ,
ngr id = 100 , i n t on ly = FALSE)
{
ran <  3 # This could vary   s t a r t with int , s l ope <= tau , s l ope > tau
i f ( miss ing ( s i gu ) ){ s i gu <  diag ( ran )}
i f ( any ( e igen ( s i gu ) $va lues < 0) | | ( det ( s i gu ) <= 0) ){
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stop (” Covariance matrix must be p o s i t i v e semi d e f i n i t e ”)}
”getD1” <  f unc t i on (q , arg , cp )
{
D <  matrix ( arg , q , l ength ( arg ) , byrow = TRUE)
D[ 1 , ] <  1
D[ 2 , ] <  pmin ( arg , cp )
D[ 3 , ] <  pmax( arg   cp , 0)
D
}
# Can a l s o use a l t sim method f o r t h i s model as no t term in l a t en t as soc
”getD2” <  f unc t i on (q , arg , cp ) # This i s needed to get c o r r e c t l a t en t a s s o c i a t i o n
{
D2 <  matrix ( arg , q , l ength ( arg ) , byrow = TRUE)
D2 [ 1 , ] <  1
D2 [ 2 , ] <  pmin ( arg , cp )
D2 [ 3 , ] <  pmax( arg   cp , 0)
D2
}
# This w i l l use d i s c r e t e time and gr id approach
” s imda t f l e x sp ” <  f unc t i on (n , ntms , b1 , b2 , gamma, s igu , vare , theta0 , theta1 , censor ing , censlam ,
truncat ion , trunctime , tau , cp , ngrid , i n ton ly=in ton ly )
{
binx <  r un i f (n,  sq r t (3 ) , s q r t (3 ) )
X2 <  cbind ( binx )
id <  1 : n
i d l <  rep ( id , each=ntms )
b inx l <  rep ( binx , each=ntms )
time <  rep ( 0 : ( ntms 1) , l ength=n⇤ntms )
X1 <  cbind ( i n t e r c e p t =1, binxl , l t ime=time )
U <  mvrnorm(n ,mu=rep (0 , ran ) , Sigma=s igu )
Ul <  U[ rep ( 1 : n , each=ntms ) , ]
D <  getD1 ( ran , time , cp )
DU <  t (D)⇤Ul
Y <  X1 %⇤% b1 + rowSums(DU) + sqr t ( vare ) ⇤ rnorm (n ⇤ ntms )
u0 <  U[ , 1 ]
u1 <  U[ , 2 ]
u2 <  U[ , 3 ]
b2x <  X2 %⇤% b2
i f ( i n t on ly ){
cens <  rep (1 , n)
uu <  r un i f (n)
i i < (theta1<0)&(uu<exp ( exp ( theta0+b2x+gamma [ 1 ] ⇤ u0 ) / theta1 ) )
survtime< rep (0 , n)
survt ime [ i i ]<  I n f
survt ime [ ! i i ]< 1⇤( l og (1  theta1⇤ l og (uu [ ! i i ] ) /exp ( theta0+b2x [ ! i i ]+gamma [ 1 ] ⇤ u0 [ ! i i ] ) ) / theta1 )
}
e l s e {
# This part i s key d i f f e r e n c e
h <  tau / ngr id
i i <  1 : ngr id
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t g r i d <  i i ⇤ h
lam0 <  matrix ( exp ( theta0 + theta1 ⇤ t g r i d ) , n , ngrid , byrow = TRUE)
hazt <  lam0 ⇤ as . vec tor ( exp ( b2x ) ) ⇤ h
DUgrid <  U %⇤% (gamma ⇤ getD2 ( ran , tgr id , cp ) ) # Change D2 f o r other models
hmat <  hazt ⇤ exp (DUgrid )
uu <  matrix ( r un i f (n ⇤ ngr id ) , n , ngr id )
tmat <  matrix ( tgr id , n , ngrid , byrow = TRUE)
tmat [ uu > hmat ] <  tau # ”NON event t imes ”
survtime <  apply ( tmat , 1 , min )
cens <  rep (0 , l ength = n)
cens [ survt ime < tau ] <  1
}
# Censoring same as be f o r e
i f ( c enso r ing ){ censt ime <   l og ( r un i f (n) ) / censlam}
e l s e { censt ime <  rep (ntms 0.999999 , n)}
i i <  censt ime < survt ime
survtime [ i i ] <  censt ime [ i i ]
cens [ i i ] <  0
l s <  rep ( survtime , each = ntms )
Y <  Y[ l s > time ]
X1 <  X1 [ l s > time , ]
i d l <  i d l [ l s > time ]
time <  time [ l s > time ]
cat (100⇤sum( cens ) /n,”% exper i enced event\n”)
l i s t ( longdat=data . frame ( id=id l ,Y, time ,X1) , survdat=data . frame ( id , survtime , cens ,X2) )
}
sim< s imda t f l e x sp (n , ntms , b1 , gamma, s igu , vare , theta0 , theta1 , censor ing , censlam , truncat ion , trunctime
, tau , cp , ngrid , i n t on ly )
l i s t ( l o n g i t ud i n a l=sim$longdat , s u r v i v a l=sim$survdat )
}
s imjointnew< f unc t i on (n = 500 , model = c (” i n t s l o p e ” , ” i n t ” , ”quad ”) , s epas soc = FALSE,
ntms = 5 , b1 = c (1 , 1 , 1) , b2 = c (1 , 1) , gamma = c (1 , 0 . 1 ) , s igu ,
vare = 0 .5 , theta0 =  3, theta1 = 1 , censo r ing = TRUE, censlam = exp( 3) ,
t runcat i on = FALSE, trunct ime = max(ntms ) , g r i d s t ep = 0 .01 ) {
h e l l o=s im jo in t (n , model , sepassoc ,
ntms , b1 , b2 , gamma, s igu ,
vare , theta0 , theta1 , censor ing , censlam ,
truncat ion , trunctime , g r i d s t ep )
qw< c (1 , 2 , 3 , 5 )
h e l l o $ l o n g i t u d i n a l=h e l l o $ l o n g i t u d i n a l
h e l l o $ s u r v i v a l=h e l l o $ s u r v i v a l [ , qw ]
l i s t ( l o n g i t ud i n a l=he l l o $ l on g i t ud i n a l , s u r v i v a l=h e l l o $ s u r v i v a l )
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}#For example
s im jo in t ( b1=c (0 , 0 , 0 ) , b2=c (0) ,gamma=c (1) , vare = 0 . 5 , theta0 =  3, theta1 = 0 , censo r ing = FALSE,
censlam = exp( 5) , u1=1,u2=1)
#The f o l l ow ing func t i on gene ra t e s the dropout and censo r ing f o r a l o n g i t ud i n a l balanced data s e t
in wide format . In t h i s ins tance , the time o f dropout i s de f ined as the time point p r i o r to
when the pat i en t f i r s t had a miss ing value .
g ene ra t e su rv i va l< f unc t i on ( object , time . co l , t imes ){
n< dim( ob j e c t ) [ 1 ]
surv=rep (0 , dim( ob j e c t ) [ 1 ] )
cens=rep (0 , dim( ob j e c t ) [ 1 ] )
i f ( l ength ( time . c o l ) != length ( t imes ) ){
#I f the number o f time po in t s are not equal to the number o f columns s e l e c t e d in wide
format , p r i n t an e r r o r message
p r in t (”Number o f columns must be equal to the number o f time po in t s ”)
}
e l s e {
#This f o r loop runs the code f o r each person i nd i v i d u a l l y
f o r ( i in 1 : n){
f o r ( j in 1 : l ength ( t imes ) ) {
#I f there i s no value at ba s e l i n e then s e t the s u r v i v a l time to the time o f b a s e l i n e
read ing and censo r ing func t i on equal to 1 .
i f ( j==1 & i s . na ( ob j e c t [ i , time . c o l [ j ] ] )==TRUE) {
surv [ i ] = times [ j ]
cens [ i ]=1
break
}
i f ( i s . na ( ob j e c t [ i , time . c o l [ j ] ] )==TRUE & j !=1) {
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# I f a pat i en t had the f i r s t value miss ing at a given time point , then assume
they dropped out immediately a f t e r the prev ious measurement was taken so the
s u r v i v a l i s equal to the time point p r i o r to the miss ing one . Censoring
func t i on i s s e t equal to 1 .
surv [ i ] = times [ j  1]
cens [ i ]=1
break
}
i f ( j==length ( t imes ) ){
#I f the pat i en t completes the study , then s e t censo r ing equal to 0 and su r v i v a l
time the time at which the l a s t read ing was measured .
surv [ i ]= times [ l ength ( t imes ) ]
cens [ i ]=0
break
}
}
}
t rans formedset< cbind ( object , surv , cens )
re turn ( t rans fo rmedset )
}
}
#The func t i on below s imu la t e s 1000 data s e t s based on the t r i a l p r op e r t i e s de s c r ibed in
s imu la t i on study 2 ( alpha , beta 0 , beta 1 , beta 2 = 0) and p l o t s the mean p r o f i l e s f o r
pa t i en t s that dropped out ( exc lud ing the pa t i en t s who dropped out at ba s e l i n e ) . tht0 i s
changed to g ive d i f f e r e n t percentages o f dropout , a long with the model parameters gam , u1 and
u2 ( va r i ance s ) . U1 and u2 were simply ed i t ed in the s im jo in t func t i on to be the input tab l e
va r i ance s o f u1 and u2 .
themeanswithoutbase l ine< f unc t i on (gam , up , ud , tht0 , tht1 ){
u=c (0 , 0 , 0 , 0 )
f o r ( i in 1 :500) {
he l l o< s im jo in t ( b1=c (0 , 0 , 0 ) , b2=c (0) ,gamma=c (gam) , vare = 0 . 5 , theta0 = tht0 , theta1 = tht1 ,
c en so r ing = FALSE, censlam = exp( 5) , u1=up , u2=ud)
nums=which ( h e l l o $ s u r v i v a l [ ,3]==1)
h=subset ( h e l l o $ l ong i t ud i n a l , id==nums [ 1 ] )
f o r ( j in 2 : l ength (nums) ){
g=subset ( h e l l o $ l on g i t ud i n a l , id==nums [ j ] )
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h=rbind (h , g )
}
h=h[ , 6]
wide <  reshape (h , v . names=”Y” , idvar=”id ” , t imevar=”time ” , d i r e c t i o n=”wide ”)
colMeans ( wide [ , 4 : 7 ] , na . rm=TRUE)
newset=gene r a t e su rv i v a l ( wide , time . c o l =4:7 , t imes=c (0 , 1 , 2 , 3 ) )
#The f o l l ow ing func t i on backwards mean outcome dropout p l o t s f o r the c o l l e c t i o n o f pa t i en t s
s p e c i f i e d by time o f dropout . ( Like a backwards ve r s i on o f Figure 2 . 9 ) . This a l l ows the means
o f each p r o f i l e to be ca l cu l a t ed .
dropoutplotbalanced< f unc t i on
( dataset , time . co l , times , type ){
yo< g en e r a t e su rv i va l ( dataset , time . co l , t imes )
n=length ( time . c o l )
ave1=time . c o l
f o r ( i in 1 : n){
h e l l o=subset ( yo , surv==times [ i ] )
ave=colMeans ( h e l l o [ time . c o l [ 1 : n ] ] , na . rm=TRUE)
f o r ( j in 1 : n){
i f ( j>i ){
ave [ j ]=NA
}
}
ave1=rbind ( ave1 , ave )
}
ave1=ave1 [ 1 , ]
ave2=cbind ( ave1 , t imes )
p r in t ( ave2 )
i f ( type==1){
p lo t ( t imes [ 1 ] , na . omit ( ave1 [ 1 ] ) , xl im=c ( t imes [ 1 ] , t imes [ n ] ) , yl im=c (min ( ave1 , na . rm=TRUE) ,max( ave1 , na .
rm=TRUE) ) , type=”o” , lwd=3,pch=2, xlab=”time ” , ylab=”value ”)
f o r ( k in 2 : n 1){
l i n e s ( t imes [ 1 : k ] , na . omit ( ave1 [ k , ] ) , c o l=k , lwd=3, type=”o” , pch=2)
}
}
i f ( type==2){
p lo t ( ave2 [ 1 , l ength ( t imes )+1]  t imes [ 1 ] , na . omit ( ave1 [ 1 ] ) , xlim=c( t imes [ n ] , 0 ) , ylim=c (min ( ave1 , na . rm=
TRUE) ,max( ave1 , na . rm=TRUE) ) , type=”o” , lwd=3,pch=2, xlab=”time ” , ylab=”value ”)
f o r ( k in 2 : n 1){
l i n e s ( (ave2 [ k , l ength ( t imes )+1]  t imes [ 1 : k ] ) , na . omit ( ave1 [ k , ] ) , c o l=k , lwd=3, type=”o” , pch=2)
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#The f o l l ow ing code c a l c u l a t e s the o v e r a l l mean dropout p r o f i l e by weight ing the mean dropout
outcomes f o r pa t i en t s that dropped out at each time point by the proport ion o f pa t i en t s that
dropped out at each time point .
meanies=c (0 , 0 , 0 , 0 )
meanies [ 4 ]=( ave2 [ 2 , 2 ]⇤ l ength ( which ( newset [ ,8]==1) )+ave2 [ 3 , 3 ]⇤ l ength ( which ( newset [ ,8]==2) )+ave2
[ 4 , 4 ]⇤ l ength ( which ( newset [ ,8]==3) ) ) /( l ength ( which ( newset [ ,8]==3) )+length ( which ( newset [ ,8]==2)
)+length ( which ( newset [ ,8]==1) ) )
meanies [ 3 ]=( ave2 [ 2 , 1 ]⇤ l ength ( which ( newset [ ,8]==1) )+ave2 [ 3 , 2 ]⇤ l ength ( which ( newset [ ,8]==2) )+ave2
[ 4 , 3 ]⇤ l ength ( which ( newset [ ,8]==3) ) ) /( l ength ( which ( newset [ ,8]==3) )+length ( which ( newset [ ,8]==2)
)+length ( which ( newset [ ,8]==1) ) )
meanies [ 2 ]=( ave2 [ 3 , 1 ]⇤ l ength ( which ( newset [ ,8]==2) )+ave2 [ 4 , 2 ]⇤ l ength ( which ( newset [ ,8]==3) ) ) /(
l ength ( which ( newset [ ,8]==3) )+length ( which ( newset [ ,8]==2) ) )
meanies [ 1 ]=( ave2 [ 4 , 1 ]⇤ l ength ( which ( newset [ ,8]==3) ) ) /( l ength ( which ( newset [ ,8]==3) ) )
p r i n t ( meanies )
}
}
meanies
}
hi=dropoutp lotba lanced (wide , time . c o l =4:7 , t imes=c (0 , 1 , 2 , 3 ) , type=2)
hi
u=rbind (u , h i )
}
u [ , 1]
u
}
e . g .
meandropoutpro f i l e s=themeanswithoutbase l ine (1 , 0 . 5 , 0 . 5 ,  4 . 8 , 0 )
meandropoutpro f i l e s=meandropoutpro f i l e [ 1 , ]
meandrops=colMeans ( meandropoutpro f i l e )
Chapter 6
#The f o l l ow ing code c a r r i e d out s e qu en t i a l d i s c r im ina t i on f o r the MAGNETIC data s e t .
#Cal l e s s e n t i a l l i b r a r i e s
l i b r a r y ( lme )
l i b r a r y (mice )
l i b r a r y ( l a t t i c e )
magnetic< read . csv (” magnetic . csv ”)
magnetic
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#Transform a l l va lues o f  9 to NA values , which i s how these are r epre s ented in the MAGNETIC data
s e t .
magnetic [ magnetic== 9] <  NA
magnetic [ magnetic== 8] <  NA
#I s o l a t e s e v e r i t y data
s eve r i t y< magnetic [ , c (1 , 2 , 3 , 7 , 11 ,15 ,19 ,23 ,27 ,31 ) ]
#f o r wheeze data
#seve r i t y< magnetic [ , c (1 , 2 , 3 , 4 , 8 , 12 , 16 , 20 , 24 ,28 ) ]
#f o r muscle data
#seve r i t y< magnetic [ , c (1 , 2 , 3 , 5 , 9 , 13 , 17 , 21 , 25 ,29 ) ]
#f o r heart data
#seve r i t y< magnetic [ , c (1 , 2 , 3 , 6 , 10 ,14 ,18 ,22 ,26 ,30 ) ]
#Use the g en e r a t e su rv i v a l func t i on in order to c r ea t e the dropout time and censo r ing in the
l o n g i t ud i n a l data s e t .
s eve r i tydropout=gene r a t e su rv i v a l ( s ev e r i t y , 4 : 1 0 , c (0 ,20 ,40 ,60 ,120 ,180 ,240) )
#Put t h i s s e v e r i t y data s e t in long format in order to f i t a standard l on g i t ud i n a l model to t h i s
part o f the data a lone .
f u l l s e v e r i t y . long = reshape ( d i r e c t i o n=”long ” , data = sever i tydropout ,
varying = l i s t ( 4 : 1 0 ) , v . names = ” sco r e ” ,
t imevar = ”time ” , t imes = c (0 ,20 ,40 ,60 ,120 ,180 ,240) )
#El iminate the miss ing va lues
f u l l s e v e r i t y . long=f u l l s e v e r i t y . long [ ! i s . na ( f u l l s e v e r i t y . l ong$ s co r e ) , ]
#Fit a non l i n e a r mixed model to the data s e t and c a l c u l a t e the r e s i d u a l s
fm1 <  lme ( s co r e ˜ time + Treatment , random = ˜ 1 + time | id , data = f u l l s e v e r i t y . long )
#The r e s i d u a l s are shown below
fm1$re s idua l s [ , 1 ]
#Join the r e s i d u a l s to the long form of the data s e t .
another=cbind ( f u l l s e v e r i t y . long [ , c ( 3 , 4 , 5 , 6 , 7 , 8 ) ] , fm1$re s idua l s [ , 1 ] )
#Put the s e v e r i t y datase t with r e s i d u a l va lues o f the l o n g i t ud i n a l f i t in wide format .
sv=reshape ( another , idvar = ” id ” , t imevar = ”time ” , d i r e c t i o n = ”wide ”)
#The code below e l im ina t e s any dup l i c a t e v a r i a b l e s and t i d i e s up the data s e t .
sv=sv [ , c (1 , 2 , 3 , 4 , 5 , 6 , 10 ,11 ,15 ,16 ,20 ,21 ,25 ,26 ,30 ,31 ,35 ,36 ) ]
#Creat ing the s l ope o f the r e s i d u a l s
d i f f e r e n c e 2 0=(sv [ ,8 ]  s i [ , 6 ] )
d i f f e r e n c e 4 0=(sv [ ,10]  s i [ , 8 ] )
d i f f e r e n c e 6 0=(sv [ ,12]  s i [ , 1 0 ] )
d i f f e r e n c e 1 2 0=(sv [ ,14]  s i [ , 1 2 ] )
d i f f e r e n c e 1 8 0=(sv [ ,16]  s i [ , 1 4 ] )
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#and attach ing t h i s to the e x i s t i n g data s e t
s eve r i tydropout=cbind ( sv , d i f f e r en c e20 , d i f f e r en c e40 , d i f f e r en c e60 , d i f f e r en c e120 ,
d i f f e r e n c e 1 8 0 )
#Transform the data in long format
another = reshape ( d i r e c t i o n=”long ” , data = sever i tydropout ,
varying = l i s t ( c (5 ,7 , 9 , 11 ,13 ,15 ,17 ) ) , v . names = ” sco r e ” ,
t imevar = ”time ” , t imes = c (0 ,20 ,40 ,60 ,120 ,180 ,240) )
#In order to c r ea t e the p l o t s we have to i d e n t i f y the r i s k s e t at each time point ( the
pa t i en t s at r i s k o f dropout ) , The f o l l ow ing code s epa ra t e s the r i s k s e t s at dropout =
40 ,60 ,120 ,180 .
r s3=subset ( another , surv .0>=40)
r s4=subset ( another , surv .0>=60)
r s5=subset ( another , surv .0>=120)
r s6=subset ( another , surv .0>=180)
#The f o l l ow ing code e l im ina t e s the unnecessary v a r i a b l e s from each r i s k s e t element o f
data .
r s3=rs3 [ , c ( 5, 6, 8, 9, 10, 11, 12, 14, 15, 16) ]
r s4=rs4 [ , c ( 5, 6, 7, 9, 10, 11, 12, 13, 15, 16) ]
r s5=rs5 [ , c ( 5, 6, 7, 8, 10, 11, 12, 13, 14, 16) ]
r s6=rs6 [ , c ( 5, 6, 7, 8, 9, 11, 12, 13, 14, 15) ]
#We separate pa t i en t s in to those that dropped out , and those that remained in the study
beyond t=40 in to two groups .
r s31=subset ( rs3 , cens .0==1 & surv .0==40 & time==40)
rs32=subset ( rs3 , surv .0!=40 & time==40)
rs31=cbind ( rs31 , r i s k=rep (1 , dim( rs31 ) [ 1 ] ) )
r s32=cbind ( rs32 , r i s k=rep (0 , dim( rs32 ) [ 1 ] ) )
#We do the same f o r t=60
rs41=subset ( rs4 , cens .0==1 & surv .0==60 & time==60)
rs42=subset ( rs4 , surv .0!=60 & time==60)
rs41=cbind ( rs41 , r i s k=rep (1 , dim( rs41 ) [ 1 ] ) )
r s42=cbind ( rs42 , r i s k=rep (0 , dim( rs42 ) [ 1 ] ) )
#We do the same f o r t=120
rs51=subset ( rs5 , cens .0==1 & surv .0==120 & time==120)
rs52=subset ( rs5 , surv .0!=120 & time==120)
rs51=cbind ( rs51 , r i s k=rep (1 , dim( rs51 ) [ 1 ] ) )
r s52=cbind ( rs52 , r i s k=rep (0 , dim( rs52 ) [ 1 ] ) )
#We do the same f o r t=180
rs61=subset ( rs6 , cens .0==1 & surv .0==180 & time==180)
rs62=subset ( rs6 , surv .0!=180 & time==180)
rs61=cbind ( rs61 , r i s k=rep (1 , dim( rs61 ) [ 1 ] ) )
r s62=cbind ( rs62 , r i s k=rep (0 , dim( rs62 ) [ 1 ] ) )
#We now p lo t the r e s i d u a l s aga in s t the s l ope o f the r e s i d u a l s f o r each r i s k s e t .
par (mfrow=c (2 , 2 ) )
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matplot ( r s32 [ 5 ] , r s32 [ 6 ] , pch=2, c o l=”grey ” , xlab=”Mean Res ids ” , ylab=”Slope o f Res ids ” ,main=”Risk
Set at t=40” , ylim=c ( 4 ,4) , xlim=c ( 4.2 ,4) )
matpoints ( r s31 [ 5 ] , r s31 [ 6 ] , pch=”x” , c o l =2)
matplot ( r s42 [ 5 ] , r s42 [ 6 ] , pch=2, c o l=”grey ” , xlab=”Mean Res ids ” , ylab=”Slope o f Res ids ” ,main=”Risk
Set at t=60” , ylim=c ( 4 ,4) , xlim=c ( 4.2 ,4) )
matpoints ( r s41 [ 5 ] , r s41 [ 6 ] , pch=”x” , c o l =2)
matplot ( r s52 [ 5 ] , r s52 [ 6 ] , pch=2, c o l=”grey ” , xlab=”Mean Res ids ” , ylab=”Slope o f Res ids ” ,main=”Risk
Set at t=120” , ylim=c ( 4 ,4) , xlim=c ( 4.2 ,4) )
matpoints ( r s51 [ 5 ] , r s51 [ 6 ] , pch=”x” , c o l =2)
matplot ( r s62 [ 5 ] , r s62 [ 6 ] , pch=2, c o l=”grey ” , xlab=”Mean Res ids ” , ylab=”Slope o f Res ids ” ,main=”Risk
Set at t=180” , ylim=c ( 4 ,4) , xlim=c ( 4.2 ,4) )
matpoints ( r s61 [ 5 ] , r s61 [ 6 ] , pch=”x” , c o l =2)
#Calcu la te the mean d i f f e r e n c e between the pa t i en t s that dropped out at t=40 and those that didn ’
t in terms o f the r e s i d u a l s and s l op e s o f r e s i d u a l s .
meandi f f31=mean( rs31 [ , 5 ] )   mean( rs32 [ , 5 ] )
meandi f f32=mean( rs31 [ , 6 ] )   mean( rs32 [ , 6 ] )
meandi f f3=c ( meandiff31 , meandi f f32 )
#Calcu la te the var iance and covar iance o f the s l op e s o f r e s i d u a l s and the r e s i d u a l s themse lves
f o r t=40
v1=var ( c ( r s31 [ , 5 ] , r s32 [ , 5 ] ) )
v2=var ( c ( r s31 [ , 6 ] , r s32 [ , 6 ] ) )
c1=cov ( c ( r s31 [ , 5 ] , r s32 [ , 5 ] ) , c ( r s31 [ , 6 ] , r s32 [ , 6 ] ) )
#Calcu la te S matrix o f covar iance f o r mahalanobis d i s t ance
S=matrix ( data = c (v1 , c1 , c1 , v2 ) , nrow = 2 , nco l = 2 , byrow = FALSE)
mahal3< t ( meandi f f3 ) %⇤% so lv e (S) %⇤% meandi f f3 # Ca l cu l a t e s Mahalanobis d i s t ance
mahal3
#Calcu la te the p value based on s h u f f l e s o f the dropouts and non dropouts , t o t a l p t s r e f e r s to the
t o t a l number o f pa t i en t s in the r i s k s e t and numberofdrops i s the number o f pa t i en t s that
dropped out at $t=40$ . 10000 s h u f f l e s o f the dropout i nd i c a t o r were used . The s hu f f l e d
Mahalanobis d i s t an c e s are s to r ed in shu f f . The proport ion o f s hu f f which show gr ea t e r
mahalanobis d i s t an c e s than the c o r r e c t one i s then used to c a l c u l a t e the p value .
r e s idg roups3=rbind ( rs31 [ , 5 : 6 ] , r s32 [ , 5 : 6 ] )
numberofdrops=dim( rs31 ) [ 1 ]
t o t a l p t s=dim( re s idg roups3 ) [ 1 ]
s hu f f=rep (0 ,10000)
f o r ( i in 1 :10000) {
s h u f f l e =(1: t o t a l p t s ) [ s o r t ( r un i f ( t o t a l p t s ) , index . re turn=TRUE) $ix ]
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change1=mean( r e s idg roups3 [ s h u f f l e [ 1 : numberofdrops ] , 1 ] ) mean( r e s idg roups3 [ s h u f f l e [ numberofdrops+1:
t o t a l p t s ] , 1 ] )
change2=mean( r e s idg roups3 [ s h u f f l e [ 1 : numberofdrops ] , 2 ] ) mean( r e s idg roups3 [ s h u f f l e [ numberofdrops+1:
t o t a l p t s ] , 2 ] )
change=c ( change1 , change2 )
shu f f [ i ]< t ( change ) %⇤% so lv e (S) %⇤% change
}
sum( shu f f > as . numeric (mahal3 ) ) /10000
#The f o l l ow ing code e s t imate s the parameters with each i nd i v i dua l pa t i en t removed in the MAGNETIC
datase t o f 508 pa t i en t s .
newests=c (0 , 0 , 0 , 0 , 0 )
f o r ( i in 1 : 508 ) {
#prepar ing the MAGNETIC datase t
magnetic< read . csv (” magnetic . csv ”)
magnetic
s eve r i t y< magnetic [ , c (1 , 2 , 3 , 7 , 11 ,15 ,19 ,23 ,27 ,31 ) ]
s e v e r i t y [ s e v e r i t y== 8] <   9
#Delete pa t i en t i
s e v e r i t y=s e v e r i t y [  i , ]
#Adding the dropout time to the s e v e r i t y dataset , s to r ed in t o t a l 4 .
t o t a l 4=gene r a t e su rv i v a l ( s ev e r i t y , 4 : 1 0 , c (0 ,20 ,40 ,60 ,120 ,180 ,240) )
#The f o l l ow ing code i s used to f i t the j o i n t model with pat i en t i removed .
t o t a l 4 . long = reshape ( d i r e c t i o n=”long ” , data = tota l4 ,
varying = l i s t ( 4 : 1 0 ) , v . names = ” sco r e ” ,
t imevar = ”time ” , t imes = c (0 ,20 ,40 ,60 ,120 ,180 ,240) )
t o t a l 4 . long [ t o t a l 4 . long== 9] <  NA
to t a l 4 . long [ t o t a l 4 . long== 8] <  NA
to t a l 4 . long = na . omit ( t o t a l 4 . long )
t o t a l 4 . surv <  UniqueVariables ( t o t a l 4 . long , var . c o l = c (” surv ” ,
” cens ”) , id . c o l = ” id ”)
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t o t a l 4 . l o n g i t <  t o t a l 4 . long [ , c (6 , 7 , 8 ) ]
t o t a l 4 . b a s e l i n e <  UniqueVariables ( t o t a l 4 . long , var . c o l =
c (”Treatment ”) , id . c o l = ” id ”)
t o t a l 4 . jd <  j o i n tda ta ( l o n g i t ud i n a l = to t a l 4 . l ong i t , s u r v i v a l =
to t a l 4 . surv , b a s e l i n e = to t a l 4 . ba s e l i n e ,
id . c o l = ” id ” , time . c o l = ” time ”)
model . jointrandom <  j o i n t ( t o t a l 4 . jd , s co r e ˜ 1 + time + Treatment , Surv ( surv , cens ) ˜ Treatment ,
model = ” i n t s l o p e ”)
#The new es t imate s o f the parameters are s to r ed .
newests2=c (model . j o i n t r a ndom$co e f f i c i e n t s $ f i x e d $ l o n g i t ud i n a l [ 1 , 1 ] , model .
j o i n t r a ndom$c o e f f i c i e n t s $ f i x e d $ l o n g i t ud i n a l [ 2 , 1 ] , model .
j o i n t r a ndom$c o e f f i c i e n t s $ f i x e d $ l o n g i t ud i n a l [ 3 , 1 ] , model .
j o i n t r andom$co e f f i c i e n t s $ f i x e d $ su r v i v a l , model . j o i n t r andom$co e f f i c i e n t s $ l a t e n t )
newests=rbind ( newests , newests2 )
}
newests=newests [ 1 , ]
newests
#Seve r i t y i s r ed e f i n ed so that a l l o r i g i n a l pa t i en t s are inc luded
s eve r i t y< magnetic [ , c (1 , 2 , 3 , 7 , 11 ,15 ,19 ,23 ,27 ,31 ) ]
#The f o l l ow ing func t i on c a l c u l a t e s the var iance / covar iance matrix based upon the jo intSE code
from the joineR package . This i s s to r ed as ”cm” .
jointcovmat< f unc t i on ( f i t t e d , n . boot , gpt , lgpt , max . i t , to l , p r i n t . d e t a i l = FALSE)
{
data <  f i t t e d $da t a
id <  f i t t ed$da t a$ sub j . c o l
time . long <  f i t t ed$da ta$ t ime . c o l
q <  l ength ( diag ( f i t t ed$ s i gma . u) )
paranames <  c ( row . names ( f i t t e d $ c o e f f i c i e n t s $ f i x e d $ l o n g i t u d i n a l ) ,
names ( f i t t e d $ c o e f f i c i e n t s $ f i x e d $ s u r v i v a l ) , names ( f i t t e d $ c o e f f i c i e n t s $ l a t e n t ) ,
paste (”U ” , 0 : ( q   1) , sep = ””) , ”Res idual ”)
compnames <  rep (”” , l ength ( paranames ) )
compnames [ 1 ] <  ” Long i tud ina l ”
lb1 <  l ength ( f i t t e d $ c o e f f i c i e n t s $ f i x e d $ l o n g i t u d i n a l [ , 1 ] )
lb2 <  l ength ( f i t t e d $ c o e f f i c i e n t s $ f i x e d $ s u r v i v a l )
l g <  l ength ( f i t t e d $ c o e f f i c i e n t s $ l a t e n t )
compnames [ lb1 + 1 ] <  ” Surv iva l ”
compnames [ lb1 + lb2 + 1 ] <  ”Assoc i a t i on ”
compnames [ lb1 + lb2 + lg + 1 ] <  ”Variance ”
i f ( miss ing ( gpt ) ) {
gpt <  3
}
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i f ( miss ing ( l gp t ) ) {
l gp t <  10
}
i f ( miss ing (max . i t ) ) {
max . i t <  200
}
i f ( miss ing ( t o l ) ) {
t o l <  0 .001
}
model <  f i t t ed$mode l
surv . formula <  f i t t ed$ f o rmu la e$ s f o rmu la
long . formula <  f i t t ed$ f o rmu l a e$ l f o rmu l a
sepas soc <  f i t t e d $ s e p a s s o c
data . surv <  cbind ( f i t t e d$da t a$ su rv i v a l , f i t t e d $da t a $ba s e l i n e )
surv . frame <  model . frame ( surv . formula , data = data . surv )
i f ( dim( surv . frame ) [ 2 ] == 1) {
n . e s t <  dim( as . matrix ( f i t t e d $ c o e f f i c i e n t s $ f i x e d $ l o n g i t u d i n a l ) ) [ 1 ] +
dim( as . matrix ( f i t t e d $ c o e f f i c i e n t s $ l a t e n t ) ) [ 1 ] + dim( as . matrix ( diag ( f i t t ed$ s i gma . u) ) )
[ 1 ] +
1
}
e l s e {
n . e s t <  dim( as . matrix ( f i t t e d $ c o e f f i c i e n t s $ f i x e d $ l o n g i t u d i n a l ) ) [ 1 ] +
dim( as . matrix ( f i t t e d $ c o e f f i c i e n t s $ f i x e d $ s u r v i v a l ) ) [ 1 ] +
dim( as . matrix ( f i t t e d $ c o e f f i c i e n t s $ l a t e n t ) ) [ 1 ] + dim( as . matrix ( diag ( f i t t ed$ s i gma . u) ) )
[ 1 ] +
1
}
out <  matrix (0 , n . boot + 2 , n . e s t )
nsubj <  l ength ( f i t t e d $da t a $ sub j e c t )
f o r ( i in 1 : n . boot ) {
s . new <  sample . j o i n tda t a ( data , nsubj , r ep l a c e = TRUE)
f i t b <  j o i n t ( data = s . new , long . formula = long . formula ,
surv . formula = surv . formula , model = model , s epas soc = sepassoc ,
gpt = gpt , max . i t = max . i t , t o l = to l , l gp t = lgpt )
b1 <  as . numeric ( as . vec tor ( as . matrix ( f i t b $ c o e f f i c i e n t s $ f i x e d $ l o n g i t u d i n a l [ ,
1 ] ) ) )
b3 <  as . numeric ( as . vec tor ( as . matrix ( f i t b $ c o e f f i c i e n t s $ l a t e n t ) ) )
b4 <  as . numeric ( as . vec tor ( as . matrix ( diag ( f i tb$s i gma . u) ) ) )
b5 <  as . numeric ( as . vec tor ( as . matrix ( f i tb$ s i gma . z ) ) )
i f ( dim( surv . frame ) [ 2 ] != 1) {
b2 <  as . numeric ( as . vec tor ( as . matrix ( f i t b $ c o e f f i c i e n t s $ f i x e d $ s u r v i v a l ) ) )
out [ i , ] <  c (b1 , b2 , b3 , b4 , b5 )
e s t s <  out [ i , ]
i f ( p r i n t . d e t a i l ) {
d e t a i l <  data . frame ( i t e r a t i o n = i , t ( e s t s ) )
names ( d e t a i l ) <  c (” I t e r a t i o n ” , paranames )
p r in t ( d e t a i l )
}
}
e l s e {
out [ i , ] <  c (b1 , b3 , b4 , b5 )
e s t s <  out [ i , ]
i f ( p r i n t . d e t a i l ) {
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d e t a i l <  data . frame ( i t e r a t i o n = i , t ( e s t s ) )
names ( d e t a i l ) <  c (” I t e r a t i o n ” , paranames )
p r in t ( d e t a i l )
}
}
}
i <  1
whi le ( out [ i , 1 ] != 0) i = i + 1
out <  out [ 1 : ( i   1) , ]
se <  0
c i 1 <  0
c i 2 <  0
i f (n . boot == 1) {
out <  matrix ( out , nrow = 1)
}
f o r ( i in 1 : l ength ( out [ 1 , ] ) ) {
se [ i ] <  sq r t ( var ( as . numeric ( out [ , i ] ) ) )
i f (n . boot < 100) {
c i 1 [ i ] <  0
c i 2 [ i ] <  0
}
e l s e {
c i 1 [ i ] <  s o r t ( as . numeric ( out [ , i ] ) ) [ 2 . 5/100 ⇤ n . boot ]
c i 2 [ i ] <  s o r t ( as . numeric ( out [ , i ] ) ) [ 97 . 5/100 ⇤ n . boot ]
}
}
i f ( dim( surv . frame ) [ 2 ] != 1) {
b1 <  data . frame ( cbind ( compnames , paranames , round ( c ( as . numeric ( as . vec tor ( as . matrix (
f i t t e d $ c o e f f i c i e n t s $ f i x e d $ l o n g i t u d i n a l ) ) ) ,
as . numeric ( as . vec tor ( as . matrix ( f i t t e d $ c o e f f i c i e n t s $ f i x e d $ s u r v i v a l ) ) ) ,
as . numeric ( as . vec tor ( as . matrix ( f i t t e d $ c o e f f i c i e n t s $ l a t e n t ) ) ) ,
as . numeric ( as . vec tor ( as . matrix ( diag ( f i t t ed$ s i gma . u) ) ) ) ,
as . numeric ( as . vec tor ( as . matrix ( f i t t ed$ s i gma . z ) ) ) ) ,
4) , round ( cbind ( se ) , 4) , round ( c i1 , 4) , round ( c i2 ,
4) ) )
}
e l s e {
b1 <  data . frame ( cbind ( compnames , paranames , round ( c ( as . numeric ( as . vec tor ( as . matrix (
f i t t e d $ c o e f f i c i e n t s $ f i x e d $ l o n g i t u d i n a l ) ) ) ,
as . numeric ( as . vec tor ( as . matrix ( f i t t e d $ c o e f f i c i e n t s $ l a t e n t ) ) ) ,
as . numeric ( as . vec tor ( as . matrix ( f i t t ed$ s i gma . z ) ) ) ,
as . numeric ( as . vec tor ( as . matrix ( diag ( f i t t ed$ s i gma . u) ) ) ) ) ,
4) , round ( cbind ( se ) , 4) , round ( c i1 , 4) , round ( c i2 ,
4) ) )
}
names ( b1 ) [ 1 : 6 ] <  c (”Component” , ”Parameter ” , ”Estimate ” ,
”SE” , ”95%Lower ” , ”95%Upper ”)
cov ( out [ , 1 : dim( out ) [ 2 ]  2 ] )
}
cm=jointcovmat (model . jointrandom , n . boot=1000)
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#Calcu la t ing d i f f e r e n c e s in parameter est imates , where ba s e l i n e i s the parameter e s t imate s o f
MAGNETIC f o r the f u l l datase t .
change = ba s e l i n e [1 :5 ]  newests [ 1 , 1 : 5 ]
f o r ( i in 2 : 508 ) {
yep=ba s e l i n e [1 :5 ]   newests [ i , 1 : 5 ]
change = rbind ( change , yep )
}
#Calcu la t ing Cook ’ s Distance
cooksd i s tance=rep (0 ,508)
f o r ( i in 1 :508)
{
cooksd i s tance [ i ]=change [ i ,]%⇤% so lv e (cm)%⇤% matrix ( change [ i , ] , nrow=3)
}
p lo t ( sever i ty$PersonId , cooksd i s tance , ylab=”In f l u en c e ” , xlab=”PersonId ” , pty=3,main=”Cook ’ s
Distance ”)
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